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ABSTRACT 
 
The outcome of naïve T cell activation and differentiation is guided by cues received from the 
cellular microenvironment, including cytokine and costimulatory signals.  Naïve T cell 
precursors can differentiate into a variety of cellular subsets, each with a unique function in the 
immune response.  In this Dissertation, we provide supporting evidence for the participation of 
costimulatory molecules in cell fate decisions.  Using an in vitro differentiation system, we 
demonstrate that costimulation through Intercellular Adhesion Molecule-1 (ICAM-1) on the 
naïve CD4+ T cell can promote differentiation to Foxp3hiCD25+CD127lo regulatory T (Treg) 
cells with suppressor function.  These results add to the evidence previously published by our lab 
that ICAM-1 can act as a costimulatory molecule in the process of activation and differentiation 
of naïve CD4+ T cells from younger individuals.  However, when naïve CD4+ T cells from older 
individuals were costimulated through ICAM-1, differentiation to effector and memory subsets 
was promoted, while differentiation to a Treg subset was impaired.  These data contribute to the 
concept that aging may alter naïve T cell activation and differentiation.  Next, we examined the 
in vivo role of ICAM-1 using mice deficient in ICAM-1 or doubly deficient in ICAM-1 and 
CD28.  ICAM-1-/- mice tended to have slightly increased CD8+ T cell function compared to 
wild-type controls, while ICAM-1-/-CD28-/- mice displayed decreased CD8+ T cell function 
during acute viral infection.  However, a lack of both ICAM-1 and CD28 did not completely 
abolish CD8+ T cell IFN-γ production or cytotoxicity.  Finally, we further compared 
costimulation of human naïve CD4+ T cells through ICAM-1 and CD28 and identified potential 
differences in the timing of activation, in cytokine secretion, and in kinase signaling. Together, 
our results suggest that costimulation through ICAM-1 can participate in the differentiation of 
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Treg cells from naïve precursors, and that differences in the costimulatory signal can influence 
differentiation outcome. 
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INTRODUCTION 
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INTRODUCTION 
Overview of the Immune System 
The immune system is a complex group of cells and molecules whose primary purpose is 
to protect us from disease.  Leukocytes are formed in the bone marrow during hematopoiesis, 
with multi-potent progenitor cells eventually giving rise to T cells, B cells, NK cells, dendritic 
cells, macrophages, neutrophils, eosinophils, and basophils (1).  Each cell type has a unique and 
essential role in the immune response.  While the innate immune system provides an immediate, 
non-specific defense against immune challenges, the adaptive immune system provides a 
response that is specific, diverse, can distinguish self from non-self, and can create 
immunological memory.  The adaptive immune response is controlled by the actions of helper T 
(TH) cells that secrete cytokines to influence the activation, differentiation, and function of 
cytotoxic T (TC) cells, other TH cells, B cells, and macrophages (2).  Immune responses are kept 
in balance by CD4+ Regulatory (Treg) cells that suppress the actions of other leukocytes (3). 
T Cell Subsets 
 Cells destined to become T cells travel from the bone marrow to the thymus to undergo 
selection and maturation.  Naïve T cells emigrate from the thymus and travel between the blood 
and peripheral lymphoid organs in search of cognate antigen.  Upon antigen encounter, they 
differentiate into effector T cells.  It was thought that memory T cells differentiated directly from 
effector T cells using a linear differentiation pathway, but more recent evidence suggests that 
memory T cells might arise from naïve T cells through a divergent differentiation pathway (4).  
T cells can also be divided into subsets of CD4+ TH cells or CD8+ TC cells.  CD4+ T cells are 
classified by the cytokines that they produce and lineage-specific transcription factors they 
express.  TH1 cells produce cytokines such as IFN-γ and IL-12 that promote cell-mediated 
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immune responses, TH2 cells produce cytokines such as IL-4 and IL-5 that promote humoral 
immune responses, and TH17 cells produce IL-17 which promotes an inflammatory response (2).  
Another type of CD4+ T cells, the Treg cell has an essential role in immune tolerance.  Natural 
Treg cells arise in the thymus, while inducible/adaptive Treg cells are induced in the periphery 
from naïve T cells activated under tolerogenic conditions (5).    
T Cell Activation and Differentiation                
Naïve T cells that receive a TCR signal plus a costimulatory signal become activated, 
proliferate, and differentiate into cell types that can participate in the immune response.  TCR 
engagement occurs with MHC Class I (for CD8 T cells) or II molecules (for CD4 molecules) on 
APCs presenting cognate antigen, along with costimulatory molecule ligation.  This interaction is 
known as the immunological synapse and involves segregation of receptors into supramolecular 
activation complexes (i.e. cSMAC, pSMAC, and dSMAC) (6).  Signal 1 initiates intracellular 
signaling cascades that begin with activation of the Src kinase Lck, which phosphorylates 
Immunoreceptor Tyrosine-based Activation Motifs (ITAMs) on the CD3 and ζ chains associated 
with the TCR (7).  Progressive phosphorylation steps lead to activation of Ras and PKC and 
release of intracellular calcium stores.  Further downstream signaling leads to activation of AP-1, 
NF-κB, and NFAT.  These transcription factors translocate to the nucleus and activate 
transcription of genes important in T cell activation, such as IL-2 (8).    
Differentiation of naïve CD4+ T cells to effector cytokine-secreting cells, memory cells, 
and inducible regulatory T (Treg) cells is described in Figure 1.1 (4).  Differentiation of naïve 
CD8+ T cells to effector cytotoxic T lymphocytes (CTLs) and memory cells during viral 
infection is described in Figure 1.2 (9).     
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Costimulatory Molecules 
 Positive costimulatory molecules include CD28, CD2, CD5, CD9, CD27, CD44, CD46, 
CD81, LFA-1, VLA-4, OX40, 4-1BB, CD40L, LIGHT, SLAM, ICOS, and ICAM-1 (10, 11).  
According to the two-signal hypothesis, T cell activation, proliferation, and differentiation will 
occur if a naïve T cells receives Signal 1 from the TCR plus Signal 2 from a costimulatory 
molecule.  However,  if a naïve T cell receives Signal 1 without Signal 2, the T cell will become 
anergic or apoptotic (12, 13).     
 CD28 is the best characterized costimulatory molecule.  CD28 is an Immunoglobulin (Ig) 
Superfamily member, containing one extracellular Ig domain, and expressed as a homodimer on 
T cells (13).  The ligands of CD28 are B7.1 (CD80) and B7.2 (CD86).  These ligands can also 
bind to the negative costimulatory molecule CTLA-4, which provides another method of 
regulating T cell activation.  The intracellular tail of CD28 has been shown to interact with PI3K, 
Vav1, ITK, TEC, Grb-2, Lck, and PKCθ to amplify TCR signaling (13).  However, ligation of 
CD28 alone without TCR triggering can activate components of the PI3K pathway (14). 
Leukocyte Function-associated Antigen-1 (LFA-1) is a member of the β2 Integrin 
Subfamily consisting of a heterodimer of CD11a and CD18 molecules.  LFA-1 is expressed by a 
variety of leukocytes, and has functions in cellular adhesion, leukocyte extravasation from the 
bloodstream, and as a costimulatory molecule.  LFA-1 exists in an inactive conformation on 
resting leukocytes, but can undergo conformational change to an active form in the process of 
“inside-out” signaling.  The primary ligands of LFA-1 are ICAM-1, -2, and -3, and JAM-1 (15).   
Intercellular Adhesion Molecule-1 (ICAM-1) is a member of the Immunoglobulin 
Superfamily (IgSF), containing 5 extracellular Ig domains, a transmembrane domain, and a short 
cytoplasmic domain (16).   ICAM-1 may also be expressed as alternatively spliced isoforms (17).  
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ICAM-1 is expressed on a variety of immune and non-immune cell types including leukocytes, 
endothelial cells, epithelial cells, fibroblasts, and keratinocytes .  ICAM-1 expression can be 
upregulated after cellular activation since the ICAM-1 promoter contains binding sites for 
transcription factors such as AP-1, NF-κB, and STAT (18).  The primary ligands of ICAM-1 are 
the β2 integrins LFA-1 (CD11a/CD18), Mac-1 (CD11b/CD18) and gp150/95 (CD11c/CD18).  
LFA-1 binds to the ICAM-1 amino-terminal domain (domain 1) (19), Mac-1 binds to domain 3 
(20), and p150,95 binds to domain 4 (21).  Rhinoviruses and erythrocytes infected with the 
malaria parasite Plasmodium falciparum use ICAM-1 as a cellular receptor, with binding 
occurring at distinct sites on domain 1 (22, 23). 
Figure 1.3 shows the sequence alignment of the human and mouse ICAM-1 cytoplasmic 
domains.  The human ICAM-1 cytoplasmic domain contains an RKIKK α-actinin binding 
sequence (24), an IKKYLRQ SHP-2 binding sequence (25), a putative SH3 domain-interacting 
PxxP motif (26), and putative phosphorylation sites (24).  Previous data from our lab suggest the 
association of signaling proteins such as Lck and Erk1/2 with an ICAM-1 signaling complex 
(27).  Our lab also previously found that stimulation of ICAM-1 alone on the Molt-3 T cell line 
could result in the transient inactivation of cdc2 kinase (28).  ICAM-1 signaling in APCs has 
been shown to involve the RhoA family of G-proteins, Abl tyrosine kinase, and Src-family 
kinases (29).  ICAM-1 expression on the vascular endothelium is important for leukocyte 
extravasation, and ICAM-1 expressed on the surface of APCs has been shown to be important as 
a costimulatory ligand for LFA-1 on the T cell.  Our lab previously published that ICAM-1 
expressed on the T cell surface itself could function as a costimulatory molecule (30).   
Aging and the Immune System 
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The aging process causes alterations to cells of the immune system and can impair 
responses to challenges such as infections and tumors.  Thymus involution that occurs through 
life leads to decreases in naïve T cell development (31).  Additionally, there are defects in 
activation of the naïve T cells that are present in older individuals (32).  Some biomarkers of 
immunosenescence that predict morbidity and mortality have been identified, known as immune 
risk profiles/phenotypes (IRPs).  These include a CD4:CD8 ratio <1, the presence of CD28(-) T 
cells, decreased T cell proliferation, decreased B cell levels, and chronic infection with 
cytomegalovirus  (32, 33) .  Some proposed therapies to increase T cell responsiveness to antigen 
are to increase expression of costimulatory molecules on APCs or tumors, add specific 
cytokines, or use adjuvants that stimulate TLRs. 
Regulatory T Cells 
T cell tolerance to self-antigens occurs through several mechanisms including thymic 
negative selection, T cell anergy, T cell ignorance, and Treg cell function (3).  Although there 
may be several subsets of Treg cells, the two most studied Treg subsets are natural Treg cells that 
develop in the thymus and inducible/adaptive Treg cells that differentiate in the periphery.  These 
two subsets share many phenotypic markers, but natural Treg cells may be distinguished by 
expression of the transcription factor Helios (34).   Treg cells suppress the activation and function 
of other leukocytes by contact-mediated mechanisms (e.g. perforin, granzyme B, and surface-
bound TGF-β (35-37)) and secretion of IL-10 (38). 
Foxp3 is a transcription factor found primarily in Treg cells.  It functions as a 
transcriptional repressor, for example, inhibiting IL-2 transcription.  Patients with FOXP3 
mutations develop a lethal autoimmune condition known as IPEX (Immune Deregulation, 
Polyendocrinopathy, Enteropathy, X-linked syndrome) (39).  Foxp3-mutant scurfy mice and 
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Foxp3-null mice also develop a lethal lymphoproliferative autoimmune syndrome due to a lack 
of Treg cell development (40).   
Some of the signaling pathways involved in Foxp3 upregulation are the Smad pathway 
after TGF-β signaling, the Stat5 pathway after IL-2 binding, activation of AP1, NFAT, and 
CREB/ATF after TCR signaling, and inhibition of the Akt/mTOR pathway due to low levels of 
costimulation (41).  Foxp3 expression is stabilized by epigenetic mechanisms such as histone 
acetylation and DNA methylation of the FOXP3 locus (41).  Important domains of Foxp3 protein 
include a proline-rich region with repressor function, a C2H2 zinc finger domain, a leucine 
zipper domain that allows for homodimerization, and a winged-helix/forkhead (FKH) domain 
that allows for nuclear translocation and transcriptional repression (42, 43). 
Some clinical trials have begun to test the safety of adoptive Treg therapy in preventing 
acute graft versus host disease (GVHD) (44).  In addition, results from animal models of 
autoimmune diseases suggest that adoptive Treg therapy might also be beneficial in the treatment 
of autoimmune diseases and asthma (45).  Clinical trials have also been conducted to determine 
if Treg depletion might allow for better anti-tumor responses during cancer treatment (46). 
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Figure 1.1.  Summary of naïve CD4+ T cell activation and differentiation.  A naïve CD4+ T cell 
encounters an APC expressing cognate antigen expressed in the context of MHC Class II.  The 
naïve CD4+ T cell undergoes clonal expansion and differentiation to populations of effector 
CD4+ TH cells or Treg cells.  These effector CD4+ T cells will eventually die by apoptosis.  
However, a subset of memory CD4+ T cells will remain that can function during a second 
encounter with the same antigen.         
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Figure 1.1 
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Figure 1.2.  Summary of naïve CD8+ T cell activation and differentiation in response to viral 
infection.  A naïve CD8+ T cell encounters an APC or virus infected cell expressing cognate 
antigen expressed in the context of MHC Class I.  The naïve CD8+ T cell undergoes clonal 
expansion and differentiation to a population of effector CTLs that will kill virus infected cells in 
the periphery.  These effector CTLs will eventually die by apoptosis.  However, a subset of 
memory CD8+ T cells will remain that can function during a second challenge with the same 
virus.      
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Figure 1.2 
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Figure 1.3.  Sequence alignment of human and mouse ICAM-1 cytoplasmic domains.  
Alignment was performed using BLAST Query ID: gi|825682|emb|CAA41977.1| 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).  Identical sequences are highlighted in yellow.  
Conservative substitutions (as determined by the BLAST substitution matrix) are highlighted in 
light blue.  In the human sequence, putative phosphorylation sites are indicated in red (24), and 
the RKIKK α-actinin binding sequence (24), the IKKYLRQ SHP-2 binding sequence (25), and 
putative SH3 domain-interacting PxxP motif (26) are indicated with a bar above the 
corresponding sequences.  
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Figure 1.3 
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DISSERTATION OVERVIEW 
ICAM-1 and Regulatory T Cell Induction 
 Our lab studies the ability of ICAM-1 expressed on the T cell surface to act as a 
costimulatory molecule to influence T cell activation and differentiation using an in vitro model 
of differentiation.  This method uses plate-bound antibodies against CD3, which mimic a TCR 
signal, plus antibodies against ICAM-1 or against CD28.  Former lab members have previously 
demonstrated differentiation of human naïve CD4+ T cells to effector and memory subsets after 
costimulation through ICAM-1 using this method (47).  In this Dissertation, we report a new role 
for ICAM-1 in the induction of a subset of Foxp3hiCD25+CD127lo Treg cells with in vitro 
suppressor function (48).      
Aging and T Cell Differentiation 
We also assessed whether the process of aging might affect the potential for naïve CD4+ 
T cells to generate effector, memory, or Treg cells.  We compared costimulation of naïve CD4+ T 
cells from older individuals (age 65 years or older) with naïve CD4+ T cells obtained from 
younger individuals.  While naïve CD4+ T cells from older individuals retained the ability to 
differentiate to effector and memory cells after ICAM-1 costimulation, they appeared to lose the 
ability to differentiate to Treg cells.    
ICAM-1 and Mouse T Cell Activation and Differentiation 
 To determine the role of ICAM-1 on T cell activation and differentiation in vivo, we 
studied whether ICAM-1 expressed on mouse T cells would function similarly to our results 
using human T cells.  Attempting to stimulate mouse CD4+ T cells through CD3+ICAM-1 did 
not appear to lead to either increased proliferation or to Treg induction.  However, we observed 
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differences in CD8+ T cell function after viral infection of ICAM-1-/- mice, ICAM-1-/-CD28-/- 
mice, and wild-type C57Bl/6 mice.        
Costimulation and Differentiation Outcome 
 One of the overall goals of our lab is to determine how differential signaling through 
costimulatory molecules can lead to distinct cell fates.  In this dissertation, we assessed the 
kinetics of activation, production of cytokines and chemokines, and expression and activation of 
kinases after costimulation through either ICAM-1 or CD28.  Our results suggest that signaling 
and functional differences can result from costimulation through ICAM-1 compared to 
costimulation through CD28.   
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ICAM-1 CAN PARTICIPATE IN REGULATORY T CELL INDUCTION 
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ABSTRACT 
Inducible regulatory T (Treg) cells can be generated from naïve cells in the periphery after 
activation under tolerogenic conditions.  The mechanisms of Treg differentiation are still being 
characterized.  We contributed to this characterization by investigating the participation of 
Intercellular Adhesion Molecule-1 (ICAM-1) in the process of Treg induction beginning with 
human naïve CD4+ T cells.  Costimulation of naïve CD4+ T cells through ICAM-1 in vitro 
without the addition of exogenous cytokines led to the formation of a population of Foxp3hi 
CD25+ CTLA-4+ CD127lo Treg cells.  In contrast, costimulation through CD28 under these 
conditions did not result in Treg induction.  The Treg cells that differentiated following 
costimulation through ICAM-1 strongly inhibited responder cell proliferation in an in vitro 
suppression assay.  We performed additional experiments to further describe the Treg cells that 
formed after costimulation through ICAM-1.  Our results 1) suggest that ICAM-1 resident on the 
surface of naïve CD4+ T cells plays a role in the differentiation of Treg cells from naïve 
precursors, 2) support the hypothesis that signaling through different costimulatory molecules 
can lead to different functional outcomes, and 3) suggest that ICAM-1 might be a possible 
signaling molecule to target for Treg-mediated therapies. 
 
NOTES 
Much of the work presented in this chapter was published by Williams et al. in 2011 in the 
journal Cellular Immunology (1). 
A patent application covering some of the work presented in this chapter was submitted by The 
University of Kansas and was approved in 2012. 
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INTRODUCTION 
The immune system employs several mechanisms to maintain peripheral tolerance 
including T cell anergy, T cell ignorance, and suppression by regulatory T (Treg) cells (2).   
Several Treg subsets have been identified and classified based on their site of development, 
mechanism of induction, or by the cytokines they produce (3, 4).  One subset of Treg cells 
develops in the thymus (natural Treg cells) while a different subset differentiates from naïve 
precursors after leaving the thymus and encountering antigen in the periphery (inducible or 
adaptive Treg cells).   Natural Treg cells are CD4+CD25+ and express the transcription factor 
Foxp3.  The expression of Foxp3 among inducible Treg subsets is variable.  Inducible Tr1 cells 
are characteristically Foxp3(-), while Treg cells induced in the presence of TGF-β or low-dose 
antigen are typically Foxp3+ (5). Although activation of Treg cells occurs in an antigen-specific 
manner, they are able to suppress other leukocytes in an antigen-independent manner (6).  This 
suppression is accomplished by both contact-mediated mechanisms involving perforin, 
granzymes, and surface-bound TGF-β (7-9) and through the immunosuppressive effects of 
soluble IL-10 independent of cell contact (10).   
There is great interest in understanding the mechanisms by which Treg cells are generated 
and in controlling the development and function of both natural and inducible Treg cells for 
therapeutic purposes.  Populations of mouse CD4+CD25(-) cells can differentiate into Treg cells 
following in vitro stimulation with the combination of anti-CD3, anti-CD28 or antigen 
presenting cells, and TGF-β (11, 12), or by delivery of peptide in vivo under sub-immunogenic 
conditions (13, 14).  Human Treg cells have been induced using autologous cell stimulation in the 
presence of IL-4 or IL-13 (15), allogeneic cell stimulation in the presence of TGF-β (16, 17), 
stimulation with immature dendritic cells plus IL-2 (18), or stimulation with murine L fibroblast 
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cell transfectants expressing hCD32, hCD58, hCD80 plus anti-CD3 in the presence of IL-2, IL-
15, IL-10 and IFNα (19).      
It is likely that the differentiation of naïve T cells to Treg cells is influenced by multiple 
factors including the cytokine environment and signaling through specific costimulatory 
molecules.  TGF-β1 is a cytokine that polarizes naïve CD4+ T cells to the Treg subset upon 
activation (11, 12, 16, 17).  IL-2 has also been shown to participate in Treg induction (20).  Some 
costimulatory molecules have been implicated in the generation of Treg cells.  The inhibitory 
molecules CTLA-4 (21) and PD-1 (22), and the positive costimulatory molecules CD46 (23), 
CD52 (24), and CD2 (25) have been shown to promote Treg induction.  Although CD28 is 
necessary for natural Treg development in the thymus, the requirement for CD28 for Treg 
induction in the periphery has been controversial (26). 
Our lab has previously shown that Intercellular Adhesion Molecule-1 (ICAM-1, CD54), 
resident on the T cell surface, can act as a classical costimulatory molecule to effect human naïve 
T cell activation and differentiation to effector and memory subsets (27, 28).  In this chapter, we 
describe a function for ICAM-1 in Treg induction.  Our data show Treg induction from human 
naïve CD4+ T cells after costimulation through ICAM-1, but not after costimulation through 
CD28.  These data support the model that the specific costimulatory signal helps regulate the 
outcome of naïve T cell differentiation. 
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MATERIALS AND METHODS 
Cell Purification 
Human naïve CD4+ T cells were isolated from peripheral blood from healthy donors using 
Ficoll-Paque PLUS (GE Healthcare, Piscataway, NJ) density-gradient centrifugation followed by 
negative selection using a StemSep Human Naïve CD4+ T Cell Enrichment Kit (StemCell 
Technologies, Vancouver, BC) as we have described previously (28).  Refer to Protocol 1 in the 
Appendix for more detail.  In selected experiments where indicated, naïve CD4+ T cells were 
isolated from human tonsil tissue.  In summary, tonsils were minced over a strainer to obtain cell 
suspensions, mononuclear cells were purified using Ficoll-Paque PLUS density-gradient 
centrifugation, and total T cells were isolated from tonsil cell suspensions using E-rosetting using 
sheep RBCs as we have described previously (29).  See Appendix Protocol 2 for a description of 
the procedure.  Next, naïve CD4+ T cells were purified using negative selection with a StemSep 
Human Naïve CD4+ T Cell Enrichment Kit (StemCell Technologies).  If the origin of the cells 
used in an experiment is not specifically given, it can be inferred that they were human naïve 
CD4+ T cells purified from peripheral blood.  Naïve cells for this study were defined as 
CD4+CD45RA+CD45RO(-)CD11aloCD27+ and routinely were >98% CD45RA+ as determined 
by flow cytometry (Fig. 2.1A).  In selected experiments where indicated, either CD25+ or 
CD25+CD127(-) T cells were purified from the stimulated cultures using either CD4+CD25+ 
Regulatory T Cell Isolation Kits or CD4+CD25+CD127(-) Regulatory T cell Isolation kits 
(Miltenyi Biotec, Auburn, CA).    
 
Cell Culture Reagents 
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Cells were cultured in complete RPMI 1640 medium (Mediatech, Herndon, VA) containing heat-
inactivated 10% FBS (Atlanta Biologicals, Lawrenceville, GA), 2 mM L-glutamine, 50 units/mL 
penicillin, and 50 µg/mL streptomycin (Invitrogen/Life Technologies, Carlsbad, CA).  No 
exogenous cytokines were added unless indicated. 
 
Stimulating Antibodies 
Anti-human ICAM-1 antibody clone R6.5D6 was either purified from serum-free hybridoma 
cultures (hybridoma purchased from ATCC, Manassas, VA) or purchased from BioXCell (West 
Lebanon, NH).  Anti-CD3ε antibody clone OKT3 was either purified from serum-free 
hybridoma culture (hybridoma purchased from ATCC) or purchased from eBioscience (San 
Diego, CA).  Anti-CD11a antibody clone HB202 was purified from serum-free hybridoma 
cultures (hybridoma purchased from ATCC).  Anti-CD28 antibody clone ANC28.1 was 
purchased from Ancell (Bayport, MN) or clone CD28.2 was purchased from BD Biosciences 
(San Jose, CA).  Clone ANC28.1 was used for most experiments.  Antibodies were titrated to 
determine the optimal concentration.  The concentration of anti-CD3 used was the highest 
concentration that did not induce proliferation of naïve CD4+ T cells unless the anti-CD3 
antibody was combined with an anti-costimulatory molecule antibody.  The concentration of the 
anti-costimulatory molecule antibodies were the lowest concentrations that gave the maximum 
proliferation when used with the selected anti-CD3 concentration.  The following antibody 
concentrations were used: anti-CD3: 1 µg/mL, anti-ICAM-1: 10 µg/mL, anti-CD11a: 10 µg/mL, 
anti-CD28: 2-5 µg/mL (dependent on the lot of anti-CD28 antibody used).  Antibodies were 
diluted in sterile PBS, added in 200 µL aliquots to flat-bottom 96-well plates, and then allowed 
to adhere for 2 hours at 37° C or overnight at 4° C.  Plates were washed 3 times with sterile PBS 
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to remove unbound antibody.  After washes, cell solutions were added to the 96-well flat-bottom 
plates at a concentration of 1.5x106 cells/mL in 200 µL (3x105 cells per well).  Cells were 
incubated in a 37 °C incubator containing a 5% CO2 atmosphere for the indicated amounts of 
time.  This procedure is also presented in Protocol 3 in the Appendix.    
 
Flow Cytometry Antibodies   
Anti-human Foxp3-PE used was either clone PCH101 from eBioscience or clone 3G3 from 
Miltenyi Biotec.  In most experiments, clone PCH101 was used.  Experiments were performed 
using Fixation/Permeabilization reagents and the accompanying protocol from eBioscience.  
Anti-CD25-FITC, anti-CD25-TriColor, anti-CD11a-FITC, anti-CD27-PE, CD62L-TriColor, 
anti-CD45RA-TriColor, anti-CD45RO-PE, anti-CD54 (ICAM-1)-PE, and anti-CD28-TriColor 
were from Caltag Laboratories/Life Technologies.  Anti-CD127-PE, anti-CD152 (CTLA-4)-PE, 
anti-CCR7-PE, and anti-integrin β7-PE-Cy5 were from BD Biosciences.  Anti-integrin α4-PE, 
and anti-integrin β1-PE-Cy5 were from eBioscience.  Anti-LAP/TGF-β1-PE was from R&D 
Systems.  Anti-phospho-p44/42MAPK-AlexaFluor488 was from Cell Signaling Technologies 
(Danvers, MA).  Isotype control antibody for anti-Foxp3-FITC clone PCH101 was Rat IgG2a-
FITC (eBioscience), isotype control antibody for anti-Foxp3-PE clone PCH101 was Rat IgG2a-
PE (Caltag/Life Technologies), and isotype control antibody for anti-Foxp3-PE clone 3G3 was 
Mouse IgG1-PE (Caltag/Life Technologies).  Isotype control antibody for anti-CD45RA-Tri was 
Mouse IgG2b-TriColor (Caltag/Life Technologies).  Isotype control antibody for anti-phospho-
p44/42MAPK-AlexaFluor488 was Mouse IgG1-AlexaFluor488.  
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Flow Cytometry Surface Staining 
At the indicated times after costimulation in culture, cells were removed from the plate and 
centrifuged, supernates were aspirated, and cells were resuspended in 100 µL cold Staining 
Buffer (Dulbecco’s PBS + 0.5% BSA).  Cells were incubated 15 minutes on ice in the dark.  
Cells were centrifuged again, supernates were aspirated, and cells were resuspended in 100 µL 
cold Staining Buffer plus fluorescently-conjugated antibodies, and incubated on ice for 20 
minutes in the dark.  Cells were washed by adding 500 µL cold Staining Buffer, centrifuging, 
and aspirating supernatant.  Cells were resuspended in 200-400 µL Staining Buffer plus 2-4% 
final percent paraformaldehyde to fix the cells.  Cells were analyzed using either a BD FACScan 
or an Accuri C6 cytometer.  Protocol 4 in the Appendix describes the surface staining procedure.      
 
Intracellular Flow Cytometry Staining for Foxp3 
Foxp3 flow cytometry staining was performed following the protocol outlined by the 
eBioscience tech sheet protocol, with modifications to the reagent volumes used as indicated 
here.  Cells were first surface stained using the protocol described above, minus the final fixation 
step.  Next, cells were placed in 400 µL eBioscience Fixation/Permeabilization Buffer and 
incubated for 30-60 minutes in the dark at 4° C in the dark.  Cells were washed with 600 µL 
Permeabilization Buffer and resuspended in 100 µL Permeabilization Buffer plus 1 µL normal 
rat serum (corresponding to anti-Foxp3 clone PCH101) or normal mouse serum (corresponding 
to anti-Foxp3 clone 3G3) and incubated for 5 minutes on ice in the dark.  Next, the titrated 
amount of anti-Foxp3 antibody was added and the tubes were gently vortexed to mix.  After 
incubating for 30 minutes on ice in the dark, the cells were washed twice with 800 µL 
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Permeabilization Buffer.  Cells were resuspended in 200-400 µL Staining Buffer plus 2-4% final 
percent paraformaldehyde. 
 
Antibodies for Cytokine Blocking 
Antibodies used for cytokine blocking experiments were anti-IL-10 (eBioscience), anti-IL-2, and 
anti-TGF-β1 (R&D Systems, Minneapolis, MN).  Isotype control antibody for anti-IL-10 was 
Rat IgG1 and isotype control antibody for anti-IL-2 and anti-TGF-β1 was Mouse IgG1 
(eBioscience). 
 
Cytokine Removal by Protein G 
Protein G Sepharose 4 Fast Flow (Amersham/GE) was centrifuged at 4° C, and the supernate 
aspirated.  The Protein G pellet was resuspended at 50% in 100 mM Tris pH 8.0.  This solution 
was centrifuged again, and the supernate aspirated.  This wash was repeated 5 times.  The 
Protein G pellet was resuspended at 50% in 100 mM Tris pH 8.0, and aliquoted into new 
Eppendorf tubes.  The solution was centrifuged and supernates aspirated.  The appropriate cell 
culture supernates were added to the tubes containing Protein G.  The samples were gently 
agitated at 4°C for 60 minutes by shaking for 30 minutes and rotating for 30 minutes.  The 
samples were centrifuged and the supernate was saved.  Supernate cytokine concentrations were 
assayed using ELISA (IL-10 or TGF-β1 ELISA from R&D Systems).  All steps were performed 
under sterile conditions.  This protocol is included as Protocol 5 in the Appendix. 
 
Addition of Exogenous Cytokines or Retinoic Acid 
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In selected experiments where indicated, the recombinant human cytokines TGF-β1 (R&D 
Systems) and IL-2 (Boehringer Mannheim) were added.  TGF-β1 was used at 10 ng/mL and IL-2 
was used at 10 U/mL.  In selected experiments where indicated, retinoic acid was added.  All-
trans Retinoic Acid was purchased from Sigma-Aldrich (St. Louis, MO).  It was dissolved in 
DMSO and used at a concentration range of 1 – 10 nM.   
   
Additional Flow Cytometry Reagents 
CFSE (5-(and-6)-carboxyfluoresceindiacetate, succinimidyl ester) was from Molecular 
Probes/Life Technologies (Carlsbad, CA) and used at 2.5 µM final concentration.    Cells were 
labeled for 10 minutes at 37° C in the dark in serum-free RPMI1640 medium at a concentration 
of 2 million cells/mL.  Cells were centrifuged at low speed for 5 minutes and supernatant 
aspirated.  Cells were washed twice in complete RPMI1640 medium.  This procedure is included 
in the Appendix as Protocol 6.   
 
Flow Cytometry Analysis 
Flow cytometry was performed using a FACScan (BD, San Jose, CA) or an Accuri C6 (Accuri 
Cytometers, Ann Arbor, MI).  Data analysis was performed using CellQuest software (BD), 
CFlow (Accuri) and FlowJo software (Tree Star, Inc., Ashland, OR). 
 
Cytokine ELISA 
Cell culture supernates were collected from stimulated cultures and used after clarification by 
centrifugation.  IL-10 production was measured using Human IL-10 ELISA Ready-Set-Go kits 
(eBioscience, San Diego, CA) or Human IL-10 Quantikine kits (R&D Systems, Minneapolis, 
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MN).  Levels of secreted TGF-β1 were determined using Human TGF-β1 Quantikine kits (R&D 
Systems).  The procedure for the Human TGF-β1 Quantikine ELISA first required activation of 
latent TGF-β1 to active TGF-β1 by addition of acid and then neutralization.  Plates were 
analyzed using an Automated Microplate Reader (BioTek, Winooski, VT) and DeltaSoft 
software (BioMetallics Inc, Princeton, NJ). 
 
Suppression Assay 
Naïve CD4+ T cells were stimulated for 10 days using anti-CD3 plus anti-ICAM-1.  On Day 10, 
the stimulated cells were spun over Ficoll-Paque (GE Healthcare, Piscataway, NJ) to remove 
dead cells.  The CD4+CD25+ Treg cells were separated from the CD4+CD25(-) cells using 
CD4+CD25+ Regulatory T Cell Isolation Kits (Miltenyi Biotec).   Also on Day 10, fresh 
peripheral blood was again obtained from the same donor and second bleed total T cells were 
isolated using Ficoll-Paque density centrifugation and a Human T Cell Enrichment Kit (StemCell 
Technologies, Vancouver, BC).  The cultured CD4+CD25+ Treg cells, the cultured CD4+CD25(-
) cells, and an aliquot of second bleed total T cells to be used as a control were each stained with 
PKH26 dye (Sigma, St. Louis, MO) at 2.5 µM concentration.  An aliquot of second bleed total T 
cells to be used as responders was labeled with CFSE (Molecular Probes/Life Technologies) at 
2.5 µM concentration.  Subsequently, the cells were cultured at Treg (or Control) Cell: Responder 
Cell ratios of 1:1, 1:2, and 1:4.  Co-cultured cells were stimulated for 5 days using anti-CD3 plus 
anti-CD28 antibodies as described above (3x105 cells/well).  Proliferation of the CFSE-labeled 
responder cell population was assessed using flow cytometry by gating out the PKH26-labeled 
Treg or control populations and analyzing proliferation of the CFSE-labeled responder 
population.  
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Human Subjects   
Peripheral blood cells were obtained after informed consent of healthy volunteers.  Procedures 
were approved by The University of Kansas Institutional Review Board.  
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RESULTS 
Costimulation of naïve CD4+ T cells through ICAM-1 induced cells with a Treg phenotype 
Our interest in differentiation outcome after costimulatory molecule ligation led us to 
investigate the possibility that costimulation through ICAM-1 might be involved in the induction 
of regulatory T cells.  We employed our in vitro model of T cell activation and differentiation by 
costimulating human naïve CD4+ cells through the TCR/CD3 complex and either ICAM-1 or 
CD28 using plate-bound antibodies to mimic an antigenic signal plus a costimulatory signal.  In 
vitro costimulation using plate-bound antibodies is a well-established method which allows us to 
focus on stimulating the cell-surface proteins of interest and avoid, as much as possible, 
additional signaling that could occur if antigen presenting cells provided the stimuli.   
Naïve CD4+ T cells were obtained from human peripheral blood in most experiments, 
but in a few experiments, where indicated, naïve CD4+ T cells were purified from human tonsil 
tissue.  Naïve CD4+ cells have been characterized phenotypically by other groups as 
CD45RA+CD45RO(-)CD11aloCD27+ (30) and also as expressing the molecules CD28, LFA-1, 
CCR7, CD62L, CD27, CD2, and VLA-4 (Very Late Antigen-4, integrin α4β1) (31).  The naïve 
CD4+ T cell population we isolated using negative selection columns was CD45RA+CD45RO(-) 
and the gated CD45RA+ cells were CD11aloCD27+ (Fig. 2.1A).  The naïve population also 
expressed the lymph node homing markers CCR7 and CD62L, the gut associated lymphoid 
tissue (GALT) homing marker LPAM-1 (Lymphocyte Peyer’s Patch Adhesion Molecule-1, 
integrin α1β7) and VLA-4 (integrin α1β1) (Fig. 2.1B).  Expression of the costimulatory 
molecules of interest in our study, ICAM-1 and CD28, were expressed at a low but detectable 
level on the resting naïve CD4+ T cells (Fig. 2.1C).  Therefore, the phenotype of the starting 
naïve CD4+ T cells used in our studies corresponded with what has been previously reported in 
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the literature (30-32).  The starting nonstimulated naïve CD4+ T cell population routinely 
contained less than 3% of Foxp3lo cells (MFI = 29, using anti-Foxp3-PE clone PCH101, mean of 
15 samples), and no Foxp3hi cells (defined in stimulated samples as MFI = 236, using anti-
Foxp3-PE clone PCH101, mean of 11 samples) (Fig. 2.1D).  The naïve cells expressed the IL-
7Rα chain (CD127) but did not express the IL-2Rα chain (CD25) (Fig. 2.1D), which is a naïve 
phenotype also previously reported (33).             
To generate both an antigenic signal and a costimulatory signal, we stimulated the 
purified naïve CD4+ T cells in 96-well plates (3x105 cells/well) coated with immobilized 
antibodies directed against CD3 plus antibodies directed against different costimulatory 
molecules.  The treatment groups usually were as follows: Nonstimulated, CD3 alone, 
CD3+ICAM-1, and CD3+CD28.  No exogenous cytokines were added to the stimulated cultures.   
 Following our lab’s investigation of the function of ICAM-1 in memory cell formation, 
we were interested in determining whether ICAM-1 was also involved in the differentiation of 
Treg cells from naïve cells.  Some inducible Treg cells have been phenotypically characterized as 
CD4+ Foxp3+ CD25+ CTLA-4+ CD127lo (5, 33-35).  In addition, CD62L is expressed on some 
types of Treg cells, and may help them home to and function in lymphoid organs (36, 37).  
CD62L is also expressed on other T cell subsets, including naïve T cells (Fig. 2.1B).  CD25 is 
the IL-2Rα chain and CD127 is the CD127 is the IL-7Rα chain.  The presence of CD25 and 
CTLA-4 and absence of CD127 is not a definitive phenotype for Treg cells since this phenotype 
occurs on some activated CD4+ cells as well (38).  The transcription factor Foxp3 is considered 
a more definitive Treg marker since ectopic Foxp3 expression can convert CD4+CD25- cells to 
CD4+CD25+ regulatory cells (39-41).  After approximately 5 days of stimulation using anti-
CD3 plus anti-ICAM-1, we detected a subset of cells with a Treg phenotype.  This population 
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expressed high levels of the intracellular Treg marker Foxp3 (Fig. 2.2A) and the cell-surface Treg 
markers CD25 and CTLA-4, did not express CD127, and remained CD62L+ (Fig. 2.2B).  In 
agreement with previous reports (42), we did not observe sizeable Treg populations in the CD3 
stimulated, or CD3+CD28 stimulated samples.  Stimulation through ICAM-1 alone did not 
generate a Treg population (data shown in Fig. 2.3A) suggesting that both an antigenic signal and 
a costimulatory signal are required for Treg induction.  In the few experiments when we 
stimulated using anti-CD3+anti-CD11a (LFA-1), we sometimes observed a small population of 
Foxp3hi cells after costimulation through CD3+CD11a , but did not observe this population in 
other experiments (data not shown).  A large population of cells stimulated by any treatment 
appeared to express intermediate levels of Foxp3.  This may indicate nonspecific Foxp3 antibody 
binding, or may correspond with an observation of other investigators in which activation 
promotes a slight transient increase in Foxp3 expression without full conversion to the Treg 
subset (43, 44).  
Treg proliferation and kinetics of Foxp3 expression 
Since we observed strong proliferation of naïve CD4+ T cells in response to ICAM-1 
costimulation, we were interested in assessing proliferation of the Treg population during the 
differentiation process.  We stained newly purified naïve CD4+ T cells with CFSE and 
stimulated them using the indicated treatment regimens (Fig. 2.3A).  After 7 days of stimulation, 
we observed that the Foxp3hi population included both undivided cells (upper right quadrant) and 
cells that had undergone cell division (upper left quadrant), suggesting that at least some of the 
differentiating Treg cells had upregulated Foxp3 without dividing.  For the cells that had both 
divided and upregulated Foxp3, we were unable to distinguish whether the cells differentiated 
and then divided, divided and then differentiated, or if both processes occurred concurrently.  
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Even though cells proliferated robustly with costimulation through CD28, we did not detect an 
appreciable population of Foxp3hi cells with this stimulation condition.  When we analyzed the 
kinetics of Treg induction, we observed that the mean percentage of Foxp3hi Treg cells was highest 
at Day 7 of stimulation through CD3+ICAM-1 (Fig. 2.3B).    
Role of cytokines in Treg differentiation after ICAM-1 costimulation 
Specific cytokines have been shown to have roles in both induction of Treg cells and in 
the mechanisms by which Treg cells suppress.  IL-10 has been shown to induce some subsets of 
Treg cells (19).  Also, one mechanism of Treg suppression is the production of the 
immunosuppressive cytokine IL-10 which functions to inhibit IL-2 production and proliferation 
of T cells (10, 45, 46).  We collected cell culture supernates from naïve CD4+ T cells stimulated 
through CD3+ICAM-1 or through CD3+CD28.  IL-10 ELISAs detected moderate amounts of 
IL-10 in supernates from cells costimulated through ICAM-1 (Fig. 2.4A).  Interestingly, the 
mean concentration of IL-10 peaked on day 7, which corresponds to the day of the highest Treg 
percentage in ICAM-1 costimulated cultures (Fig. 2.3B).  TGF-β1 is another Treg-associated 
cytokine that has been shown to be involved both in Treg induction and in suppression by Treg 
cells (9, 16, 42).  Although TGF-β1 secretion was highly variable among 4 experiments 
conducted, both costimulation through ICAM-1 and through CD28 led to secretion of TGF-β1 
(Fig. 2.4B).  Since we were detecting cytokine secretion by cells in the entire culture, we cannot 
determine whether the Treg cells themselves were secreting either IL-10 or TGF-β1.  We can only 
conclude that some cells in the cultures were secreting these cytokines after stimulation.   
Treg cells have been shown by other groups to use cell-surface TGF-β1 to suppress other 
leukocytes, and to express cell-surface TGF-β complexed with LAP (latency-associated peptide) 
(9, 47, 48).  We detected expression of surface TGF-β1 using an antibody that would bind to 
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LAP.  We found that some newly isolated naïve CD4+ T cells expressed LAP/TGF-β1, and that 
some of the Foxp3hi cells generated after CD3+ICAM-1 stimulation expressed LAP/TGF-β1.  
However, some Foxp3lo cells also expressed LAP/TGF-β1 after CD3+ICAM-1 stimulation and 
some cells expressed LAP/TGF-β1 after CD3+CD28 stimulation (Fig. 2.4C).  Therefore, in our 
experiments, LAP/TGF-β1 does not appear to be a Treg-specific marker.  We chose not to analyze 
secretion of IL-2 since a former graduate student in Dr. Benedict’s lab, Dr. Jake Kohlmeier, had 
previously shown that costimulation through either CD3+ICAM-1 or CD3+CD28 led to 
production of high IL-2 levels (28).     
Other investigators have shown that the addition of exogenous TGF-β1 plus IL-2 can 
upregulate Foxp3 expression  due to TGF-β1 signaling through Smad3, and IL-2 signaling 
through STAT3 and STAT5 (20, 49, 50).  In our stimulation regimen, we do not add exogenous 
IL-2 or TGF-β1, yet still observe a population of inducible Treg cells.  To determine if adding 
exogenous TGF-β1 plus IL-2 could further enhance Treg induction in our cell culture system, we 
added 10 ng/mL TGF-β1 and 10 U/mL IL-2 to the culture medium.  Addition of exogenous 
TGF-β1 plus IL-2 lead to an increase in the percentage of Foxp3hi cells after costimulation 
through ICAM-1 (Fig. 2.5).         
 To determine if the Treg-associated cytokines we detected after costimulation through 
ICAM-1 were necessary for the Treg induction process, we used blocking antibodies against IL-2, 
IL-10, and TGF-β1 to inhibit their function.  Blocking IL-10 or TGF-β1 did not appear to 
decrease the percentage of Foxp3hi cells.  In contrast, blocking IL-2 abrogated Treg induction 
(Fig. 2.6A,B).  This result supports the observation from other groups that IL-2 is important in 
Foxp3 induction, but challenges the observation from other groups that TGF-β1 is important in 
Foxp3 induction (49, 50).  To verify that the blocking antibodies had sufficiently inhibited IL-10 
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and TGF-β1 in the cultures, we added Protein G to the supernates to remove the antibody-
cytokine complexes and then assayed the cleared supernates using IL-10 and TGF-β1 ELISAs to 
determine if any free cytokine remained (see Protocol 5 in the Appendix for further detail).  
Using this method, IL-10 was effectively removed, but an average of 674 pg/mL TGF-β1 
remained after removal of anti-TGF-β1/TGF-β1 complexes.  Since some TGF-β1 remained, we 
can’t eliminate the possibility that TGF-β1is involved in Treg induction in our system.  However, 
TGF-β1 was both secreted and surface expressed by cells costimulated through CD3+ICAM-1 
and by cells costimulated through CD3+CD28.  This indicates that costimulation through ICAM-
1 provides unique signals leading to Treg induction that costimulation through CD28 does not 
provide.        
Signaling in induced Treg cells and modulation of phenotype 
To begin to identify some of the signaling processes occurring after costimulation 
through ICAM-1 that might lead to Treg induction, we used intracellular flow cytometry to detect 
the activation status of p44/42 MAPK Erk1/2.  Anti-phospho-p44/42MAPK-AlexaFluor488 
antibody detects phosphorylation of MAPK residues Thr202 and Tyr204.  MAPK 
phosphorylation can occur after many cellular events including TCR stimulation and cytokine 
stimulation to effect T cell activation and differentiation (51).  A recent paper showed increased 
MAPK phosphorylation in activated Treg cells (52).  MAPK is activated after IL-2 signaling (50) 
and TCR stimulation, which are two events necessary for Treg induction after ICAM-1 
costimulation (Fig. 2.2A and Fig. 2.6).  In addition, former graduate student Dr. Chintana 
Chirathaworn observed that ICAM-1 could co-localize with MAPK in immunoprecipitation 
experiments, suggesting it might be involved in ICAM-1 related activation or differentiation 
pathways (53).  We observed that both costimulation through CD3+ICAM-1 and costimulation 
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through CD3+CD28 lead to phosphorylation of p44/42 MAPK, even several days after activation 
(Fig. 2.7A).  When Treg cells induced by costimulation through CD3+ICAM-1 were isolated 
using magnetic selection columns, the percentage of cells with activated p44/42 MAPK was 
increased compared to the total population of cells costimulated through CD3+ICAM-1 (Fig. 
2.7A,B).  This does not provide evidence that MAPK activation is involved in Treg induction 
specifically, but it does show that the differentiated Treg cells were using the MAPK pathway in 
some cellular process.   
 Other groups have shown that addition of retinoic acid can lead to the induction of Treg 
cells and the upregulation of gut homing markers CCR9 and LPAM-1 (integrin α4β7), and that 
specialized dendritic cells in the GALT (gut-associated lymphoid tissue) can produce retinoic 
acid to help convert naïve cells to Treg cells (54-57).  In vivo, this is thought to be an important 
mechanism of mucosal tolerance.  To determine if addition of retinoic acid could modulate Treg 
induction or phenotype, we added 1-10 nM all-trans retinoic acid to stimulated cultures.  Unlike 
other experiments presented in this chapter, we isolated naïve CD4+ T cells from tonsil tissue 
instead of peripheral blood for this experiment.  In contrast to published data, we in general did 
not see an increase in Treg induction after addition of retinoic acid.  However, the GALT homing 
marker LPAM-1 (integrin αa4β7) was increased on both non-Treg cells and most notably on 
Foxp3hi cells (Fig. 2.8).  Since this experiment was done in vitro, one can only speculate that 
increased levels of LPAM-1 might allow these cells to remain in the gut environment in vivo. 
Treg cells induced after ICAM-1 costimulation have suppressor function  
To verify that the CD4+CD25+Foxp3hi population generated after ICAM-1 costimulation 
could function as Treg cells, we tested whether these cells could suppress the activation and 
proliferation of other T cells in an in vitro suppression assay (Fig. 2.9A).  We first isolated naïve 
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CD4+ T cells and stimulated them using anti-CD3 plus anti-ICAM-1.  After 10 days of 
stimulation, the stimulated cells were collected and separated into CD4+CD25+ and 
CD4+CD25(-) populations.  These cells were labeled with a membrane-binding fluorescent dye, 
PKH26, to allow them to be gated out of the flow cytometry profile.  This allowed us to analyze 
proliferation of the responder cells only.  Also on this day, total T cells were collected from the 
peripheral blood of the original donor.  A group of these total T cells was labeled with PKH26 to 
use as control cells.  The remaining cells were labeled with the intracellular dye CFSE.  Thus, the 
populations of cells used in the suppression assay were: 1) CFSE-labeled Responder T cells 
(newly isolated), 2) PKH26-labeled Control T cells (newly isolated), 3) PKH26-labeled 
CD4+CD25+ Treg cells (from stimulated cultures), and 4) PKH26-labeled Control CD4+CD25(-) 
cells (from stimulated cultures).  The cells were cultured at Treg (or Control): Responder cell 
ratios of 1:4, 1:2 and 1:1 and stimulated with anti-CD3 plus anti-CD28 for 5 days.  Proliferation 
of the CFSE-labeled responder cell population was measured by flow cytometry after gating-out 
the PKH26-labeled Treg or control cells. 
 When the CD4+CD25+ cells that had differentiated in cultures costimulated through 
ICAM-1 were added to the responder cells, responder cell proliferation was greatly diminished.  
Figure 2.9B shows a suppression assay performed at a Treg: Responder cell ratio of 1:4.  In this 
experiment, only 15.4% of the responder cells divided when CD4+CD25+ Treg cells were added 
to the culture and only one round of cell division occurred.  In contrast, when responder cells 
only were measured or when control T cells or CD4+CD25(-) cells were added to the culture, 
over 50% of the responder cells divided and multiple rounds of cell division were observed.  At 
each Treg: Responder ratio, the CD4+CD25+ Treg cells inhibited responder cell proliferation, and 
a dose-dependent effect was observed (Fig. 2.9C).  The CD4+CD25(-) cells weakly inhibited 
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responder cell proliferation in some experiments.  This type of response has been observed by 
other investigators (58), and could possibly be due to the presence of CD25(-) cells with 
suppressor function, or due to contamination of CD4+CD25+ cells in the CD4+CD25(-) 
population (purity of the CD4+CD25- population was >90%, data not shown).  This experiment 
provides evidence that the cells exhibiting a Treg phenotype can possess suppressive capabilities. 
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Figure 2.1. The initially purified cell population displayed a naïve phenotype.  (A) Purified 
human naïve CD4+ T cells were CD45RA+ (left panel, cells stained with anti-CD45RA are 
shown in bold and cells stained with isotype control are shown in thin gray), CD45RO(-) (middle 
panel), and CD11aloCD27+ (right panel).  The CD11a vs. CD27 plot was created after gating on 
CD45RA+ cells.  Representative of greater than 10 experiments (left and right panels) or 6 
experiments (middle panel).  (B) Homing marker expression patterns on the naïve CD4+ T cells 
were CCR7+CD62L+ (left panel), integrin α4β7+ (middle panel), and integrin α4β1+ (right 
panel).  Representative of 4 experiments.  (C)  Costimulatory molecule expression of ICAM-1 
and CD28 on the initial naïve CD4+ T cell population.  Representative of 1 experiment.  (D) A 
small percentage of the naïve cells were weakly Foxp3+ (left panel, cells stained with anti-Foxp3 
are shown in bold and cells stained with isotype control are shown in thin gray), and the cells are 
primarily CD25(-)CD127+ (right panel).  Representative of greater than 10 experiments.   
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Figure 2.1 
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Figure 2.2.  T cells with a Foxp3+CD25+ Treg phenotype were induced following costimulation 
of human naïve CD4+ T cells through ICAM-1, but not CD28.  (A) Naïve CD4+ T cells were 
stimulated as indicated for 14 days and then analyzed by flow cytometry.  The cells stained with 
anti-Foxp3 antibody are shown in bold whereas cells stained with isotype control are in thin 
gray.  Representative of greater than 10 experiments.  (B) Naïve CD4+ T cells were stimulated 
with anti-CD3 plus either anti-ICAM-1 or anti-CD28 and analyzed by flow cytometry for 
expression of CD25 at 7 days, CTLA-4 at 14 days, and CD127 or CD62L at 10 days of 
stimulation.  Representative of greater than 10 experiments (CD25 or CD127 vs. Foxp3) or 3 
experiments (CTLA-4 or CD62L vs. Foxp3).   
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Figure 2.2 
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Figure 2.3. Cells undergoing differentiation to Treg cells were proliferative, and high levels of 
Foxp3 expression were maintained for at least 10 days.  (A) Naïve CD4+ T cells were stained 
with CFSE and stimulated as indicated.  Cell division and Foxp3 expression were analyzed after 
7 days.  Representative of 4 experiments.  (B) Kinetics of Foxp3 induction were measured for 
cells stimulated through CD3 (hatched bars), CD3+ICAM-1 (closed bars), or CD3+CD28 (gray 
bars).  The mean percentage of Foxp3hi cells in 5 separate experiments is shown for each time 
point +/- SEM.  The asterisk indicates a statistically significant difference between the 
percentage of Foxp3hi cells after costimulation through ICAM-1 and the percentage of Foxp3hi 
cells after costimulation through CD28 (paired t-Test, one tail p<0.05).   There were no other 
significant differences. 
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Figure 2.3 
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Figure 2.4.  Costimulation through ICAM-1 enhances IL-10 secretion, but not TGF-β1 secretion 
when compared to costimulation through CD28.  (A) Human naïve CD4+ T cells were 
stimulated with anti-CD3+anti-ICAM-1 or anti-CD3+anti-CD28.  Cell culture supernates from 
the indicated times were assayed using IL-10 ELISA.  Data are the means of duplicate samples 
from three experiments + S.E.M.  (B) Cell culture supernates from the indicated times were 
assayed using TGF-β1 ELISA.  Data are the means of duplicate samples from four experiments 
+ S.E.M.  The hatched bar indicates the mean concentration of TGF-β1 detected in the medium 
alone.  The asterisk indicates a statistically significant difference between the concentration of 
TGF-β1 after costimulation through CD28 compared to the concentration of TGF-β1 after 
costimulation through ICAM-1 (paired t-Test, two tail p<0.05).   There were no other significant 
differences.  (C) Expression of LAP/membrane TGF-β1 (mTGF-β1) on the surface of naïve 
CD4+ T cells before stimulation (left panel) or after stimulation for 7 days (right panels).  
Representative of 5 experiments for Day 0 nonstimulated cells and representative of 2 
experiments after stimulation. 
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Figure 2.4 
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Figure 2.5.  Addition of exogenous TGF-β1 plus IL-2 increases the percentage of naïve CD4+ T 
cells that differentiate after ICAM-1 costimulation.  Naïve CD4+ T cells were stimulated for 7 
days in the presence of exogenously added TGF-β1 (10 ng/mL) plus IL-2 (10 U/mL), and then 
analyzed for expression of Foxp3 and CD25.  Representative of 2 experiments.
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Figure 2.5 
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Figure 2.6. Treg differentiation after ICAM-1 costimulation required IL-2, but not IL-10.  (A) 
Human naïve CD4+ T cells were stimulated with anti-CD3+anti-ICAM-1 for 10 days in the 
presence of the blocking antibodies indicated.  Blocking antibodies were added at 20 µg/ml on 
Day 0 and again on Day 5.  Representative of 4 experiments.  (B) Summary of the creation of 
Foxp3hi cells in the presence of cytokine-directed blocking antibody.  Data are mean of 4 
experiments + SEM. The asterisk indicates a significant difference between sample with 
blocking antibody and sample without (paired t-Test, one tail p ≤ 0.05). 
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Figure 2.6 
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Figure 2.7.  Costimulation through ICAM-1 leads to p44/42 MAPK Erk1/2 activation during the 
activation and differentiation process.  (A) Intracellular phospho-p44/42 MAPK was detected on 
Day 13 of stimulation. Representative of 4 experiments performed on days 7-13 of stimulation.  
(B) In the same experiment shown in panel (A), CD127(-)CD25+ cells were isolated from the 
CD3+ICAM-1 stimulated cultures using magnetic separation after 13 days of stimulation.  The 
bold black histograms indicate staining with anti-phospho-p44/42MAPK antibody and the thin 
grey histograms indicate staining with the isotype control antibody.  Representative of 3 
experiments performed on Days 7-13 of stimulation. 
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Figure 2.7 
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Figure 2.8.  The GALT homing marker integrin α4β7 (LPAM-1, Lymphocyte Peyer’s Patch 
Adhesion Molecule-1) can be upregulated upon addition of retinoic acid.  Naïve CD4+ T cells 
were purified from tonsil tissue and stimulated with anti-CD3+anti-ICAM-1 with or without 
either 10 nM retinoic acid or DMSO control.  The integrin α4β7 heterodimer and the Treg marker 
Foxp3 were analyzed at day 8.  The percentages and MFIs shown measure cells contained in the 
upper right quadrants only. Representative of 3 experiments using naïve CD4+ T cells from 
tonsil. 
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Figure 2.8 
 
  
59 
 
Figure 2.9. CD4+CD25+ cells induced after costimulation through ICAM-1 suppressed 
responder cell proliferation.  (A) Diagram of the experimental procedure.  Human naïve CD4+ T 
cells were stimulated with anti-CD3+anti-ICAM-1 to induce differentiation to cells with a Treg 
phenotype.  After 10 days, cells were magnetically separated into CD4+CD25+ and 
CD4+CD25(-), and labeled with PKH26 dye to allow them to be gated out of the flow cytometry 
profile, facilitating analysis of proliferation by only responder cells.  Also on day 10, total T cells 
to be used as responders were collected by a second bleed of the original donor.  One aliquot of 
responder cells was labeled with PKH26 to use as control.  The remaining cells were labeled 
with CFSE and used as responders.  Thus, the populations of cells used in the suppression assay 
were: 1) CFSE-labeled Responder T cells (newly isolated), 2) PKH26-labeled Control T cells 
(newly isolated), 3) PKH26-labeled CD4+CD25+ Treg cells (from stimulated cultures), and 4) 
PKH26-labeled CD4+CD25(-) cells (from stimulated cultures).  The cells were cultured at Treg 
(or Control): Responder cell ratios of 1:4, 1:2 and 1:1 and stimulated with anti-CD3+anti-CD28 
for 5 days to induce proliferation.  Proliferation of the responder cell population was measured 
by flow cytometry after gating-out the PKH26-labeled Treg or control cells.  (B) CD4+CD25+ 
Treg cells [or control T cells or CD25(-) cells] at a Treg: responder ratio of 1:4.  The percentage of 
cells undergoing cell division is shown.  Representative of 3 experiments.  (C) Proliferation data 
from all three Treg: responder ratios are presented for Treg cells (CD4+CD25+, hatched bars) as 
well as the control T cells (closed bars).  The data are shown as the mean % proliferation of 
responder cells from 3 separate experiments.  Asterisks indicate statistically significant 
differences between control T cell samples and samples with added CD25+ cells (normalized to 
samples containing CFSE-labeled responder cells only, paired t-Test, one tail p<0.05). 
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Figure 2.9 
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DISCUSSION 
The data presented in this chapter suggest a previously unknown role for ICAM-1 in Treg 
induction from human naïve precursors.  Stimulation of human naïve CD4+ T cells (Fig. 2.1) 
through CD3+ICAM-1 generated a population of Foxp3+ CD25+ CTLA-4+ CD127lo cells (Fig. 
2.2A,B).  This phenotype corresponds to a Treg phenotype described by other groups.  It is 
notable that the Treg cells induced after costimulation through ICAM-1 retain high expression of 
CD62L.  Although our experiments were conducted in vitro, it is known that cells use CD62L to 
enter lymphoid tissues such as lymph nodes in vivo.  Although it is speculative, the presence of 
CD62L on the surface of the Treg cells that we detect might indicate that they would function as 
suppressor cells in lymphoid organs rather than at sites of inflammation.  Our data indicate that 
the ICAM-1 induced Treg cells are proliferative at some stage of differentiation (Fig. 2.3A).  On 
average, we detect the highest percentage of Treg cells at Day 7 of our stimulation cultures, 
although this varies among subjects (Fig. 2.3B).  In contrast, cells with a Treg phenotype were not 
generated by costimulation through CD3+CD28.   
By assaying supernates from CD3+ICAM-1 and CD3+CD28 stimulated cultures, we 
detected more IL-10 secreted after ICAM-1 costimulation (Fig. 2.4A).  Similar amounts of TGF-
β1 were secreted after costimulation through either treatment, although mean TGF-β1 secretion 
was slightly higher on Day 10 of costimulation with CD3+CD28 (Fig. 2.4B).  Cells stimulated 
through CD3+ICAM-1 and cells stimulated through CD3+CD28 expressed low levels of surface 
LAP/TGF-β1 (Fig. 2.4C).  The addition of exogenous TGF-β1 plus IL-2, a method that is 
standard in the literature to induce Treg cells, enhanced Treg formation after costimulation through 
ICAM-1 (Fig. 2.5).  This result might indicate that the IL-2 and/or TGF-β1 produced by cells 
costimulated though ICAM-1 might be involved in Treg induction in our system.  However, a 
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counter-argument is the result that CD3+CD28 stimulation also resulted in production of IL-2 
and TGF-β1, without Treg induction.   Since we did not measure expression of cytokine receptors 
on the differentiating cells, we cannot determine if cells stimulated through CD3+ICAM-1 and 
cells stimulated through CD3+CD28 had the same ability to respond to cytokines present in the 
cultures.  To further address the question of cytokine participation, we used blocking antibodies 
to attempt to inhibit the IL-2, TGF-β1, and IL-10 produced after CD3+ICAM-1 stimulation (Fig. 
2.6A,B).  Blocking these cytokines revealed that IL-2 was necessary for Treg induction after 
costimulation through ICAM-1.  Since TGF-β1 could only be partially blocked, it remains 
possible that it had a role in Treg induction in our system.   
Our results thus far indicated that signaling through the TCR/CD3 complex, ICAM-1, 
and IL-2R were important in differentiation of Treg cells using our methods.  To begin to ask 
what intracellular signaling cascades might be involved in either Treg induction or function, we 
selected a signaling molecule involved in a multitude of T cell processes, p44/42 MAPK, and 
analyzed whether it was activated/phosporylated during the differentiation process in Treg cells.  
We found that this molecule was activated in the majority of induced Treg cells, suggesting that 
the MAPK signaling pathway might be involved in a process such as Treg differentiation, 
survival, or function (Fig. 2.7).  Addition of retinoic acid did not greatly increase the percentage 
of differentiating Treg cells, but it did upregulate the GALT homing marker LPAM-1 (Fig. 2.8).  
Although this was an in vitro experiment, this result provides an example of how different 
factors in the microenvironment influence the resulting cellular phenotype.  It may also 
demonstrate a way to program Treg cells to home to certain sites in the body, which might be 
useful in Treg-directed therapies.  Finally, we determined that the ICAM-1 induced Treg cells 
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could function as Treg cells in an in vitro suppression assay by strongly inhibiting proliferation of 
autologous T cells (Fig. 2.9B,C).  
Findings from other groups support a role for ICAM-1 in Treg differentiation or function.  
Mouse and human regulatory T cells express higher levels of ICAM-1 than non-Treg cells (59, 
60).  A more recent study showed that ICAM-1-/- mice have fewer Treg cells in peripheral organs 
and an increased immune response Mycobacterium tuberculosis infection compared to wild-type 
mice (61).  Although one study reported that ICAM-1 is not required for mouse CD25+ Treg 
suppressor function (62), the role of ICAM-1 resident on human naïve cells in Treg differentiation 
has not been investigated until now.     
Many outcomes are possible from naive CD4+ T cell differentiation, including TH1 cells, 
TH2 cells, TH17 cells, memory cells, and Treg cells.  The specific tissue microenvironment that the 
naïve CD4+ T cell encounters will provide varying concentrations and types of cytokines, 
chemokines, and costimulatory molecule ligands that can polarize the differentiating T cell to 
specific lineages (63).  On the other side of the equation, the differentiating T cell can respond 
differently to the cues in the microenvironment depending on the surface molecules that the T 
cell expresses.  While dogma holds that naïve CD4+ T cells are a relatively homogenous 
population, new evidence suggests that several subpopulations actually exist (64).  This may lead 
to differential naïve T cell responses to the same microenvironment. 
Induction of Treg cells after costimulation through ICAM-1 is consistent with what one 
would expect to be beneficial in controlling an immune response once that immune response is 
no longer needed.  In CD3+ICAM-1 stimulated cultures, induction of Treg cells is delayed for 5-7 
days after stimulation.  If we speculate and apply this observation to an in vivo scenario, the 
induced Treg cells might function to suppress activated cells after an immune response has 
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already been initiated.  In addition, signaling through ICAM-1 may provide an important sensing 
mechanism to the naïve T cell.  While ICAM-1 is expressed on diverse cell types, the ICAM-1 
ligands, LFA-1 (CD11a/CD18), Mac-1 (CD18/CD11b) and gp150/95 (CD18/CD11c) are 
expressed only on leukocytes.  Also, for a strong interaction to occur between ICAM-1 and LFA-
1, the heterodimers of LFA-1 must be in an activated conformation (65).  Thus, signaling 
through ICAM-1 resident on a T cell may provide a mechanism by which the T cell can perceive 
that it is interacting with an activated leukocyte.  Although it is speculative, one can imagine that 
a naïve CD4+ T cell in a lymphoid organ might encounter an activated APC both presenting 
cognate antigen and expressing ICAM-1 ligands in the active conformation which might lead to 
the differentiation outcome described in this chapter.   
   In summary, we have shown that stimulation of human naïve CD4+ T cells through 
CD3+ICAM-1 induced the differentiation of a population of Treg cells.  These cells expressed a 
Treg phenotype as Foxp3+ CD25+ CTLA-4+ CD127lo and suppressed the activation and 
proliferation of responder T cells in co-culture experiments.  These results suggest that 
costimulation through ICAM-1 might be worth further study for possible Treg-directed therapies 
for immune conditions such as autoimmune diseases, allergies and asthma, and organ-transplant 
tolerance.  One proposed treatment methodology might be to obtain blood from a patient, induce 
Treg cells in culture by costimulating through ICAM-1, purify the Treg population, and reintroduce 
the Treg cells back into the same patient to initiate immune tolerance.    
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CHAPTER 3 
 
AGING MAY AFFECT NAÏVE CD4+ T CELL DIFFERENTIATION TO 
REGULATORY T CELLS 
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ABSTRACT 
Aging is accompanied by immunosenescence, the loss of proper immune system function.  Due 
to thymic involution, naïve T cell development is gradually diminished.  T cell activation and 
differentiation are also modified in older individuals.  These age-related changes are expected to 
weaken immune responses to infections and to vaccination, and to increase the likelihood of 
cancer development.  In this chapter, we compare costimulation of naïve CD4+ T cells obtained 
from the peripheral blood of older individuals (65 years of age or older) with naïve CD4+ T cells 
obtained from the peripheral blood of younger individuals (under age 65, typically ages 20-30 in 
our study).  Unlike data obtained from younger individuals, costimulation of naïve CD4+ T cells 
from older individuals through ICAM-1 did not commonly lead to induction of a population of 
Foxp3hi regulatory T (Treg) cells.  These results support existing data that changes in T cell 
differentiation may occur during the process of aging.     
 
 
 
 
 
 
 
 
 
NOTES 
Some of the work presented in this chapter is included in a paper in preparation (Dotson et al.).  
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INTRODUCTION 
Advances in medicine and public health have greatly improved the average life 
expectancy in the U.S., from 47.3 years for a child born in 1900 to 76.9 years for a child born in 
2000 (1).  As we age, changes take place on genetic, biochemical, and cellular levels that can 
lead to functional decline and subsequent health problems (2).  Alterations can occur due to 
events such as DNA damage, telomere shortening, oxidative stress, altered protein glycation, or 
decreased proteasome function (3).  Many age-related changes occur in the immune system, with 
consequences that include an increased risk for infections, cancers, and some inflammatory and 
autoimmune diseases.  As one example of how aging affects the immune response, statistics 
show that 80-90% of deaths related to influenza virus infection occur in older individuals (4).   
Many cells of the immune system and stages of the immune response undergo 
remodeling during the aging process.  During hematopoiesis, the number of hematopoietic stem 
cells (HSCs) decreases with age in humans and most mouse strains studied, except for C57Bl/6 
mice (5).  Also, hematopoiesis favors myeloid over lymphoid development in older individuals 
(6).  The thymus begins to involute about a year after birth and gradually becomes smaller with 
age, with a concomitant decrease in naïve T cell output (7).  While naïve T cells continue to be 
produced by the thymus in aged mice, in contrast, adult human naïve T cells are mostly 
generated by proliferation of existing naïve T cells in the periphery (8).  The percentages of 
naïve CD4+ and naïve CD8+ T cells in peripheral blood decreases, with concurrent increases in 
the percentage of memory T cells (9).  Changes also occur in T cell function in older individuals.  
In naïve CD4+ T cells, there is poor immunological synapse formation which leads to decreased 
intracellular signaling after TCR triggering.  This in turn leads to decreased T cell proliferation, 
decreased IL-2 production, and decreased cytokine help to B cells (3).  CD8+ T cells exhibit 
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decreased cytotoxic responses in older individuals.  A substantial percentage of T cells, 
especially within the CD8+ subset, down-regulate the costimulatory molecule CD28, most likely 
due to chronic antigenic stimulation (10).  Both CD8+ and CD4+ T cells can undergo clonal 
expansion, leading to decreased TCR diversity (11).  A sizeable percentage of these clonally 
expanded cells is specific for cytomegalovirus (CMV) (12).  The clonally expanded cells are 
proposed to take up space in secondary lymphoid tissues, leaving less room for the naïve T cells 
that emigrate from the thymus and contributing to a reduced naïve/memory T cell ratio compared 
to younger individuals (12, 13).  Cytokine profiles also have been shown to change with aging, 
with Th2 responses favored over Th1 responses (3).       
Previously published data describing age-related changes in Treg cell numbers and 
function have been inconsistent.  Some studies suggest that Foxp3hi Treg cell percentages slightly 
but statistically significantly increase with aging, both in human peripheral blood and C57Bl/6 
mouse tissues, but not in mouse peripheral blood (14, 15).  However, other investigators reported 
that Foxp3hi Treg cell percentages were similar between younger and older individuals (16).  One 
review compared 14 studies that analyzed the percentage of CD4+CD25hi Treg cells in human 
blood, and only 3 of these studies found that the percentage of Treg cells correlated with age (17).  
Some reports have shown that Treg cells in older individuals still function well as suppressor cells 
and have suggested that they may contribute to decreased immune responses seen in older 
individuals.  For example, mouse studies have suggested that Treg cells can impair anti-tumor 
responses in aged Balb/c mice (18), can influence the reactivation of chronic infections (14), and 
can increase in percentage in aged mice during influenza virus infection (19).  In vitro 
experiments using cells from humans (16) or C57Bl/6 and Balb/c mice (19) showed no age-
related changes in Treg-mediated suppression of T cell proliferation.  However, a Balb/c mouse 
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study showed age-related Treg defects in some suppressor functions such as preventing cytokine 
production and decreasing DTH responses (20).  (Depending on the study, young mice were 
between 2-6 months of age, and aged mice were between 20-28 months of age.)  Taken together, 
the existing literature connecting Treg cells and aging has been inconsistent.   
Seeming to contradict the decreased immune responses described in older individuals, 
there is also an increased occurrence of some inflammatory and autoimmune diseases with aging.  
Older individuals have increased production of inflammatory cytokines such as IL-6 and TNF-α 
and increased numbers of Th17 cells (3, 11).  Some diseases associated with aging such as 
atherosclerosis and Alzheimer’s disease are recognized to have inflammatory components (3).  
Autoantibody production has been reported to be increased in older individuals, and some 
autoimmune diseases such as Hashimoto’s thyroiditis, Sjogren’s disease, and pulmonary fibrosis 
can have a late-onset (3, 21).  Another connection between aging and autoimmunity is evidence 
that the immune systems of patients with autoimmune diseases show premature aging 
characteristics such as fewer naïve T cells and T cells with shortened telomeres (10).  The 
precise role of Treg cells in late-onset autoimmunity and inflammatory disease is still to be 
determined.   
In this chapter, we asked if ICAM-1 could provide a costimulatory signal in naïve CD4+ 
T cells from older individuals in a similar manner to our results from younger individuals using 
our in vitro culture system.  We found some similarities and some differences between groups 
when analyzing differentiation outcome.   
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MATERIALS AND METHODS 
Cell Purification 
Naïve CD4+ T cells were isolated from the peripheral blood of healthy donors using the same 
procedure described in the Materials and Methods in Chapter 2 and Appendix Protocol 1.  Naïve 
CD4+ T cells for this study were defined as CD45RA+CD11aloCD27+ or CD45RO(-) 
CD11aloCD27+.     
 
Cell Culture Reagents 
Cell culture reagents used in this chapter are the same as those described in the Chapter 2 
Materials and Methods. 
 
Addition of Exogenous Cytokines 
In most experiments, no exogenous cytokines were added to the cell cultures.  However, in one 
experiment, where indicated, we added recombinant human TGF-β1 (R&D Systems, 
Minneapolis, MN) and IL-2 (Boehringer Mannheim/Roche, Mannheim, Germany) as described 
in the Chapter 2 Materials and Methods.  TGF-β1 was used at 10 ng/mL and IL-2 was used at 10 
U/mL.      
 
Stimulating Antibodies 
The antibody clones, antibody concentrations, method of adhering antibodies to the tissue-
culture plates, and method of antibody-mediated stimulation of cells used in this chapter are the 
same as those described in the Chapter 2 Materials and Methods and Appendix Protocol 3. 
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Flow Cytometry Antibodies   
Information for most flow cytometry antibodies used in this chapter is listed in the Chapter 2 
Materials and Methods.  Antibodies used in this chapter, but not listed in Chapter 2 are anti-
CD4-FITC and anti-CD4-TriColor which were from Caltag/Life Technologies (Carlsbad, CA). 
 
Flow Cytometry Surface Staining 
The flow cytometry staining procedure to detect cell-surface proteins is described in the Chapter 
2 Materials and Methods and Appendix Protocol 4. 
 
Intracellular Flow Cytometry Staining for Foxp3 
The flow cytometry staining procedure to detect intracellular Foxp3 protein followed the 
protocol outlined by the eBioscience technical sheet, with minor modifications described in the 
Materials and Methods in Chapter 2. 
 
Flow Cytometry Analysis 
Flow cytometry and data analysis were performed as described in the Chapter 2 Materials and 
Methods. 
 
Cytokine ELISA 
The concentration of TGF-β1 secreted by stimulated cells was analyzed by ELISA using Human 
TGF-β1 Quantikine kits (R&D Systems) as described in the Chapter 2 Materials and Methods. 
 
Statistical Analysis 
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Statistical significance was determined using either t-Tests or One-way ANOVA to compare the 
groups indicated.  Differences were considered statistically significant if p < 0.05.  Data shown 
in graphs were analyzed by either Microsoft Excel (Redmond, WA) or GraphPad Prism (La 
Jolla, CA).     
 
Human Subjects   
Peripheral blood was obtained after informed consent of healthy volunteers.  Procedures were 
approved by The University of Kansas Institutional Review Board.  Subjects were categorized as 
“older individuals” if they were 65 years of age or older, and “younger individuals” if they were 
less than 65 years of age.  The older individuals in our study were 8 men between the ages of 67 
to 81 years at the time of blood donation, with an average age of 74 years in the 14 experiments 
performed.  Younger individuals were typically between the ages of 20 to 30, and included both 
men and women.   
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RESULTS 
Cells purified from older and younger subjects had similar expression of the proteins studied  
To begin to examine how aging might affect naïve CD4+ T cell activation and 
differentiation, we isolated naïve CD4+ T cells from the peripheral blood of healthy older 
individuals and compared the responses of these cells to results previously obtained with naïve 
CD4+ T cells from younger subjects (22, 23).  In particular, I was interested in determining 
whether naïve CD4+ T cells from older subjects could differentiate to Foxp3hi Treg cells in a 
similar manner to our studies in younger individuals described in Chapter 2.   
We first analyzed the native percentage of Foxp3+ cells in the total CD4+ population in 
PBMCs from older individuals.  As mentioned in the Introduction to this chapter, previously 
published data on this subject have been inconsistent.  We detected Foxp3+ cells in the CD4+ 
population, and found that the percentage of Foxp3+ cells was similar between groups of older 
individuals and younger individuals in the absence of stimulation.  The difference between 
groups was slight and not statistically significant (Fig. 3.1A,B).     
Next, we analyzed the phenotype of the naïve CD4+ T cells isolated from older 
individuals and compared them to the equivalent population from younger individuals.  Even 
though the thymus begins to involute around one year of age and becomes progressively smaller 
over time, older individuals still have a small amount of functional thymus and some naïve T 
cells (7).  The phenotype of the naïve CD4+ T cells purified using the StemSep Human Naïve 
CD4+ T Cell Enrichment Kit was similar between older and younger subjects for the protein 
markers we analyzed (Fig. 3.2A,B,C and Fig. 2.1).   Naïve CD4+ T cells from both older and 
younger individuals expressed CD45RA, which is the isoform of CD45 expressed on naïve T 
cells (Fig. 3.2A).  Also like younger individuals, older individuals had naïve CD4+ T cells that 
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expressed high levels of the selectin CD62L (Fig. 3.2B), and low but detectable levels of the 
costimulatory molecules ICAM-1 and CD28 (Fig. 3.2C).  It should be noted that the data in 
Figure 3.2 are preliminary since only 1 experiment was performed in some cases.  However, 
another graduate student in our lab, Abby Dotson, also obtained data that support the results 
shown in Figure 3.2 (data not shown).  Also of note, the purity and yield of naïve CD4+ T cells 
was sometimes lower for older individuals, although this was variable among subjects (data not 
shown).  When experiments were conducted with a less pure naïve population, there may have 
been error associated with contaminating non-naive cells.   
Corresponding to results from younger individuals (Fig. 2.1), there was a small 
population of Foxp3lo cells in the newly isolated naïve CD4+ T cell population from older 
individuals (Fig. 3.3A).  The profile of CD127 (IL-7Rα) and CD25 (IL-2Rα) expression was also 
similar between groups (Fig. 3.3B).  The results presented in Fig. 3.2 and 3.3 suggest that the 
naïve CD4+ T cells are phenotypically similar, at least for the limited number of proteins we 
studied.      
Some costimulation results were similar between groups, while others differed 
Using our in vitro cell culture system, we next studied whether activation and 
differentiation to functional cells might be altered by aging.  The literature suggests that TCR 
stimulation is often impaired in T cells from older individuals (3).  Naïve CD4+ T cells from 
older individuals were stimulated using the methods described in Chapter 2.  Antibodies against 
CD3, CD3+ICAM-1, CD3+LFA-1 (CD11a), and CD3+CD28 were used as agents to induce 
stimulation.  While the initial phenotype of naïve T cells appeared similar between the older and 
younger subjects studied, the cells sometimes differed in how they responded to stimulation.   
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An important outcome of costimulation that we studied was cellular proliferation.  
Classic costimulatory molecules enhance T cell proliferation and survival after activation.  Abby 
Dotson analyzed whether naïve CD4+ T cells treated with various stimuli could expand in 
number in culture.  Cell numbers were counted by adding flow cytometry counting beads to cell 
samples and analyzing samples using a BD FACScan.  Over the course of 14 days of stimulation, 
cell numbers in culture increased after costimulation through ICAM-1 or LFA-1, but decreased 
after stimulation through CD3 alone or costimulation through CD28 (data not shown, are 
presented in Abby Dotson’s dissertation).  These data suggest that proliferation was occurring 
after costimulation through ICAM-1 and LFA-1.  Proliferation could also have been occurring 
after stimulation through CD3 alone or costimulation through CD28, but these results could have 
been masked if there was concurrent cell death.  These data contrast with data previously 
obtained from younger individuals in which costimulation through both ICAM-1 and CD28 
increased cell numbers, while costimulation through LFA-1 did not, although data were only 
presented to Day 7 of stimulation in our lab’s previous study (22).  Further studies using CFSE 
as a cell proliferation dye and Annexin V and 7-AAD as cell death tracking reagents will help to 
further clarify how well cells are proliferating and surviving.   
Next, we analyzed the ability of naïve CD4+ T cells from older individuals to 
differentiate to various cell types.  My project focused on differentiation to Treg cells, while 
Abby’s project focused on differentiation to effector and memory cells.  Data showing that either 
CD3+ICAM-1 or CD3+CD28 stimulation of naïve CD4+ T cells from younger individuals can 
generate a memory population were previously published by our lab (22).  Some of Abby’s data 
on effector and memory differentiation from naïve CD4+ T cells from older individuals are 
shown in Figure 3.4.  After 14 days in culture, both costimulation through ICAM-1 and through 
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CD28 yielded populations with phenotypes of effector cells [CD45RA(-) and CD11ahiCD27+ 
within the CD45RA(-) gate] and memory cells [CD45RA(-) and CD11ahiCD27(-) within the 
CD45RA(-) gate].  Cells costimulated through LFA-1 (CD11a) did not appear to up-regulate 
CD11a, and therefore did not display either a typical effector or memory phenotype.  Even 
though the mean percentage of memory cells at Day 14 of stimulation was similar between 
CD3+ICAM-1 and CD3+CD28 stimulation, the mean number of memory cells per cell culture 
well was higher after CD3+ICAM-1 stimulation than after CD3+CD28 stimulation (data not 
shown, data are presented in Abby Dotson’s dissertation).  These data suggest that while naïve 
CD4+ T cells from older individuals were able to differentiate to memory cells after 
costimulation through CD28, they perhaps did not proliferate as well or survive as well as naïve 
CD4+ T cells costimulated through ICAM-1.   
 My project was to determine if naïve CD4+ T cells from older individuals could 
differentiate to Foxp3hi Treg cells in the same manner as cells from younger individuals.  Cells 
were stimulated for various time-points (range of 3-14 days, most often analyzed at 7 days) and 
then analyzed for the expression of Treg markers Foxp3 and CD25.  In contrast to results obtained 
using naïve CD4+ T cells from younger individuals (Fig. 2.2B) (23), naïve CD4+ T cells from 
older individuals did not routinely differentiate to Foxp3hi cells (Fig. 3.5A,B).  We conducted 
experiments using naïve CD4+ T cells obtained from 7 older subjects.  Out of 9 experiments 
performed, 7 experiments showed that the naïve cells from older individuals did not differentiate 
to a population of Foxp3hi cells.  However, in 2 experiments we detected a Foxp3hi population 
when naïve cells from older individuals were stimulated.  In 1 of these experiments we detected 
approximately 12% Foxp3hi cells after costimulation through ICAM-1 and approximately 11% of 
Foxp3hi cells after costimulation through CD28 on Day 7 of stimulation, and in 1 experiment we 
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detected approximately 8% Foxp3hi cells after costimulation through CD28 on Day 7 of 
stimulation.  Results from the experiments performed on Day 7 of stimulation are averaged in 
Figure 3.5B for groups of both older and younger individuals.  These data indicate that, in most 
experiments, naïve CD4+ T cells from older individuals did not differentiate to a Treg phenotype 
in the same manner as naïve CD4+ T cells from younger individuals after costimulation through 
ICAM-1.  A CD25+ population with intermediate Foxp3 expression (Foxp3int) was generated 
following stimulation of naïve CD4+ T cells from older individuals by each stimulation 
treatment (Fig. 3.5A).  The phenotype of this population suggests that it most likely represents 
activated, non-Treg cells.     
To begin to understand why the naïve CD4+ T cells from older individuals did not 
typically differentiate to Foxp3hi cells after costimulation through ICAM-1, we asked if the cells 
were also able to differentiate to Foxp3hi cells using the established method of adding exogenous 
TGF-β1 plus IL-2 cytokines to stimulated cultures (24).  Results from this experiment might 
suggest whether the cells were defective in a general Treg differentiation process or were 
defective in differentiation specifically involving ICAM-1.  When exogenous TGF-β1 plus IL-2 
were added to the cultures, we observed enhanced differentiation of Foxp3hi cells after both 
costimulation through ICAM-1 and CD28 (Fig. 3.6).  Because differentiation after cytokine 
addition was observed after both costimulation treatments, we concluded that differentiation in 
this experiment was due to the presence of an activation signal plus Treg-inducing cytokines.  
However, this experiment was only performed once, so repeat experiments would be required to 
support this conclusion.  Also, the population of Foxp3hi cells after CD3+CD28 costimulation 
without cytokine treatment was anomalous in this experiment.  
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We also began to study what cytokines the naïve CD4+ T cells from older individuals 
could secrete after costimulation.  We were interested in TGF-β1 since it is an 
immunosuppressive cytokine, and it has been shown to induce Treg differentiation in vitro (25).  
Figure 3.7 shows TGF-β1 ELISA results using supernates collected after 7 days of stimulation.  
TGF-β1 was produced by the cells obtained from the two older subjects when cells were 
costimulated through either ICAM-1 or CD28.  Although the TGF-β1 concentration varied 
greatly between the two older subjects tested, the mean TGF-β1 concentration was similar to 
results from younger individuals (Fig. 2.4).  This indicates that although cells with a Foxp3hi Treg 
phenotype did not differentiate, there were cells in cultures costimulated through either ICAM-1 
or CD28 that could produce TGF-β1.   
Summary of Differentiation Results 
Results for our differentiation studies are summarized in Table 3.1.  Naïve CD4+ T cells 
from older individuals could differentiate to cells with the phenotype of effector and memory, 
but usually not Treg cells, after both costimulation through ICAM-1 or CD28.  Naïve CD4+ T 
cells from younger individuals could differentiate to cells with the phenotype of effector, 
memory, and Treg cells after costimulation though ICAM-1, but only effector and memory after 
costimulation through CD28.     
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Figure 3.1.  (A) The PBMC populations isolated from older individuals and younger individuals 
contained similar percentages of Foxp3+ cells before stimulation.  Newly purified PBMCs from 
younger and older subjects were stained for expression of CD4, CD25, and Foxp3.  The Foxp3 
vs. CD25 dot plots represent cells within the CD4+ gate.  Representative of PBMCs from 6 older 
individuals and 5 younger individuals.  (B) The mean percentage of CD4+ PBMCs that are 
Foxp3+.  Data are the mean of 6 samples from older individuals and 5 samples from younger 
individuals ± SEM.  Differences between older and younger individuals were not statistically 
significant.   
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Figure 3.1   
 
  
91 
 
Figure 3.2.  The newly purified naïve CD4+ T cell population appeared phenotypically similar 
in older and younger individuals.  Data for younger individuals are the same as shown in Figure 
2.1, or are adaptations of Figure 2.1.  (A) The naïve CD4+ T cell population is CD45RA+.  
Representative of 1 experiment using cells from an older individual and greater than 10 
experiments using cells from younger individuals.  (B) The naïve CD4+ T cell population is 
CD62L+.  Representative of 1 experiment using cells from an older individual and 4 experiments 
using cells from younger individuals.  (C) The naïve CD4+ T cell population expresses low but 
detectable levels of ICAM-1 and CD28.  Representative of 1 experiment using cells from an 
older individual and 1 experiment using cells from a younger individual. 
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Figure 3.2 
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Figure 3.3.  A small percentage of the newly purified naïve CD4+ T cells from both older 
individuals and younger individuals is Foxp3lo.  Data for younger individuals are the same as 
shown in Figure 2.1.  (A) A small percentage of the naïve cells was weakly Foxp3+.  
Representative of 8 experiments using cells from older individuals and greater than 10 
experiments using cells from younger individuals.  (B) The naïve CD4+ T cells were primarily 
CD25(-)CD127+.  Representative of 2 experiments using cells from older individuals and greater 
than 10 experiments using cells from younger individuals.     
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Figure 3.3 
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Figure 3.4.  Naïve CD4+ T cells purified from older individuals can differentiate to effector and 
memory phenotypes after costimulation through either ICAM-1 or CD28.  This figure shows 
data gathered by graduate student Abby Dotson, and is also presented in her dissertation and in a 
manuscript in preparation.  Naïve CD4+ T cells from older individuals were stimulated for 14 
days and then analyzed for expression of CD11a and CD27 after gating on either the CD45RA+ 
cells (upper left panel) or CD45RA(-) cells.  In plots in which cells were gated on CD45RA(-) 
cells, effector cells are represented in the upper right quadrant, while memory cells are 
represented in the lower right quadrant. Representative of between 3-6 experiments (3 
experiments for costimulation through LFA-1, and 6 experiments for costimulation through 
either ICAM-1 or CD28).   
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Figure 3.4 
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Figure 3.5.  Naïve CD4+ T cells purified from older individuals and costimulated through 
ICAM-1 or CD28 do not routinely differentiate to Foxp3hi cells.  (A) Naïve CD4+ T cells from 
an older individual were stimulated as indicated for 7 days and then stained for the Treg markers 
Foxp3 and CD25.  Data from cells obtained from a younger individual are shown for 
comparison.  Representative of 7 experiments for older individuals and greater than 10 
experiments for younger individuals.  Experiments were conducted using naïve CD4+ T cells 
from 7 different older subjects on Days 7-14 of stimulation in 9 total experiments.  In 
experiments using cells from older subjects, 7 experiments gave negative results and 2 
experiments gave a positive result for a Foxp3hi population.  (B) Comparison of induction of 
Foxp3hi CD25+ cells using cells obtained from older or younger individuals.  Data are the means 
of 4-6 experiments for cells from older individuals (4 experiments for CD3 stimulation and 6 
experiments for both ICAM-1 and CD28 costimulation) and 7-11 experiments for cells from 
younger individuals (7 experiments for stimulation through CD3, 11 experiments for 
costimulation through ICAM-1 or CD28) on Day 7 of stimulation ± SEM.  The asterisks indicate 
statistically significant differences between the percentage of Foxp3hi CD25+ cells after 
stimulation of cells from younger individuals through CD3 and the percentage of Foxp3hi CD25+ 
cells after stimulation of cells from younger individuals through CD3+ICAM-1 (One-way 
ANOVA with Tukey’s Multiple Comparison post-test, ** p<0.01), and between the percentage 
of Foxp3hi CD25+ cells after stimulation of cells from younger individuals through CD3+ICAM-
1 and the percentage of Foxp3hi CD25+ cells after stimulation of cells from younger individuals 
through CD3+CD28 (One-way ANOVA with Tukey’s Multiple Comparison post-test, * p<0.05).   
There were no other significant differences.  
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Figure 3.5 
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Figure 3.6.  Naïve CD4+ T cells from an older individual could differentiate to cells with a 
Foxp3hi CD25+ Treg phenotype.  Exogenous TGF-β1 (10 ng/mL) plus IL-2 (10 U/mL) were 
added to cultures at the beginning of stimulation.  Naïve CD4+ T cells were stimulated in the 
presence of exogenous TGF-β1 plus IL-2 for 7 days.  Representative of 1 experiment using cells 
from an older subject.
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Figure 3.6 
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Figure 3.7.  Naïve CD4+ T cells from older individuals secrete TGF-β1 after costimulation 
through either ICAM-1 or CD28.  Naïve CD4+ T cells from older individuals were stimulated as 
indicated for 7 days.  Cell culture supernates were collected, clarified by centrifugation, and 
analyzed by ELISA.  Data are the means of duplicate samples from 2 experiments using cells 
from older individuals and 4 experiments using cells from younger individuals ± SEM.  
Differences between older and younger individuals, comparing the same stimulation treatments, 
were not statistically significant.  TGF-β1 secretion data for younger individuals can also be 
found in Figure 2.4B. 
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Figure 3.7 
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Table 3.1.  Summary of results in our differentiation studies using naïve CD4+ T cells from 
older and younger individuals.  Treg differentiation results are presented in Chapter 2 of this 
dissertation and Williams et al. (23) (younger individuals) and Chapter 3 of this dissertation 
(older individuals).  Results for effector and memory differentiation were presented in Dr. Jake 
Kohlmeier’s dissertation (26) and Kohlmeier et al. (22) (younger individuals) and are presented 
in Abby Dotson’s dissertation (older individuals). 
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Table 3.1 
  Older Individuals Younger Individuals 
  ICAM-1 CD28 ICAM-1 CD28 
Differentiation to Effector Phenotype + + + + 
Differentiation to Memory Phenotype + + + + 
Differentiation to Treg Phenotype - - + - 
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DISCUSSION 
Accumulating data indicate that T cell activation and differentiation are modified as we 
age.  In this chapter, we studied the role of the costimulatory molecules ICAM-1 and CD28 on 
the process of naïve CD4+ T cell differentiation in vitro.  I studied differentiation to cells with a 
Treg phenotype while Abby Dotson studied differentiation to cells with effector and memory 
phenotypes.  Our data suggest that some outcomes of costimulation may differ between naïve 
CD4+ T cells from older and younger individuals, while others are the same. 
 When we compared the percentage of Foxp3+ cells in the total CD4+ population in 
PBMCs, we detected similar percentages between older and younger subjects.  The mean 
percentage of Foxp3+ cells was slightly higher for older individuals, but the increase was not 
statistically significant (Fig. 3.1).  Our data are comparable to those of Hwang et al. (16).  
However, these data contrast with other studies showing increases in the percentage of Treg cells 
with age (11, 14).   
 While thymic output of naïve T cells is known to decrease with aging, less is known 
about possible phenotypic and functional changes in naïve T cells in older individuals.  Naïve 
CD4+ T cells from older and younger subjects had similar phenotypes (Fig. 3.2, 3.3).  A 
limitation to these results is that some experiments were preliminary and only included 1 sample 
per age group.  Additional experiments should be performed to support these data and to study 
the expression of other proteins of interest. 
 We employed our in vitro naïve T cell differentiation system to determine if there were 
differences in outcome after costimulation of naïve CD4+ T cells from older individuals 
compared with younger individuals.  Cells from older individuals expanded in culture the best 
after costimulation through ICAM-1 (data not shown, data are presented in Abby Dotson’s 
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dissertation).  Abby Dotson also showed that naïve CD4+ T cells from older individuals could 
differentiate to effector and memory phenotypes after costimulation through either ICAM-1 or 
CD28 (Fig. 3.4).  With the exception of 2 older subjects, costimulation of naïve CD4+ T cells 
did not generate a population of cells with a Foxp3hi Treg phenotype (Fig. 3.5A,B).  This 
contrasts with our previous results studying naïve CD4+ T cells from younger individuals in 
which costimulation through ICAM-1 routinely yielded a Treg population.   
To determine if the reduced differentiation to cells with a Foxp3hi Treg phenotype was due 
to an ICAM-1-specific effect or a general defect in Treg differentiation, we analyzed whether Treg 
differentiation could occur in the presence of exogenous cytokines.  Cells with a Foxp3hi Treg 
phenotype were induced when exogenous TGF-β1 plus IL-2 were added to stimulated cultures in 
one experiment (Fig. 3.6).  These preliminary data suggest that naïve CD4+ T cells from older 
individuals had the ability to differentiate to Treg cells since they differentiated using stimuli that 
are generally known to generate Treg cells.  However, it should be noted that this experiment was 
only performed once.  These preliminary results show that the diminished Treg induction seen 
using naïve cells from older individuals can be overcome with the addition of exogenous TGF-β1 
plus IL-2.   
We do not yet have definitive answers for why 1) naïve CD4+ T cells from older subjects 
did not typically differentiate to Foxp3hi Treg cells after costimulation through ICAM-1, or 2) in 2 
experiments, the older subjects had cells that differentiated to a Foxp3hi Treg population, while in 
the other 7 experiments, Treg cells did not differentiate.  Decreased Treg induction could possibly 
occur if TCR or ICAM-1 signaling strength differed between naïve CD4+ T cells from older and 
younger individuals.  However, costimulation through ICAM-1 up-regulated expression of CD25 
(IL-2Rα), which is a protein found on both Treg cells and activated T cells, indicating that cell 
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activation occurred (Fig. 3.5).  As further evidence that T cell activation occurred after ICAM-1 
costimulation, we observed expansion of cell number (data not shown, are presented in Abby 
Dotson’s dissertation) and differentiation to effector and memory cells (Fig. 3.4).  Costimulation 
through ICAM-1 also led to the production of TGF-β1 in concentrations similar to that produced 
by naïve CD4+ T cells from younger individuals.  Therefore, it appears that signal strength 
through the TCR plus ICAM-1 was sufficient.   
Another possibility is that a specific signaling pathway was impaired in cells from older 
individuals.  One possibility might be lower IL-2 production.  Secretion of IL-2 by T cells has 
been shown to be reduced in both older individuals (27) and aged mice (28).  Haynes et al. 
further showed that when exogenous IL-2 was added to naïve CD4+ T cells from aged mice, 
effector cell differentiation and production of IL-2 was increased to levels seen in young mice 
(28).  We and others have previously shown that IL-2 was necessary for Treg differentiation in 
cells from younger individuals (Fig. 2.6) (23).  We did not collect data on IL-2 secretion from 
cells from older individuals, so we do not know if there is a difference in IL-2 production 
between age groups.  If less IL-2 was secreted by stimulated naïve CD4+ T cells from older 
individuals, this might explain why we see diminished Treg induction from older individuals in 
our study.   
Another possibility is that Treg cells can differentiate after ICAM-1 costimulation, but the 
timing of differentiation is different.  We did experiments from Days 3-14 to detect Treg cells, but 
it was rare that there were enough starting naïve CD4+ T cells available to do a time-course 
experiment for each individual.  Therefore, most often the cells from older subjects were tested 
on Day 7 of stimulation.  So, it remains possible that we missed the time-point that they 
differentiated.  In addition, even though we were most interested in detecting Foxp3hi Treg cells, it 
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is possible that there were Foxp3int Treg cells that differentiated.  Performing suppression assays 
using magnetically isolated CD25+ cells would reveal whether there were suppressor cells in the 
stimulated cultures even though Foxp3hi cells were not present.  
Naïve CD4+ T cells did differentiate to Foxp3hi cells in 1 experiment after costimulation 
through ICAM-1 or CD28 and in a second experiment after costimulation through CD28.  The 
heterogeneity in results might suggest that some older individuals have cells that behave more 
like cells from younger individuals than others.  The subject who displayed Foxp3hi cells after 
costimulation through ICAM-1 and after costimulation through CD28 was one of the youngest of 
the older individuals tested.  The other subject who displayed Foxp3hi cells after costimulation 
through CD28 had been tested in other experiments and had not shown induction of Foxp3hi cells 
in the past.  It remains possible that these two results are anomalous due to some artifact in the 
culture that led to differentiation occurring in these two individuals.  Also, because we do not 
gather data regarding their medical histories, we do not know if any of the subjects have 
underlying health issues that might possibly skew the immune response toward or away from 
Treg differentiation.  Also, genetic variability and differences in previous exposure to infectious 
agents and other environmental factors would be expected to lead to heterogeneity among 
immune responses.   
The studies described in this Chapter and in Abby Dotson’s dissertation describe a role 
for ICAM-1 in the activation and differentiation of naïve CD4+ T cells obtained from older 
individuals.  Even though aging has been reported to affect activation and differentiation, naïve 
CD4+ T cells from older individuals can still respond to costimulation through ICAM-1 in vitro 
to cause expansion in cell number and differentiation to effector and memory subsets.  However, 
differentiation to Treg cells seemed to be impaired in most cases.  If one were to greatly speculate 
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and translate our in vitro results to an in vivo immune response in a microenvironment in which 
the naïve CD4+ T cell were stimulated by an APC expressing an ICAM-1 ligand in the absence 
of Treg-inducing cytokines, one might predict that naïve CD4+ T cells from older individuals 
might favor differentiation to effector and memory, but not Treg cells.  This differentiation profile 
would be expected to promote defense against infections and cancers, but might also promote 
autoimmunity and inflammation.   
As mentioned in the Introduction, there are some differences between data presented in 
this Chapter and similar studies by other investigators, as well as inconsistencies within the 
immunosenescence literature in general.  Differences in mouse studies could arise from strain 
differences between C57Bl/6 and Balb/c mice.  Not only do these mouse strains favor different 
Th responses, Balb/c mice have higher percentages of CD4+CD25hi Treg cells (29).  In human 
studies, selecting different criteria based on age, sex, and health of the participants could affect 
results.  For example, one study found that changes in cytokine production that occurred during 
aging varied between the groups of women and men (30).  In our study, older individuals were 
65 years or older, were all men, and were in at least reasonably good health (i.e. no acute severe 
illness, not taking immunosuppressive drugs).  Some possibly beneficial changes to an expanded 
study would be to enroll subjects from a variety of ethnic groups and socioeconomic 
backgrounds and both sexes, which would better represent the aging population in the U.S.  
Overall, aging research will be improved by collaborative efforts and long-term longitudinal 
studies. 
Studying costimulatory molecules during aging will help us understand how the immune 
system is remodeled during aging and how this affects disease risk.  Studies have indicated that 
improving costimulatory signaling can improve immune responses.  For example, a study in 
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Balb/c mice showed that aged mice did not reject a tumor well unless the tumor expressed the 
costimulatory ligand CD80 or agonist anti-OX40 antibody was added (31).  The costimulatory 
molecule CD28 is decreased on many T cells in older individuals, especially CD8+ T cells, but 
also CD4+ T cells (32).  However, the costimulatory molecule LFA-1 is increased on T cells in 
aging and has been proposed to perhaps contribute to autoimmunity (21).  Much is left to be 
learned about the contributions of costimulatory molecules to effective immune responses in 
older individuals.  From a mechanistic standpoint, it will be important to determine what 
signaling pathways ICAM-1 uses and how these might be altered in older individuals leading to 
possible Treg differentiation differences.  From a therapeutic standpoint, it might be useful to 
stimulate through ICAM-1 to strengthen immune responses.  This might be especially useful if 
follow-up studies were to confirm that costimulation through ICAM-1 amplified an effector and 
memory response, but not a Treg response in most older individuals.   
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CHAPTER 4 
 
FUNCTION OF ICAM-1 ON MOUSE T CELL ACTIVATION AND 
DIFFERENTIATION 
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ABSTRACT 
Differentiation of naïve T cells to populations of effector, memory, and regulatory T (Treg) cells 
occurs after signaling through the T cell receptor, accompanied by signals from costimulatory 
molecules and cytokines in the cellular microenvironment.  Our lab has shown that ICAM-1 
expressed on human T cells can receive a costimulatory signal, leading to activation and 
differentiation to effector, memory, and Treg subsets.  In this chapter, we investigated whether 
ICAM-1 could similarly deliver a costimulatory signal that would influence cellular 
differentiation in mouse T cells.  We used an in vitro culture system and commercially available 
antibodies to attempt to signal through ICAM-1.  However, we did not observe differentiation of 
mouse CD4+ T cells to a Treg phenotype after costimulation through ICAM-1 unless exogenous 
cytokines were added to the cultures.  Induction of mouse Treg cells after ICAM-1 costimulation 
plus cytokine signaling was not greater than that observed with controls, indicating that ICAM-1 
was not involved in the process.  These data may suggest possible differences in the process of 
Treg induction in human T cells compared with mouse T cells.  In a related project, we studied 
the role of ICAM-1 on T cell activation and differentiation in vivo in mice deficient in ICAM-1 
or deficient in both ICAM-1 and CD28.  Mice were infected with vesicular stomatitis virus 
(VSV) and the ability of CD8+ T cells to become activated and secrete IFN-γ, display cytolytic 
function, and differentiate to memory cells was tested.  Our results indicated that mice deficient 
in both ICAM-1 and CD28 could still initiate cell-mediated immune responses, although 
sometimes at different levels than observed in wild-type mice.      
 
NOTES 
Some data presented in this chapter are included in a paper in preparation (Williams et al.).  
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INTRODUCTION 
Our group has previously demonstrated in vitro that ICAM-1 resident on the human T 
cell surface can also act as a costimulatory molecule on the T cell itself by activating 
phosphatidylinositol 3-kinase, increasing proliferation, and inducing cytokine secretion (1) and 
can guide the in vitro differentiation of human naïve CD4+ T cells to both Foxp3+ Treg cells (2) 
and to CD45RA(-)CD11a+CD27(-) memory cells (3).  Other groups have studied the function of 
ICAM-1 in vivo in mouse models of disease.  One mouse strain that is deficient in ICAM-1, 
Icam1tm1Jcgr, was made by disrupting exon 4 in the Icam1 gene (4).  This ICAM-1 deficient 
mouse showed increased numbers of circulating neutrophils and lymphocytes, decreased MLR 
and DTH responses, and was resistant to the lethal effects of  LPS or S. aureus exotoxin (4).  
Another ICAM-1 deficient mouse strain is the Icam1tm1Bay which was made by disrupting exon 5 
in the Icam1 gene (5).  However, there is evidence that these two strains of ICAM-1 deficient 
mice are not truly ICAM-1 null.  While they do not express full-length ICAM-1 which contains 5 
extracellular domains, the ICAM-1 “deficient” mice can express alternatively spliced ICAM-1 
isoforms.  Some of these isoforms still contain the LFA-1 binding site, and in the Icam1tm1Bay 
mouse some of the isoforms contain the Mac-1 binding site.  True ICAM-1 null mice were later 
generated by deleting the entire Icam1 coding region (6).   
The Icam1tm1Jcgr strain is the ICAM-1deficient strain most commonly used, and will be 
referred to as ICAM-1-/- in this chapter unless otherwise indicated.  Interestingly, ICAM-1-/- mice 
have fewer Treg cells and a stronger response to tuberculosis infection (7).  In the experimental 
autoimmune encephalomyelitis (EAE) mouse model for MS, disease progression is dependent 
upon the strain of ICAM-1 mutant mouse studied, which the authors concluded was related to the 
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alternatively-spliced ICAM-1 isoforms expressed.  The Icam1tm1Jcgr strain actually had attenuated 
EAE symptoms compared to wild-type mice and to Icam1tm1Bay mice (8).   
There are some notable biochemical differences between human and mouse ICAM-1.  
Mouse and human ICAM-1 share only 65% DNA homology and 50% protein homology (9).  
However, the ICAM-1 residues that are important for LFA-1 binding are conserved between the 
two species (10).  The human ICAM-1 cytoplasmic domain contains a putative SH3 domain-
interacting PxxP motif (11) and an IKKYRLQ sequence with some similarity to SH2 domain-
interacting immunoreceptor tyrosine inhibition motifs (ITIMs) (12).  The PxxP sequence is not 
present in mouse ICAM-1, and an IRIYKLQ sequence is found in mouse instead of the human 
ICAM-1 IKKYRLQ sequence.  
In Part I of this chapter, we studied whether signaling through mouse ICAM-1 resident 
on the mouse T cell surface would lead to differentiation.  We observed that, in contrast to our 
results with human T cells, ICAM-1 costimulation did not lead to differentiation to mouse 
inducible Treg cells.  In Part II of this chapter, we studied whether ICAM-1 and CD28 are 
required for CD8+ T cell activation and differentiation in a mouse model of VSV infection.  We 
observed that in the absence of both ICAM-1 and CD28, CD8+ T cells could still become 
activated and differentiate to both CTLs and memory CD8+ T cells, although some differences 
between groups were observed.   
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MATERIALS AND METHODS 
Part I 
Mice 
C57Bl/6J and Balb/cJ mice were purchased from The Jackson Laboratory (Bar Harbor, ME).  
Protocols were approved by the University of Kansas Institutional Animal Care and Use 
Committee. 
 
Cell Purification 
Total splenocytes were isolated from C57Bl/6 mice of typically age 7 to 16 weeks as described 
in Protocol 8 in the Appendix to this Dissertation.  Splenocytes were purified by gently mincing 
over a strainer and then lysing red blood cells using ACK Lysing Buffer (150 mM NH4Cl, 10 
mM KHCO3, 100 µM Na2EDTA, pH = 7.2-7.4).  CD4+ T cells were purified using StemSep 
Mouse CD4+ T Cell Enrichment Kits and Total T cells were purified using StemSep Mouse T 
Cell Enrichment Kits (StemCell Technologies) using the manufacturer’s recommended 
protocols.  Cells were cultured in complete RPMI 1640 medium (Mediatech, Herndon, VA), 
which contained 10% FBS (Atlanta Biologicals, Lawrenceville, GA), 2 mM L-glutamine, 50 
units/mL penicillin, and 50 µg/mL streptomycin (Invitrogen/Life Technologies, Carlsbad, CA).  
In addition, 1% sodium pyruvate, 1% non-essential amino acids (Invitrogen/Life Technologies), 
and 50 µM β-mercaptoethanol (Calbiochem) were added to the complete RPMI 1640 medium in 
many of the mouse cell culture experiments. 
 
Antibodies and Reagents 
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Antibodies used to attempt to stimulate mouse cells are listed in Table 4.1.  The following clones 
of anti-CD3 were used:  OKT3 (eBioscience or hybridoma purchased from ATCC), 145-2C11 
(BD Biosciences, San Jose, CA), KT3 (Chemicon), 500A2 (BD Biosciences), and C363.29B 
(Southern Biotech). The following clones of anti-ICAM-1 were used: R6.5D6 (BioXCell or 
hybridoma purchased from ATCC), 3E2 (BD Biosciences), 166623 (R&D Systems, 
Minneapolis, MN), YN1/1.7.4 (eBioscience), BE2961 (Biodesign), 3E2B (Chemicon), and 
functional grade or purified KAT-1 (eBioscience).  Anti-CD28 (clone 37.51) was purchased 
from BD Biosciences.  All stimulating antibodies tested were anti-mouse antibodies with the 
exceptions of OKT3 and R6.5D6 which are anti-human antibodies.  Flow cytometry staining of 
mouse T cells was performed using anti-Foxp3-PE (eBioscience) and anti-CD25-TriColor 
(Invitrogen/Life Technologies).  Recombinant human TGF-β1 was purchased from R&D 
Systems and used at 2 ng/mL, and recombinant human IL-2 was purchased from Boehringer 
Mannheim/Roche (Mannheim, Germany) and used at 50 U/mL.  Although these cytokines are 
derived from human cytokine sequences, they are known to cross-react with mouse.  CFSE (5-
(and-6)-carboxyfluoresceindiacetate, succinimidyl ester) was purchased from Molecular 
Probes/Life Technologies.  Flow cytometry was performed using a FACScan (BD, San Jose, 
CA) or an Accuri C6 (Accuri Cytometers, Ann Arbor, MI), and data was analyzed using 
CellQuest (BD), CFlow (Accuri) and FlowJo software (Tree Star, Inc., Ashland, OR).   
 
T Cell Stimulation 
Stimulation of mouse CD4+ T cells or total T cells was performed using plate-bound antibodies 
as described in the Chapter 2 Materials and Methods.  Antibodies in PBS were adhered to tissue-
culture treated flat-bottom 96-well plates by incubation at 37 degrees for 2 hours, followed by 
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washing of the wells 3 times with PBS.  For experiments using mouse cells, antibodies were 
tested at the concentrations listed in Table 4.1.  Most mouse Treg experiments used anti-CD3ε 
clone 500A2 at 0.5 µg/mL, anti-ICAM-1 clone KAT-1 or clone YN1/1.7.4 at 10 µg/mL, and 
anti-CD28 clone 37.51 at 2.5 µg/mL.  Cells were stimulated at 1.5x106 cells/mL in 200 µL of 
culture medium.  
 
Suppression Assay 
Mouse CD4+ T cells were stimulated for 5 days using the parameters described in this chapter.  
On day 5, the cells were spun over Lympholyte-M (Cedarlane Laboratories, Burlington, NC) to 
remove debris as described in the Appendix in Protocol 9.  These stimulated cells served as 
potential suppressor cells in the experiment.  Also on day 5, new total T cells were purified from 
mouse spleen, and then labeled with CFSE dye.  These total T cells served as responder T cells.  
Cells were mixed in culture at a 1:2 Stimulated to Responder cell ratio.  Co-cultured cells were 
stimulated with anti-CD3 plus anti-CD28 for between 3-5 days.  Proliferation of the CFSE-
labeled responder cells was measured by gating out the unlabeled stimulated cells and 
determining proliferation of the responder cells only.  Further details are provided in the 
Appendix in Protocol 10. 
 
Part II 
Mice 
C57Bl/6J mice, ICAM-1-/- mice (strain B6.129S4-Icam1tm1Jcgr/J), CD28-/- mice (strain B6.129S2-
Cd28tm1Mak/J ), and TCRβ-/- mice (strain B6.129P2-Tcrb/J) were purchased from The Jackson 
Laboratory.  ICAM-1-/- and CD28-/- mice were crossed to generate ICAM-1-/-CD28-/- mice, and 
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genotyping was performed by Dr. Jake Kohlmeier as described in his Dissertation (13).  
Protocols were approved by the University of Kansas Institutional Animal Care and Use 
Committee. 
 
Reagents 
MHC Class I specific VSV peptide VSV NP52-59 (sequence RGYVYQGL) was obtained from 
SynPep (Dublin, CA).  Flow cytometry staining of mouse T cells was performed using anti-IFN-
γ-FITC (BD Biosciences), anti-F4-80-PE (Caltag/Life Technologies) and either anti-CD8a-
PerCP (BD Biosciences) or anti-CD8a-TriColor (Caltag/Life Technologies).  Recombinant 
human IL-2 was purchased from Boehringer Mannheim/Roche and used at 50 U/mL.  Flow 
cytometry was performed using a FACScan, and data was analyzed using CellQuest (BD) and 
FlowJo software (Tree Star, Inc.).     
 
Vesicular Stomatitis Virus Infection 
Vesicular Stomatitis Virus (VSV) Indiana strain was purchased from ATCC.  Dr. Jake 
Kohlmeier grew the virus in cell culture and determined the virus titer.  Mice were infected i.v. 
with 1x106 PFU VSV via tail vein injection.  This is a nonlethal VSV dose in immunocompetent 
mice.  Mice were typically infected at 8-10 weeks of age.  Immune responses were tested at day 
7 post-infection for acute responses or day 70 post-infection for memory responses. 
 
Cell Purification 
Total splenocytes were isolated from mice as described in Protocol 8 in the Appendix to this 
Dissertation.  Splenocytes were purified by gently mincing over a strainer and then lysing red 
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blood cells using ACK Lysing Buffer.  Total T cells were purified using StemSep Mouse T Cell 
Enrichment Kits (StemCell Technologies).  The cell culture medium used was RPMI 1640 
(Mediatech), which contained 10% FBS (Atlanta Biologicals), 2 mM L-glutamine, 50 units/mL 
penicillin, and 50 µg/mL streptomycin (Invitrogen).   
 
T cell Adoptive Transfer 
Total T cells were isolated from splenocytes as described above.  5 x 106 donor T cells in sterile 
PBS were injected via tail vein into 4-6 week old recipient TCRβ-/- mice.  4 weeks later, recipient 
mice (at 8-10 weeks of age) were infected with 1x106 PFU of VSV via tail vein injection.  
 
Intracellular Cytokine Assay 
IFN-γ production by CD8+ T cells was determined using an intracellular cytokine assay as 
described in Appendix Protocol 11.  Splenocytes were purified from mice on day 7 post 
infection.  Splenocytes were incubated in round-bottom 96-well plates for 5-6 hours at 1x106 
cells/well in 200 µL complete RPMI1640 medium containing 3 µM monensin, 50 U/mL IL-2, 
with or without 2 µg/mL VSV peptide.  After incubation, splenocytes were surface stained for 
CD8 and F4/80 and intracellularly stained for IFN-γ as described in Appendix Protocol 11.  
Permeabilization buffers and monensin were purchased from BD Biosciences. 
 
In vivo cytotoxicity assay 
The cytolytic ability of CD8+ T cells was determined using in vivo cytotoxicity assays as 
described in Appendix Protocol 12.  Splenocytes were purified from uninfected donor mice and 
stained with 5 µM PKH26 dye (Sigma, St. Louis, MO) following the manufacturer’s protocol.  
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The stained cells were separated into two groups: a CFSElo group that was stained with 0.5 µM 
CFSE and a CFSEhi group that was stained with 5 µM CFSE.  The CFSEhi group was incubated 
with 5 µg/mL VSV peptide for 1 hour.  The CFSElo (unpulsed targets) and CFSEhi (VSV 
peptide-pulsed targets) groups were combined.  5x106 unpulsed targets and 5x106 VSV-pulsed 
targets were i.v. injected into recipient mice 7 days post-infection.  16 hours later, splenocytes 
were purified from recipient mice and the Percent Specific Lysis was determined using the 
equation used by Byers et al. (14).  The Percent Specific Lysis was calculated as: [(# of unpulsed 
targets x A - # of VSV peptide-pulsed targets)/# of unpulsed targets x A] x 100%, where A = 
[number of unpulsed targets/# of VSV peptide-pulsed targets] in uninfected control mice. 
 
Statistical Analysis 
One-way ANOVA and Tukey’s post-test were performed to compare the results from each 
mouse genotype using GraphPad Prism (15).  GraphPad Prism was used to detect any possible 
outliers using the Robust regression and OUTlier removal (ROUT) method for automatic outlier 
elimination and the Grubb’s test.  No outliers were identified using either method. 
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RESULTS 
Part I: Costimulation of mouse T cells through ICAM-1 may differ from costimulation of human 
T cells 
Various costimulatory molecules can participate in the activation and differentiation of 
naïve T cells, and our previous results have revealed a role for ICAM-1 in the process of 
differentiation to effector, memory and Treg subsets from human naïve CD4+ T cells. 
To follow our studies in human T cells, we next attempted to study the effects of ICAM-1 
costimulation on the differentiation of mouse CD4+ T cells.  Strains of mice used for 
experiments were C57Bl/6 and Balb/c.  We chose to begin experiments using total CD4+ T cells, 
rather than naïve CD4+ T cells, since we did not have a satisfactory method of obtaining mouse 
naïve CD4+ T cells.  The starting CD4+ T cell population purified from spleen is expected to 
contain approximately 70% CD44lo naïve cells (16).  To determine if ICAM-1 could generate a 
costimulatory signal to initiate C57Bl/6 T cell activation and differentiation, we used anti-CD3 
plus anti-ICAM-1 antibodies to attempt to costimulate mouse total T cells.  As shown in Figure 
4.1, adding anti-CD28 antibody caused a dramatic increase in proliferation, whereas adding anti-
ICAM-1 either caused no effect or seemed to have a blocking effect.  It should be noted that this 
experiment was only performed once using total T cells; however, similar results were obtained 
in two additional experiments using total CD4+ T cells (data not shown).  These results differ 
from those previously published by another group, in which mouse CD4+ and CD8+ T cells 
expanded in number when anti-ICAM-1antibody was added to the stimulation regimen, although 
the stimulation conditions varied between our experiments and their experiments (17).   
Although cellular proliferation did not appear to be increased after ICAM-1 costimulation 
in our experiments, it is possible that cellular differentiation was affected by ICAM-1 
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costimulation.  A collaborator on this project, graduate student Abby Dotson, studied the 
capacity of mouse Balb/c CD4+ T cells to differentiate to central memory cells following 
stimulation through ICAM-1 in one preliminary experiment.  She found that after gating on the 
CD44hi cells, more of the CD44hi cells had a CD127+CD62L+ central memory phenotype after 
costimulation through either ICAM-1 or CD28 when compared to stimulation through CD3 
alone (data not shown, data appear in Abby Dotson’s dissertation).  This preliminary experiment 
suggested that differentiation might be altered after addition of anti-ICAM-1 antibodies to the 
culture conditions.      
To determine whether ICAM-1 costimulation could induce the differentiation of mouse 
Treg cells, C57Bl/6 splenic CD4+ T cells were stimulated through CD3+ICAM-1 for 5 days using 
plate-bound antibodies and then analyzed for the Treg phenotypic markers Foxp3 and CD25.  
Several clones and concentrations of anti-CD3 and anti-ICAM-1 antibodies were tested through 
the course of this project (Table 4.1).  As shown in Figure 4.2A, costimulation through ICAM-1 
on mouse CD4+ T cell did not yield Foxp3+ cells, nor did the control stimulations.  However, 
when the exogenous cytokines TGF-β1 and IL-2 were added to stimulated cultures, a sizable 
Foxp3+ population was observed (Fig. 4.2B).  This was most likely due to the effects of TGF-β1 
and IL-2 rather than an ICAM-1 specific effect, since this Foxp3+ population was observed with 
CD3 stimulation alone and with CD28 costimulation.  The contribution of TGF-β1 to Treg 
induction has previously been reported by others (18, 19).      
Even though costimulation of mouse CD4+ T cells through ICAM-1 did not generate a 
population with a Treg phenotype, we questioned whether ICAM-1 costimulation could still lead 
to cells with suppressive capabilities.  We performed a suppression assay similar to that used by 
other investigators to establish Treg function (20).  In our assay, we used CFSE-labeled total 
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mouse T cells as responder cells and mouse CD4+ T cells previously stimulated through 
CD3+ICAM-1 as potential suppressor cells at a 1:2 Stimulated:Responder cell ratio (Fig. 4.3).  
Responder cell proliferation did not decrease when cells previously stimulated through 
CD3+ICAM-1 were added to cultures.  It should be noted that in some experiments, the ratio of 
Stimulated:Responder cells was less than 1:2 due to a low number of viable stimulated cells 
recovered after the Lympholyte-M spin.  In some instances, responder cell proliferation 
diminished very slightly when cells stimulated in the presence of TGF-β1 plus IL-2 were added 
as potential suppressor cells, but this was not a consistent effect.  These data demonstrate that 
mouse CD4+ T cells stimulated through CD3+ICAM-1 using commercially available antibodies 
do not differentiate into Treg cells.  These results contrast markedly with our studies in which Treg 
induction occurs after costimulation through ICAM-1 using human naïve CD4+ T cells obtained 
from younger individuals.       
 
Part II:  Neither ICAM-1 nor CD28 is required for CD8+ T cell activation and differentiation 
during VSV infection 
 In a separate but related project, the role of ICAM-1 and CD28 in T cell activation and 
differentiation were studied using mice deficient in these costimulatory molecules.  Former 
graduate student, Dr. Jake Kohlmeier, crossed the B6.129S4-Icam1tm1Jcgr and B6.129S2-
Cd28tm1Mak mice to generate mice deficient in both ICAM-1 and CD28.   ICAM-1-/-CD28-/- mice 
were viable and fertile and had normal percentages of peripheral CD4+ and CD8+ T cells in the 
spleen.  Jake found that ICAM-1-/- mice, CD28-/- mice, and ICAM-1-/-CD28-/- mice each had 
subtle differences in thymic double-negative stages of development compared to wild-type 
C57Bl/6 mice (13).  Jake began experiments to test the immune response of ICAM-1-/-CD28-/- 
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mice during VSV infection, and I later completed the project.  The data presented in this Chapter 
are an accumulation of the VSV infection experiments that we completed. 
We directed our study to CD8+ T cells which play a principal role in cell-mediated 
immune responses.  During viral infection, naïve CD8+ T cells become primed in peripheral 
lymphoid organs (e.g. lymph nodes, spleen) by APCs presenting viral antigen on MHC Class I 
molecules.  Activated CD8+ T cells undergo clonal expansion, differentiate into cytotoxic T 
lymphocytes (CTLs), and acquire the ability to migrate to the site of infection.  CTLs will act at 
the site of infection by secreting cytokines such as IFN-γ and killing virus-infected cells through 
perforin and granzymes.  Effector CTLs will die after the acute infection has been cleared, but a 
subset of memory cells will remain that can be activated upon a secondary infection with the 
same virus (21).  During VSV infection, components of both the cell-mediated and humoral 
immune responses are activated.  Studies using mice deficient in either T cells or B cells have 
shown that antibodies are required in the early stage of VSV infection, at least if the route of 
infection is i.v. (22).  T cells are required in later stages of the infection (23).   
Cd28tm1Mak  mice that are deficient in CD28 have T cells with a decreased response to 
lectin stimulation, decreased basal antibody concentrations, impairments in antibody class 
switching, and lack germinal center formation after VSV infection (24, 25).   CD28-deficient 
mice have previously been shown to have reduced, but not absent, IFN-γ production by CD8+ T 
cells after VSV infection (26).  Studies using mice deficient in both B7-1 and B7-2 have also 
shown impairments in antibody class switching and CTL generation (27).  CD8+ T cells are 
more dependent on CD28 costimulation during VSV infection than during LCMV infection, due 
to a lower extent and duration of infection in VSV compared to LCMV (28). 
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Icam1tm1Jcgr mice have increased leukocyte counts in the blood, decreased MLR and DTH 
responses, and show increased survival after injection of LPS or S. aureus exotoxin compared to 
wild-type mice (4).  ICAM-1 deficient mice have decreased T cell activation and proliferation in 
vitro and in vivo due to a lack of ICAM-1 on the APC (29).  ICAM-1 expression on DCs is 
critical for stable interactions with CD8+ T cells to generate T cell memory (30).  In vitro 
experiments using leukocytes from CD28 deficient mice have demonstrated that stimulation 
provided by ICAM-1 on the APC is required if CD28 is absent on the T cell (31).  ICAM-1 on 
the APC is especially important in providing a second signal to primed CD8+ T cells since many 
target cells do not express B7-1 or B7-2.  Together, these studies suggest that if both CD28 and 
ICAM-1 were missing, the immune response to a viral infection would be expected to be 
impaired.  
 To assess CD8+ T cell function with and without the contribution of ICAM-1 and CD28, 
we infected C57Bl/6 mice, ICAM-1-/- mice, and ICAM-1-/-CD28-/- mice with 1x106 PFU of VSV 
strain Indiana by i.v. tail vein injection.  After 7 days of infection, splenocytes were purified from 
infected mice and in vitro cytokine assays were performed to determine whether the lack of two 
important costimulatory molecules would affect activation of CD8+ T cells during viral 
infection.  As expected for uninfected control C57Bl/6 mice, very few CD8+ T cells were 
specific for VSV antigen, and therefore, very few CD8+ T cells produced IFN-γ (Fig. 4.4A, left 
panels).  Very few CD8+ T cells produced IFN-γ when VSV peptide was not added to the culture 
(Fig. 4.4A, bottom panels).  The cells producing IFN-γ in the groups with no peptide may 
represent bystander activation of CD8+ T cells, or represent a low level of nonspecific flow 
cytometry staining.  In all three genotypes of mice (C57Bl/6, ICAM-1-/-, ICAM-1-/-CD28-/-), 
VSV peptide addition to the culture led to a greatly increased percentage of CD8+ T cells 
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producing intracellular IFN-γ.  This indicated that there were virus-specific CD8+ T cells that 
had become activated and clonally expanded during the 7 days of infection in vivo.  Interestingly, 
slightly increased percentage of cells were producing IFN-γ in the ICAM-1-/- mice, while a 
reduced percentage of cells were producing IFN-γ in the ICAM-1-/-CD28-/- mice (Fig. 4.4B).  
Unfortunately, CD28-/- mice were not available for this study as a comparison group.   
 Because ICAM-1 is expressed on many different cell types, including APCs, we wanted 
to narrow our study to the effect of ICAM-1 costimulation on the T cell alone.  To accomplish 
this, we performed T cell adoptive therapy experiments whereby we purified total T cells from 
each of the genotypes of interest and i.v. injected them into TCRβ-/- mice which lack αβ T cells.  
Four weeks after T cell adoptive transfer, the mice were infected with VSV.  IFN-γ production 
by CD8+ T cells was analyzed 7 days post-infection (Fig. 4.5A, B).  Although differences were 
not statistically significant, results followed the same trends as the acute response shown in 
Figure 4.4, with a slightly heightened response in mice with transferred ICAM-1-/- T cells and a 
lowered response in mice with transferred ICAM-1-/-CD28-/- T cells.  It is of note that the TCRβ-/- 
mice without transferred T cells still survived VSV infection.  Others have shown that mice 
lacking αβ T cells still have functional γδ T cells that can produce IFN-γ and provide help for 
antibody class switching (32).            
 Next, an in vivo cytotoxicity assay was performed to determine if CD8+ T cells had 
differentiated into functional CTLs with cytolytic function.  Similar assays have been previously 
performed by other groups (14, 33).  Total splenocytes were purified from control uninfected 
mice and stained with PKH26 dye.  The splenocytes were divided in two groups as described in 
the Materials and Methods.  The unpulsed target group was labeled with a low CFSE 
concentration and was incubated without peptide.  The VSV peptide-pulsed target group was 
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labeled with a high CFSE concentration and was incubated with VSV peptide.  The two groups 
were pooled and i.v. injected into recipient mice that had been infected with VSV 7 days earlier.  
16 hours after transfer of donor cells, splenocytes were purified from the infected recipient mice 
and cell killing of target cells was determined by flow cytometry (Fig. 4.6A).  The calculated % 
Specific Lysis was decreased ICAM-1-/-CD28-/- mice, suggesting that deficiency in both ICAM-1 
and CD28 impaired CTL cytotoxic ability (Fig. 4.6B).   
 To evaluate the memory CD8+ T cell responses, mice were again infected with VSV and 
the % of memory CD8+ T cells specific for VSV peptide was determined 70 days post-infection.  
This should be a sufficient amount of time for the acute response to occur, for effector CTLs to 
die, and for differentiation of memory CD8+ T cells.  Figure 4.7 shows the results for C57Bl/6, 
ICAM-1-/-, and ICAM-1-/-CD28-/- mice.  As expected, the percentage of memory CD8+ T cells 
specific for VSV peptide is lower than the percentage of effector CD8+ T cells that had been 
specific for VSV peptide (Fig. 4.4), since fewer numbers of memory cells are needed for 
surveillance than the number of effector cells needed to combat an acute infection.  Similar to the 
results of the effector CD8+ T cells (Fig. 4.4), ICAM-1-/- mice had a stronger response than 
C57Bl/6 mice and ICAM-1-/-CD28-/- mice.  In contrast, ICAM-1-/-CD28-/- mice had a slightly 
elevated response compared to C57Bl/6 mice, although differences were not statistically 
significant.  The memory response of adoptively transferred T cells from each group of mice was 
also examined (Fig. 4.8).  In this case, ICAM-1-/-CD28-/- transferred CD8+ T cells had the 
greatest IFN-γ response, although there was much variability among mice in this experiment and 
differences between groups were not statistically significant.  The results from the memory 
experiments suggest that there may be less dependence on ICAM-1 and CD28 signaling in either 
the differentiation of memory CD8+ T cells or the initiation of memory responses.  
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Table 4.1.  Antibodies used in this study and the concentrations at which they were tested to 
attempt to induce Treg differentiation.  All antibodies are anti-mouse antibodies with the 
exceptions of the anti-human antibody clones OKT3 and R6.5D6.   
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Table 4.1 
Antibody Clone Concentrations Tested (µg/mL) 
Anti-CD3   
OKT3 0.5 
145-2C11 0.01,  0.05,  0.1,  0.5,  1,  5 
KT3 0.5 
500A2 0.01,  0.05,  0.1,  0.5 
C363.29B 0.5 
Anti-ICAM-1   
R6.5D6 10 
3E2 10,  20 
166623 1,  20 
YN1/1.7.4 10 
BE2961 10,  20 
3E2B 10,  20 
KAT-1 10 
Anti-CD28   
37.51 2.5 
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Figure 4.1.  Stimulation of mouse total T cells through CD3+ICAM-1 does not appear to 
increase proliferation.  Total T cells were isolated from C57Bl/6 mouse spleens, stained with 
CFSE, and stimulated in vitro using anti-CD3 (clone 500A2, used at 0.5 µg/mL) alone or in 
combination with anti-ICAM-1 (clones KAT-1 or YN1/1.7.4, used at 10 µg/mL) or anti-CD28 
(clone 37.51, used at 2.5 µg/mL).  Proliferation was assessed at Day 5 of stimulation by CSFE 
dilution.  Representative of one experiment using mouse C57Bl/6 total T cells.   
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Figure 4.1 
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Figure 4.2.  Mouse CD4+ T cells stimulated through CD3+ICAM-1 do not differentiate to a Treg 
phenotype unless exogenous cytokines are added.  (A) C57Bl/6 CD4+ T cells were stimulated as 
indicated in the absence of exogenous cytokines for 5 days and analyzed by flow cytometry.  
Representative of 7 experiments for anti-ICAM-1 clone KAT-1 and 3 experiments for clone 
YN1/1.7.4.  Representative of a total of 18 experiments for all anti-ICAM-1 clones tested.  (B) 
C57Bl/6 CD4+ T cells were stimulated as indicated for 5 days in the presence of the exogenous 
cytokines TGF-β1 and IL-2.  Representative of 2 experiments for anti-ICAM-1 clone KAT-1 and 
3 experiments for clone YN1/1.7.4.    
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Figure 4.2 
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Figure 4.3.  Mouse CD4+ T cells stimulated through CD3+ICAM-1 are not suppressive.  
Suppression assays were performed using total T cells isolated from splenocytes as responder 
cells, and cells previously stimulated using the indicated stimulation treatments as potential 
suppressor cells.  CD4+ T cells from mouse spleens were stimulated for 5 days using anti-CD3 
(clone 500A2, used at 0.5 µg/mL) plus either anti-ICAM-1 (clone YN1/1.7.4, used at 10 µg/mL) 
or anti-CD28 (used at 2.5 µg/mL).  Where indicated, the cytokines TGF-β1 and IL-2 were added 
to cultures.  After 5 days of stimulation the cells were spun over Lympholyte-M to remove dead 
cells, and the recovered live cells were added to the CFSE-labeled responder cells at a 1:2 
Stimulated:Responder cell ratio.  In some experiments, the actual ratio of Stimulated:Responder 
cells used was less than 1:2.  The co-cultured cells were stimulated using anti-CD3 plus anti-
CD28 antibodies for 3-5 days and proliferation of the responder cells was analyzed using flow 
cytometry.  Representative of 4 experiments.   
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Figure 4.3 
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Figure 4.4.  CD8+ T cells from ICAM-1-deficient and ICAM-1/CD28-double deficient mice 
produce IFN-γ after VSV infection.  (A) C57Bl/6, ICAM-1-/-, and ICAM-1-/-CD28-/- mice were 
infected i.v. with 1x106 PFU of VSV.  Seven days after infection, splenocytes were isolated from 
infected mice and cultured for 5-6 hours in the presence or absence of VSV peptide specific for 
MHC Class I as described in the Materials and Methods and Appendix Protocol 8.  After 
incubation, the splenocytes were stained for CD8, F4/80, and intracellularly for expression of 
IFN-γ and analyzed by flow cytometry.  Macrophages were excluded from the analysis by gating 
out the F4/80+ cells.  The percentage shown in the upper right quadrants represents the 
percentage of CD8+ T cells that were IFN-γ+.  This value was calculated as: [# IFN-γ+CD8+ 
cells/(# IFN-γ+CD8+ cells + # IFN-γ(-)CD8+ cells)] x 100%.  Representative of 3-8 mice per 
group.  (B) The data in panel (A) are shown as the mean +/- SEM for each group.  One-way 
ANOVA and Tukey’s Multiple Comparison post-test were performed to compare the results 
from each group of mice.  The asterisk indicates a statistically significant difference between the 
percentage of CD8+ cells producing IFN-γ in the splenocyte culture from ICAM-1-/- mice 
compared to ICAM-1-/-CD28-/- mice (* p < 0.05).    
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Figure 4.4. 
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Figure 4.5.  Adoptively transferred T cells from ICAM-1-deficient and ICAM-1/CD28-double 
deficient mice produce IFN-γ after VSV infection.  (A) T cells were purified from C57Bl/6, 
ICAM-1-/-, and ICAM-1-/-CD28-/- mice and transferred by i.v. injection into TCRβ-/- mice.  Four 
weeks after adoptive T cell transfer, these TCRβ-/- recipient mice were infected i.v. with 1x106 
PFU of VSV.  Seven days after infection, splenocytes were isolated from infected mice and 
cultured for 5-6 hours in the presence or absence of VSV peptide specific for MHC Class I.  
After incubation, the splenocytes were stained for CD8, F4/80, and intracellularly for expression 
of IFN-γ and analyzed by flow cytometry.  Macrophages were excluded from the analysis by 
gating out the F4/80+ cells.  The percentage shown in the upper right quadrants represents the 
percentage of CD8+ T cells that were IFN-γ+.  Representative of 4-7 mice per group.  (B) The 
data in panel (A) are shown as the mean +/- SEM for each group.  One-way ANOVA and 
Tukey’s Multiple Comparison post-test were performed to compare the results from each group 
of mice.  There were no statistically significant differences among the groups.       
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Figure 4.5 
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Figure 4.6.  CD8+ T cells from ICAM-1-deficient and ICAM-1/CD28-double deficient mice 
have cytolytic function in vivo.  (A) In vivo cytotoxicity assays were performed as described in 
the Materials and Methods and Appendix Protocol 12.  CFSElo cells represent control 
splenocytes and CFSEhi cells represent splenocytes loaded with VSV peptide.  CFSElo and 
CFSEhi cells from uninfected donor mice were i.v. injected into VSV-infected mice at a 1:1 ratio.  
Sixteen hours after cell transfer, splenocytes were isolated from the mice and the proportion of 
donor cells killed by the recipient mouse’s immune system was determined by flow cytometry.  
Before analysis, autofluorescent cells were gated out, and PKH26+ transferred cells were gated 
on to give the plots shown in (A).  Percentages of cells in the CFSElo and CFSEhi peaks are 
shown.  Representative of 3-4 mice per group.  (B) The data in panel (A) were used to calculate 
the % Specific Lysis as described in the Materials and Methods.  Results are shown as the mean 
+/- SEM for each group.  One-way ANOVA and Tukey’s Multiple Comparison post-test were 
performed to compare the results from each group of mice.  The asterisks indicate statistically 
significant differences between the percent specific lysis by C57Bl/6 mice compared to ICAM-1-
/-CD28-/- mice (* p < 0.05), and the percent specific lysis by ICAM-1-/- mice compared to ICAM-
1-/-CD28-/- mice (* p < 0.05).      
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Figure 4.6 
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Figure 4.7.  A CD8+ T cell memory response is generated in ICAM-1-deficient and ICAM-
1/CD28-double deficient mice after VSV infection.  (A) C57Bl/6, ICAM-1-/-, and ICAM-1-/-
CD28-/- mice were infected i.v. with 1x106 PFU of VSV.  Seventy days after infection, 
splenocytes were isolated from infected mice and cultured and cultured for 5-6 hours in the 
presence or absence of VSV peptide specific for MHC Class I.  After incubation, the splenocytes 
were stained for CD8, F4/80, and intracellularly for expression of IFN-γ and analyzed by flow 
cytometry.  Macrophages were excluded from the analysis by gating out the F4/80+ cells.  The 
percentage shown in the upper right quadrants represents the percentage of CD8+ T cells that 
were IFN-γ+.  Representative of 3-4 mice per group.  (B) The data in panel (A) are shown as the 
mean +/- SEM for each group.  One-way ANOVA and Tukey’s Multiple Comparison post-test 
were performed to compare the results from each group of mice.  The asterisks indicate 
statistically significant differences between the percentage of CD8+ cells producing IFN-γ in the 
splenocyte culture from C57Bl/6 mice compared to  ICAM-1-/- mice (*** p < 0.001), and the 
percentage of CD8+ cells producing IFN-γ in the splenocyte culture from ICAM-1-/- mice 
compared to ICAM-1-/-CD28-/- mice (** p < 0.01).  
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Figure 4.7 
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Figure 4.8.  A CD8+ T cell memory response is generated after VSV infection in TCR-β-/- mice 
with adoptively transferred T cells from ICAM-1 and ICAM-1/CD28 double deficient mice.  (A) 
T cells were purified from C57Bl/6, ICAM-1-/-, and ICAM-1-/-CD28-/- mice and transferred by 
i.v. injection into TCRβ-/- mice.  Four weeks after adoptive T cell transfer, these TCRβ-/- recipient 
mice were infected i.v. with 1x106 PFU of VSV.  Seventy days after infection, splenocytes were 
isolated from infected mice and cultured for 5-6 hours in the presence or absence of VSV peptide 
specific for MHC Class I.  After incubation, the splenocytes were stained for CD8, F4/80, and 
intracellularly for expression of IFN-γ and analyzed by flow cytometry.  Macrophages were 
excluded from the analysis by gating out the F4/80+ cells.  The percentage shown in the upper 
right quadrants represents the percentage of CD8+ T cells that were IFN-γ+.  Representative of 
3-5 mice per group.  (B) The data in panel (A) are shown as the mean +/- SEM for each group.  
One-way ANOVA and Tukey’s Multiple Comparison post-test were performed to compare the 
results from each group of mice.  There were no statistically significant differences among the 
groups.        
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Figure 4.8 
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DISCUSSION 
 Following our studies using human naïve CD4+ T cells, we asked if costimulation 
through ICAM-1 yielded similar differentiation when using mouse CD4+ T cells.  Activation 
and differentiation might be predicted to be similar since the extracellular domains of human and 
mouse ICAM-1 are similar.  However, there could be differences due to interspecies variations 
such as the nonconserved regions in the cytoplasmic domain of ICAM-1.  We found that while 
costimulation through ICAM-1 in human naïve CD4+ T cells induces differentiation to Treg and 
memory cells, costimulation through ICAM-1 on mouse CD4+ T cells did not yield inducible 
Treg cells (Fig. 4.2A).  These cells neither expressed Foxp3 nor lead to suppression of responder 
T cell proliferation (Fig. 4.2A, Fig. 4.3).     
 The differences we observed in Treg induction can be speculated to be due to several 
factors.  First, the differences in the intracellular domain of ICAM-1 between human and mouse 
species may determine whether downstream signaling molecules can cause differentiation.  
Secondly, the in vitro system of stimulating ICAM-1 using plate-bound antibodies against 
ICAM-1 has limitations.  Even though we tried six clones of commercially available anti-mouse 
ICAM-1 and one clone of anti-human ICAM-1, we did not observe increased proliferation or 
differentiation to Treg cells (Fig. 4.1, 4.2A).  It is possible that the antibodies we used did not 
bind to motifs on ICAM-1 that would generate the proper signal or signal strength needed for 
activation or differentiation.  Lastly, there could be other yet unidentified differences between 
human and mouse ICAM-1 function that led to the differences we observed.   
 Although many characteristics of the immune system are the same in humans and mice, 
there are differences that have been identified as well (reviewed in (34)).  For example, when 
comparing expression of CD28 on mouse and human T cells, almost all mouse T cells express 
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CD28, while only 80% of human CD4+ T cells and 50% of human CD8+ T cells express CD28.  
After activation, human T cells but not mouse T cells, can express MHC Class II.  In the EAE 
mouse model for multiple sclerosis, blocking IFN-γ protects mice from the disease, but blocking 
IFN-γ actually worsens the disease in patients with MS.  Unfortunately, mouse studies of the 
immune system do not always directly translate to human studies.   
 Despite our lack of evidence that mouse ICAM-1 is involved in Treg induction, there are 
some hints from the literature that ICAM-1 may be involved in Treg function.  ICAM-1 is 
expressed at higher levels on Treg cells versus non-Treg cells in both mice and humans (35, 36).   
Icam1tm1Jcgr mice have fewer Treg cells in peripheral organs and a heightened immune response to 
infection with Mycobacterium tuberculosis (7).  Mice deficient in an ICAM-1 ligand, LFA-1, 
have an approximately 50% decrease in Treg numbers, decreased Treg suppressor function, and 
show an impairment in inducible Treg differentiation (37). 
The effect of removing a particular costimulatory molecule is often dependent upon the 
mouse strain or disease studied.  For example, CD28-deficient mice have a reduced immune 
response to some autoimmune diseases, but a heightened immune response to diabetes in the 
NOD model (38).  As another example, C57Bl/6 mice deficient in ICAM-1 due to the 
Icam1tm1Jcgr mutation have an increased immune response to M. tuberculosis infection (7), but 
are protected from developing diabetes when crossed with an NOD mouse strain (39).  In 
addition, the outcome of EAE induction differed significantly between the Icam1tm1Jcgr  strain 
and the Icam1tm1Bay strain (8).   
 As mentioned above, it has been previously reported that ICAM-1 mutant mice have 
similar percentages of Treg cells in the thymus, but lower percentages of Treg cells in the 
periphery than wild-type mice (7, 40).  The project studying the effects of ICAM-1 and CD28 
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deficiency on the efficacy of anti-viral responses was performed before our project to study Treg 
differentiation began, and before reagents to identify Treg cells were commercially available.  
Therefore, we do not know whether the sometimes heightened CD8+ T cell response to VSV 
seen in the Icam1tm1Jcgr  strain was influenced by a deficiency in Treg numbers or function. 
 Our results looking at IFN-γ production by activated CD8+ T cells demonstrates the 
progression of an anti-viral immune response.  Endogenously there are a low percentage of 
CD8+ T cells specific for a viral antigen, such as the VSV peptide used in our study.  After 
infection, these virus-specific CD8+ T cells become activated and undergo clonal expansion to 
generate a population of cells capable of producing IFN-γ (Fig. 4.4, 4.5) and causing cytolysis of 
target cells (Fig. 4.6).  After the infection has been cleared, memory CD8+ T cells remain that 
are capable of responding to a second challenge with the same infective agent (Fig. 4.7, 4.8).  Of 
course, other cells and cytokines are involved in the anti-viral response, but we chose to focus on 
CD8+ T cells for our initial studies.   
ICAM-1 has multiple roles in the immune system as an adhesion molecule, a 
costimulatory ligand on APCs, and as a costimulatory molecule on human T cells.  Our data in 
Part I suggest that differences may exist between the ability of ICAM-1 on human T cells and 
mouse T cells to influence differentiation.  Results in Part II show that ICAM-1 and CD28 play a 
role in the immune response to VSV, but are not required for the CD8+ T cell response.  A better 
understanding of costimulatory molecule function during immune responses will aid in designing 
effective therapies, such as improved vaccines or treatments for viral infections.   
 
 
 
154 
 
CHAPTER 4 ACKNOWLEDGEMENTS 
 In Part I of this Chapter, I would like to acknowledge the collaboration of former 
graduate students Dr. Abby Dotson and Courtney Gdowski.  Abby collaborated with me in 
testing the different antibody clones by studying expression of the activation marker CD69 and 
differentiation of mouse CD4+ T cells to central memory T cells.  Courtney assisted with the 
mouse T cell suppression assays and some of the experiments to detect differentiation or 
expansion of Treg cells.  In Part II of this Chapter, I would like to acknowledge the substantial 
work of former graduate student Dr. Jake Kohlmeier.  Jake did the initial work to begin this 
project, such as crossing and genotyping the ICAM-1-/-CD28-/- double knockout mice and 
determining the VSV titer.  He performed the initial experiments using VSV infected mice and 
trained me in the procedures so I could finish the remaining experiments after his departure from 
KU.  I would also like to thank the Animal Care Unit, especially Jodi Troup, for training and 
assistance.  The project to study differentiation of mouse CD4+ T cells to Treg cells was 
supported by grants from the Great Plains Diabetes Institute and the KU BIO Center.     
 
 
 
 
 
  
155 
 
REFERENCES 
1. Chirathaworn C, Kohlmeier JE, Tibbetts SA, Rumsey LM, Chan MA, Benedict SH. 
2002. Stimulation through intercellular adhesion molecule-1 provides a second signal for 
T cell activation. J Immunol 168: 5530-7 
2. Williams KM, Dotson AL, Otto AR, Kohlmeier JE, Benedict SH. 2011. Choice of 
resident costimulatory molecule can influence cell fate in human naive CD4+ T cell 
differentiation. Cell Immunol 271: 418-27 
3. Kohlmeier JE, Chan MA, Benedict SH. 2006. Costimulation of naive human CD4 T cells 
through intercellular adhesion molecule-1 promotes differentiation to a memory 
phenotype that is not strictly the result of multiple rounds of cell division. Immunology 
118: 549-58 
4. Xu H, Gonzalo JA, St Pierre Y, Williams IR, Kupper TS, Cotran RS, Springer TA, 
Gutierrez-Ramos JC. 1994. Leukocytosis and resistance to septic shock in intercellular 
adhesion molecule 1-deficient mice. J Exp Med 180: 95-109 
5. Sligh JE, Jr., Ballantyne CM, Rich SS, Hawkins HK, Smith CW, Bradley A, Beaudet AL. 
1993. Inflammatory and immune responses are impaired in mice deficient in intercellular 
adhesion molecule 1. Proc Natl Acad Sci U S A 90: 8529-33 
6. Dunne JL, Collins RG, Beaudet AL, Ballantyne CM, Ley K. 2003. Mac-1, but not LFA-
1, uses intercellular adhesion molecule-1 to mediate slow leukocyte rolling in TNF-alpha-
induced inflammation. J Immunol 171: 6105-11 
7. Windish HP, Lin PL, Mattila JT, Green AM, Onuoha EO, Kane LP, Flynn JL. 2009. 
Aberrant TGF-beta signaling reduces T regulatory cells in ICAM-1-deficient mice, 
156 
 
increasing the inflammatory response to Mycobacterium tuberculosis. J Leukoc Biol 86: 
713-25 
8. Hu X, Barnum SR, Wohler JE, Schoeb TR, Bullard DC. 2010. Differential ICAM-1 
isoform expression regulates the development and progression of experimental 
autoimmune encephalomyelitis. Mol Immunol 47: 1692-700 
9. Siu G, Hedrick SM, Brian AA. 1989. Isolation of the murine intercellular adhesion 
molecule 1 (ICAM-1) gene. ICAM-1 enhances antigen-specific T cell activation. J 
Immunol 143: 3813-20 
10. Johnston SC, Dustin ML, Hibbs ML, Springer TA. 1990. On the species specificity of the 
interaction of LFA-1 with intercellular adhesion molecules. J Immunol 145: 1181-7 
11. Feller SM, Ren R, Hanafusa H, Baltimore D. 1994. SH2 and SH3 domains as molecular 
adhesives: the interactions of Crk and Abl. Trends Biochem Sci 19: 453-8 
12. Lebedeva T, Dustin ML, Sykulev Y. 2005. ICAM-1 co-stimulates target cells to facilitate 
antigen presentation. Curr Opin Immunol 17: 251-8 
13. Kohlmeier JE. 2004. Intercellular Adhesion Molecule-1 (ICAM-1) influences T cell 
activation and development. Ph D thesis. University of Kansas, Molecular Biosciences. 
xvi, 259 leaves pp. 
14. Byers AM, Kemball CC, Moser JM, Lukacher AE. 2003. Cutting edge: rapid in vivo 
CTL activity by polyoma virus-specific effector and memory CD8+ T cells. J Immunol 
171: 17-21 
15. Motulsky H. 2010. Intuitive biostatistics : a nonmathematical guide to statistical 
thinking. New York: Oxford University Press 
157 
 
16. Budd RC, Cerottini JC, Horvath C, Bron C, Pedrazzini T, Howe RC, MacDonald HR. 
1987. Distinction of virgin and memory T lymphocytes. Stable acquisition of the Pgp-1 
glycoprotein concomitant with antigenic stimulation. J Immunol 138: 3120-9 
17. Maraskovsky E, Troutt AB, Kelso A. 1992. Co-engagement of CD3 with LFA-1 or 
ICAM-1 adhesion molecules enhances the frequency of activation of single murine CD4+ 
and CD8+ T cells and induces synthesis of IL-3 and IFN-gamma but not IL-4 or IL-6. Int 
Immunol 4: 475-85 
18. Park HB, Paik DJ, Jang E, Hong S, Youn J. 2004. Acquisition of anergic and suppressive 
activities in transforming growth factor-beta-costimulated CD4+CD25- T cells. Int 
Immunol 16: 1203-13 
19. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM. 2003. 
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells 
by TGF-beta induction of transcription factor Foxp3. J Exp Med 198: 1875-86 
20. Oida T, Xu L, Weiner HL, Kitani A, Strober W. 2006. TGF-beta-mediated suppression 
by CD4+CD25+ T cells is facilitated by CTLA-4 signaling. J Immunol 177: 2331-9 
21. Zhang N, Bevan MJ. 2011. CD8(+) T cells: foot soldiers of the immune system. 
Immunity 35: 161-8 
22. Moseman EA, Iannacone M, Bosurgi L, Tonti E, Chevrier N, Tumanov A, Fu YX, 
Hacohen N, von Andrian UH. 2012. B cell maintenance of subcapsular sinus 
macrophages protects against a fatal viral infection independent of adaptive immunity. 
Immunity 36: 415-26 
158 
 
23. Thomsen AR, Nansen A, Andersen C, Johansen J, Marker O, Christensen JP. 1997. 
Cooperation of B cells and T cells is required for survival of mice infected with vesicular 
stomatitis virus. Int Immunol 9: 1757-66 
24. Shahinian A, Pfeffer K, Lee KP, Kundig TM, Kishihara K, Wakeham A, Kawai K, 
Ohashi PS, Thompson CB, Mak TW. 1993. Differential T cell costimulatory 
requirements in CD28-deficient mice. Science 261: 609-12 
25. Nishina H, Bachmann M, Oliveira-dos-Santos AJ, Kozieradzki I, Fischer KD, Odermatt 
B, Wakeham A, Shahinian A, Takimoto H, Bernstein A, Mak TW, Woodgett JR, Ohashi 
PS, Penninger JM. 1997. Impaired CD28-mediated interleukin 2 production and 
proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein 
kinase kinase 4 (MKK4)-deficient T lymphocytes. J Exp Med 186: 941-53 
26. Andreasen SO, Christensen JE, Marker O, Thomsen AR. 2000. Role of CD40 ligand and 
CD28 in induction and maintenance of antiviral CD8+ effector T cell responses. J 
Immunol 164: 3689-97 
27. McAdam AJ, Farkash EA, Gewurz BE, Sharpe AH. 2000. B7 costimulation is critical for 
antibody class switching and CD8(+) cytotoxic T-lymphocyte generation in the host 
response to vesicular stomatitis virus. J Virol 74: 203-8 
28. Kundig TM, Shahinian A, Kawai K, Mittrucker HW, Sebzda E, Bachmann MF, Mak 
TW, Ohashi PS. 1996. Duration of TCR stimulation determines costimulatory 
requirement of T cells. Immunity 5: 41-52 
29. Parameswaran N, Suresh R, Bal V, Rath S, George A. 2005. Lack of ICAM-1 on APCs 
during T cell priming leads to poor generation of central memory cells. J Immunol 175: 
2201-11 
159 
 
30. Scholer A, Hugues S, Boissonnas A, Fetler L, Amigorena S. 2008. Intercellular adhesion 
molecule-1-dependent stable interactions between T cells and dendritic cells determine 
CD8+ T cell memory. Immunity 28: 258-70 
31. Gaglia JL, Greenfield EA, Mattoo A, Sharpe AH, Freeman GJ, Kuchroo VK. 2000. 
Intercellular adhesion molecule 1 is critical for activation of CD28-deficient T cells. J 
Immunol 165: 6091-8 
32. Maloy KJ, Odermatt B, Hengartner H, Zinkernagel RM. 1998. Interferon gamma-
producing gammadelta T cell-dependent antibody isotype switching in the absence of 
germinal center formation during virus infection. Proc Natl Acad Sci U S A 95: 1160-5 
33. Oehen S, Brduscha-Riem K. 1998. Differentiation of naive CTL to effector and memory 
CTL: correlation of effector function with phenotype and cell division. J Immunol 161: 
5338-46 
34. Mestas J, Hughes CC. 2004. Of mice and not men: differences between mouse and 
human immunology. J Immunol 172: 2731-8 
35. Kohm AP, Carpentier PA, Anger HA, Miller SD. 2002. Cutting edge: CD4+CD25+ 
regulatory T cells suppress antigen-specific autoreactive immune responses and central 
nervous system inflammation during active experimental autoimmune encephalomyelitis. 
J Immunol 169: 4712-6 
36. Knoechel B, Lohr J, Zhu S, Wong L, Hu D, Ausubel L, Abbas AK. 2006. Functional and 
molecular comparison of anergic and regulatory T lymphocytes. J Immunol 176: 6473-83 
37. Wohler J, Bullard D, Schoeb T, Barnum S. 2009. LFA-1 is critical for regulatory T cell 
homeostasis and function. Mol Immunol 46: 2424-8 
160 
 
38. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA. 
2000. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ 
immunoregulatory T cells that control autoimmune diabetes. Immunity 12: 431-40 
39. Martin S, van den Engel NK, Vinke A, Heidenthal E, Schulte B, Kolb H. 2001. Dominant 
role of intercellular adhesion molecule-1 in the pathogenesis of autoimmune diabetes in 
non-obese diabetic mice. J Autoimmun 17: 109-17 
40. Sakaguchi S. 2004. Naturally arising CD4+ regulatory t cells for immunologic self-
tolerance and negative control of immune responses. Annu Rev Immunol 22: 531-62 
 
 
  
161 
 
 
 
 
 
 
CHAPTER 5 
 
THE SPECIFIC COSTIMULATORY SIGNAL CAN INFLUENCE NAÏVE 
CD4+ T CELL ACTIVATION AND DIFFERENTIATION OUTCOME 
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ABSTRACT 
The two-signal hypothesis asserts that an antigenic signal plus a costimulatory signal must be 
received by a naïve T cell for full activation and differentiation to occur.  Naïve T cells undergo 
anergy or apoptosis after receipt of a signal through the TCR alone (signal 1) without also 
receiving a costimulatory signal (signal 2).  While the best studied costimulatory molecule is 
CD28, many other proteins on the T cell surface are capable of delivering costimulatory signals.  
Our lab has previously shown that Intercellular Adhesion Molecule-1 (ICAM-1), when expressed 
on the naïve CD4+ T cell surface, can function as a costimulatory molecule to promote T cell 
activation and differentiation.  In this chapter, we investigated some differences in signaling and 
functional outcome after costimulation through ICAM-1 compared to costimulation through 
CD28.   
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INTRODUCTION 
 Naïve T cell differentiation is thought to be influenced by several factors including 1) the 
strength of the TCR signal, 2) polarizing cytokines, and 3) costimulatory molecules expressed on 
the T cell and APC (1-3).  Costimulatory signals 1) enhance cellular proliferation, 2) increase IL-
2 production, 3) promote cell survival, and 4) induce cellular differentiation (4).  TCR signaling 
plus costimulation activates several intracellular signaling pathways to induce gene expression, 
including the NF-κB, NFAT, AP1, and MYC pathways (5).  These changes in gene expression 
influence both activation and regulation of the immune response (6).  In the absence of 
costimulation, the T cell becomes anergic or apoptotic as a mechanism of immune tolerance.   
 While the classic costimulatory molecule is CD28, alternate costimulatory molecules 
include CD2, CD5, CD9, CD27, CD44, CD46, CD81, LFA-1, VLA-4, OX40, 4-1BB, CD40L, 
LIGHT, SLAM, ICOS, and the negative regulatory proteins CTLA-4 and PD-1 (4, 7).  In 
addition, our lab previously determined that ICAM-1 on the T cell surface could function as a 
costimulatory molecule (8).  Some costimulatory molecules such as CD28, LFA-1 (9), and 
ICAM-1 (10) are expressed on naïve T cells.  In contrast, most members of the Tumor Necrosis 
Factor Receptor (TNFR) family, such as OX40, 4-1BB, and CD40L, are not expressed on naïve 
T cells, but rather are upregulated upon T cell activation.  
 There are differing theories regarding the precise function of costimulatory molecules.  
Some studies suggest that costimulatory molecules simply enhance TCR signaling and do not 
deliver unique signals.  One study showed that increasing the dose of antigenic stimulus plus 
costimulation led to changes in the cytokines that T cells secreted, suggesting that costimulatory 
molecules can lower the threshold for activation, but do not favor distinct differentiation 
pathways themselves (11).  Another study found that CD28 signals through some of the same 
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molecules as the TCR, and that costimulation through CD28 will increase or decrease expression 
of genes induced by TCR stimulation, but not induce new genes (5).   
However, other results argue in favor of differences between costimulatory molecules 
and a role greater than simply enhancing TCR signaling.  Our lab and others have showed that 
signaling through CD28 can favor TH2 cytokines and maintain TH1 cytokine signaling, while 
signaling through LFA-1 can favor TH1 cytokines (3, 12).  Our lab also found differences in 
cytokine secretion and cell survival among T cells costimulated by CD28, LFA-1, or ICAM-1 (8, 
10).  Signaling differences have been demonstrated between the Tumor Necrosis Factor Receptor 
(TNFR) family members that are known to signal through TNF receptor-associated factor 
(TRAF) adaptor proteins, and CD28 which is not associated with TRAF (13).  Signaling 
differences were also shown between human naïve CD4+ T cells costimulated through CD28 or 
CD2, since it was shown that CD28 signaling led to greater NF-κB phosphorylation, while CD2 
signaling led to greater S6-ribosomal protein phosphorylation (14).   From the perspective of the 
APC, dendritic cells (DC) can be classified by how they favor different types of T cell responses.  
DC1 cells polarize induce differentiation of TH1 cells, DC2 cells induce TH2 cells, and regulatory 
DC cells induce Treg cells due to the cytokines produced and coreceptors expressed by each 
dendritic cell subset (2, 15).   
In this chapter, we compare signaling and functional outcomes between the costimuli 
ICAM-1 and CD28.  Although both are members of the Immunoglobulin Superfamily, there are 
many differences between these molecules that, in theory, could potentially lead to differences in 
signaling.  CD28 is a transmembrane protein containing one extracellular immunoglobulin (Ig) 
domain, and is often expressed as a homodimer (5).  The ligands of CD28, B7.1 (CD80) and 
B7.2 (CD86), are found on professional APCs.  The intracellular tail of CD28 has been shown to 
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interact with PI3K, Vav1, ITK, TEC, Grb-2, and Lck (5).  ICAM-1 is a transmembrane protein 
with 5 extracellular Ig domains, and is often expressed as a homodimer.  The primary ligands of 
ICAM-1 are expressed on leukocytes and are LFA-1 (CD11a/CD18), Mac-1 (CD18/CD11b) and 
p150,95 (CD18/CD11c).  ICAM-1 was found to associate laterally with IL-2Rα, and HLA Class 
I and II molecules in the HUT-102B2 T cell line and JY B cell line (16, 17).  The proteins that 
interact with the ICAM-1 cytoplasmic tail are still being identified, although data from our lab 
suggests the association of signaling proteins such as Lck and Erk1/2 (18).  Stimulating ICAM-1 
on APCs has been shown to activate the RhoA family of G-proteins, Abl tyrosine kinase, and 
Src-family kinases (19).     
Comparing costimulation through ICAM-1 and CD28 in vitro we show 1) the timing of 
activation and proliferation differ, 2) the cytokines and chemokines secreted differ, and 3) the 
kinases activated differ.  The results presented in this chapter further support the hypothesis that 
the nature of the costimulatory molecule is a factor that influences the outcome of naïve CD4+ T 
cell stimulation.     
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MATERIALS AND METHODS 
Cell Purification 
Naïve CD4+ T cells were isolated from the peripheral blood of healthy donors using the same 
procedure described in the Materials and Methods in Chapter 2 and Appendix Protocol 1.  Naïve 
CD4+ T cells for this study were defined as CD45RA+CD11aloCD27+ or CD45RO(-
)CD11aloCD27+.     
 
Cell Culture Reagents 
Cell culture reagents used in this chapter are the same as those described in the Chapter 2 
Materials and Methods. 
 
Stimulating Antibodies 
The antibody clones, antibody concentrations, method of adhering antibodies to the tissue-
culture plates, and method of antibody-mediated stimulation of cells used in this chapter are the 
same as those described in the Chapter 2 Materials and Methods and Appendix Protocol 3. 
 
Flow Cytometry Antibodies   
Anti-CD25-TriColor was purchased from Caltag/Life Technologies (Carlsbad, CA). 
 
Flow Cytometry Surface Staining 
The flow cytometry staining procedure to detect cell-surface proteins is described in the Chapter 
2 Materials and Methods and Appendix Protocol 4. 
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Flow Cytometry Analysis 
Flow cytometry and data analysis were performed as described in the Chapter 2 Materials and 
Methods. 
 
Luminex 
Cell culture supernates were collected from stimulated cultures and used after clarification by 
centrifugation.  Cytokine and chemokine production was measured using a Human Cytokine 25-
Plex kit (Biosource/Life Technologies, Carlsbad, CA).  The protocol followed was that supplied 
in the manufacturer’s technical manual and used by Dr. Marcia Chan’s lab at Children’s Mercy 
Hospital in Kansas City, MO.  A summary of the protocol will be provided in this chapter.  First, 
the provided 96-well filter plate was washed with Wash Solution.  All washes were performed 
using a vacuum manifold for aspiration.  Next, the 25-plex antibody-coated beads were added to 
the plate, and the plate was washed twice with Wash Solution.  Incubation Buffer was added to 
each well, the standards were added to the appropriate wells, Assay Diluent and the Samples 
were added to the appropriate wells, and the plate was incubated for 2 hours.  The plate was then 
washed twice with Wash Solution.  The biotinylated-detector antibodies were added and 
incubated for 1 hour, and the plate was washed twice with Wash Solution.  Streptavidin-RPE 
was added and incubated 30 minutes, and the plate was washed three times using Wash Solution.  
Finally, 100 µL Wash Solution was added to each well.  Cytokine concentrations were analyzed 
using a Luminex 200 (Luminex, Austin, TX) and STarStation 2.3 software (Applied Cytometry, 
Sheffield, UK).   
 
Kinase Array 
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Cell lysates were prepared using Cell Lysis Buffer from Cell Signaling Technology (Danvers, 
MA) and the manufacturer’s recommended lysis protocol.  The cells analyzed were naïve CD4+ 
T cells that had been stimulated for 4.5 days in culture using either anti-CD3 plus anti-ICAM-1 
antibodies or anti-CD3 plus anti-CD28 antibodies as previously described in the Chapter 2 
Materials and Methods.  To summarize the lysis procedure, stimulated cells were removed from 
the cell culture plate, pooled, centrifuged, and the supernate was aspirated.  The cell pellets were 
resuspended in cold PBS plus Inhibitors solution (containing 0.1 M sodium orthovanadate and 
0.5M EDTA), then centrifuged, and the supernate was aspirated.  The cell pellet was 
resuspended in 100 µL Cell Lysis Buffer (Cell Signaling Technology) with 1 mM PMSF added, 
and incubated for 5 minutes on ice.  Cell lysates were briefly vortexed, then centrifuged for 10 
minutes at 4°C, and supernates were collected.  Next, 100 µL Lysis Buffer was added to the 
pellet, vortexed briefly, and incubated for 5 minutes on ice.  This second step cell lysate was 
centrifuged for 10 minutes at 4°C, and the supernate was added to the supernate collected after 
the first lysis.  Cell lysates were stored at -70°C.  Before use, the lysate protein concentrations 
were determined using a standard Bradford Assay.  Activated kinases were detected using 
Tyrosine Kinase Substrate I CelluSpots Kinase Substrate Arrays (Intavis Bioanalytical 
Instruments AG, Koeln, Germany) and a Phos-Tag 300/460 Phosphoprotein Blot Stain kit 
(Perkin Elmer Life and Analytical Sciences, Inc., Shelton, CT).  The protocol used was that 
supplied in the manufacturers’ technical manuals and used by Dr. Marcia Chan’s Lab at 
Children’s Mercy Hospital.  To summarize the procedure, first, the arrays were blocked in Phos-
Tag Blocking Buffer for 2 hours, then washed briefly with deionized water.  Cell lysates were 
added to 10 µM ATP, 2.5 mM DTT, and HTScan Tyrosine Kinase Buffer (Cell Signaling 
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Technology) and this solution was added to the arrays and incubated for 1.5 hours.  The arrays 
were washed twice in Phos-Tag Wash Buffer, followed by addition of the Phos-Tag Stain and 
incubation for 1 hour.  The arrays were washed three times in Wash/Destain Buffer, then rinsed 
briefly in deionized water and allowed to air dry.  The arrays were analyzed using a Storm 860 
Molecular Imager (Molecular Dynamics/GE Healthcare Life Sciences, Pittsburgh, PA) with 
ImageQuant software (GE Healthcare Life Sciences).  
 
Human Subjects   
Peripheral blood was obtained after informed consent of healthy volunteers.  Procedures were 
approved by The University of Kansas Institutional Review Board.  
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RESULTS 
The kinetics of activation of naïve CD4+ T cells differ when stimulated through ICAM-1 
compared with CD28 
 When performing experiments studying naïve CD4+ T cell activation and differentiation 
in our in vitro culture system, we observed that cells appeared to become activated faster and 
proliferate sooner when they were stimulated through CD3+CD28 compared to being stimulated 
through CD3+ICAM-1.  Former graduate student Jake Kohlmeier had previously shown that 
total T cells costimulated through ICAM-1 had a delay in proliferation compared to total T cells 
costimulated through CD28 (20).  To study the timing of activation of naïve CD4+ T cells after 
costimulation through ICAM-1 or CD28, we analyzed expression of the activation marker CD25 
and proliferation over three time-points.  As expected from previous data, we found that 
activation of naïve CD4+ T cells occurred sooner after costimulation through CD28 than through 
ICAM-1 (Fig. 5.1A,B,C).   At Day 3 of stimulation, a greater proportion of cells expressed 
CD25 (Fig. 5.1B) and had divided at least once (Fig. 5.1C) when they were costimulated by 
CD28 compared with ICAM-1.  The differences between cells stimulated through ICAM-1 and 
CD28 were not statistically significant at Days 5 and 7 of stimulation as the proportion of 
activated cells increased for both sets of stimuli.   
The cytokines produced by naïve CD4+ T cells differ after costimulation through ICAM-1 
compared with CD28 
 After naïve T cells undergo activation, they produce cytokines that help to control the 
immune response and chemokines that direct cell movement during immune responses.  T cell 
subsets are often characterized by the types of cytokines they secrete.  Some cytokines propagate 
an inflammatory response (e.g. IL-6, TNF-α), a TH1/cellular immune response (e.g. IFN-gamma, 
171 
 
IL-12), or a TH2/humoral immune response (e.g. IL-4, IL-5), while some suppress immune 
responses (e.g. IL-10, TGF-β1).  Besides orchestrating cell migration, chemokines can also 
influence T cell differentiation either by acting on the APC or the T cell itself (21).  We 
compared the cytokines and chemokines produced by naïve CD4+ T cells after costimulation 
through ICAM-1 with those produced after costimulation through CD28 using a multiplex 
Luminex assay.  This particular Luminex kit allowed us to analyze 25 cytokines and chemokines 
simultaneously using the same cell culture supernate samples.  It should be noted that this 
experiment was only performed once using cell culture supernates from one subject because the 
intention of this multiplex experiment was to provide preliminary data.  This experiment was 
done in collaboration with Abby Dotson and with assistance from Dr. Marcia Chan and Nicole 
Gigliotti at Children’s Mercy Hospital in Kansas City, MO.   
The cytokines and chemokines we analyzed and their corresponding functions are listed 
in Table 5.1 and are grouped by the classification scheme used by the company that 
manufactured the Luminex kit (i.e. Biosource).  The graphs showing the concentration of each 
cytokine or chemokine versus the Day of Stimulation that the sample was collected are shown in 
Figures 5.2-5.5.  Varying results were observed for each cytokine and chemokine studied.   A 
summary of the results showing which cytokines had highest production after CD3+ICAM-1 
stimulation, highest production after CD3+CD28 stimulation, similar production after each 
stimulation treatment, or were not produced or only produced in low amounts are listed in Table 
5.2.  Each stimulation treatment produced a variety of cytokines.  CD3+ICAM-1 produced 
higher concentrations of some cytokines with immunosuppressive or anti-inflammatory 
properties (e.g. IL-10, IL-1R antagonist), while CD3+CD28 produced higher concentrations of 
172 
 
the pro-inflammatory cytokine IL-17.  Both CD3+ICAM-1 and CD3+CD28 treatments produced 
TH1 (e.g. IFN-γ) and TH2 (e.g. IL-4 or IL-5) cytokines. 
The kinases activated differ after costimulation through ICAM-1 compared with CD28 
 To compare what kinases are activated after costimulation through ICAM-1 or CD28, we 
used Kinase Substrate Arrays.  These arrays consist of a 26 x 76 mm glass slide, containing 384 
peptide substrates in duplicate (768 spots total) per slide.  The peptide substrates are 15-mer 
peptides bound to cellulose by the C-terminus, with an acetylated N-terminus to increase 
stability.  Each peptide substrate has a target kinase with specificity for that substrate. Therefore, 
solutions such as cell lysates containing kinases of interest can be screened.  Detection occurs 
using a Phos-tag dye that binds to phosphoserine, phosphothreonine, and phosphotyrosine 
residues, and is attached to a fluorophore.  This experiment was done in collaboration with Abby 
Dotson and with assistance from Dr. Marcia Chan and Nicole Gigliotti at Children’s Mercy 
Hospital in Kansas City, MO.  It should be noted that this experiment was only performed once, 
since it was intended to provide preliminary data.     
 When we compared lysates from cells stimulated through CD3+ICAM-1 with lysates 
from cells stimulated through CD3+CD28, we found some kinases that weren’t activated (data 
not shown), some kinases that were activated in both cell samples, and some kinases that 
appeared to be specific to one of the stimuli (Fig. 5.6, Table 5.3).  The stimulation time-point of 
4.5 days was chosen because in previous differentiation experiments, this seemed to be a critical 
time-point where naïve CD4+ T cells that had been activated began to differentiate to effector, 
memory, and Treg phenotypes.  Some of the kinases detected were expected to be activated in 
stimulated T cells (e.g. Lck, Syk), while others were more unexpected (e.g. PDGFR, IGF1R).  
173 
 
The results from this kinase array experiment suggest some signaling pathways that might vary 
between ICAM-1 and CD28.         
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Figure 5.1.  Naïve CD4+ T cells costimulated through CD28 undergo activation and 
proliferation sooner than naïve CD4+ T cells costimulated through ICAM-1.  (A) Naïve CD4+ T 
cells were labeled with CFSE and stimulated for between 3-7 days.  Cells were stained for 
expression of CD25 on the days of analysis.  Representative of 3 experiments.  (B) The kinetics 
of CD25 expression are shown as the means for 3 experiments ± SEM.  The asterisk indicates a 
statistically significant difference between the percentage of CD25+ cells after costimulation 
through ICAM-1 and the percentage of CD25+ cells after costimulation through CD28 (paired t-
Test, one tail p<0.05).  (C)  The kinetics of proliferation are shown as the means of 3 
experiments ± SEM.  The asterisks indicate a statistically significant difference between the 
percentage of cells that had divided after costimulation through ICAM-1 and the percentage of 
cells that had divided after costimulation through CD28 (paired t-Test, one tail p<0.01).   There 
were no other significant differences.  
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Figure 5.1.   
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Table 5.1.  The cytokines and chemokines analyzed in the Luminex assay are listed with their 
associated immunological functions (22, 23).   
177 
 
Table 5.1  
Cytokine Function 
Inflammatory Panel   
GM-CSF Growth of hematopoietic progenitor cells; differentiation of granulocytes and 
monocytes   
IL-1β Inflammation 
  
IL-1 Receptor Antagonist Anti-inflammatory 
  
IL-6 Inflammation 
  
IL-8 (CXCL8) Migration of granulocytes and T cells; innate immunity; inflammation 
  
TNF-α Inflammation 
  
Cytokine I Panel   
IFN-γ Activation, growth, and differentiation of T cells, B cells, NK cells, and 
macrophages; TH1 response   
IL-2 Growth and differentiation of T cells, B cells, and NK cells; TH1 response 
  
sIL-2 Receptor Detected in some cancers, infections, and autoimmune and inflammatory 
conditions; function unknown   
IL-4 Growth of B cells, T cells, and monocytes; TH2 response 
  
IL-5 Differentiation of eosinophils; TH2 response 
  
IL-10 Immune suppression; TH2 response 
  
Cytokine II Panel   
IFN-α Resistance to viral infection 
  
IL-7 Growth of T cell and B cell progenitors  
  
IL-12 TH1 response 
  
IL-13 TH2 response 
  
IL-15 Growth and differentiation of T cells and NK cells 
  
IL-17 Response to extracellular pathogens; autoimmunity; inflammation  
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Chemokine Panel   
Eotaxin (CCL11) Migration of eosinophils, basophils, and mast cells; degranulation; TH2 response 
  
IP-10 (CXCL10) Migration of T cells; promotion of atherosclerosis; TH1 response 
  
MCP-1 (CCL2) Migration of monocytes, basophils, T cells, NK cells, and progenitor cells; CD4+ T 
cell differentiation; innate immunity; TH2 response   
MIG (CXCL9) Migration of T cells and progenitor cells; TH1 response 
  
MIP-1α (CCL3) Migration of monocytes, granulocytes, dendritic cells, T cells, B cells, NK cells, 
and progenitor cells; CD4+ T cell differentiation; innate immunity; TH1 response   
MIP-1β (CCL4) Migration of monocytes, dendritic, T cells, NK cells, and progenitor cells; innate 
immunity; TH1 response   
RANTES (CCL5) Migration of granulocytes, dendritic, T cells, and NK cells; innate immunity; TH1 
and TH2 responses    
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Figure 5.2.  Luminex “Inflammatory” Panel.  Cell culture supernates were collected and 
analyzed by Luminex for the following analytes: A) GM-CSF, B) IL-1β, C) IL-1 Receptor 
Antagonist, D) IL-6, E) IL-8, F) TNF-α.  Medium = complete RPMI medium, NS = 
nonstimulated (nonstimulated cell supernates were collected after 1 hour in culture).  Data are 
the mean of duplicate samples from one experiment. 
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Figure 5.2 
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Figure 5.3.  Luminex “Cytokine I” Panel.  Cell culture supernates were collected and analyzed 
by Luminex for the following analytes: A) IFN-γ, B) IL-2, C) sIL-2R, D) IL-4, E) IL-5, F) IL-10.  
Medium = complete RPMI medium, NS = nonstimulated.  Data are the mean of duplicate 
samples from one experiment. 
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Figure 5.3 
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Figure 5.4.  Luminex “Cytokine II” Panel.  Cell culture supernates were collected and analyzed 
by Luminex for the following analytes: A) IFN-α, B) IL-7, C) IL-12, D) IL-13, E) IL-15, F) IL-
17.  Medium = complete RPMI medium, NS = nonstimulated.  Data are the mean of duplicate 
samples from one experiment. 
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Figure 5.4 
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Figure 5.5.  Luminex “Chemokine” Panel.  Cell culture supernates were collected and analyzed 
by Luminex for the following analytes: A) Eotaxin, B) IP-10, C) MCP-1, D) MIG, E) MIP-1α, F) 
MIP-1β, G) RANTES.  Medium = complete RPMI medium, NS = nonstimulated.  Data are the 
mean of duplicate samples from one experiment. 
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Figure 5.5 
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Table 5.2.  Summary of Luminex results indicating the stimulation treatment that favored 
production of each cytokine and chemokine.  
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Table 5.2 
Higher 
Concentrations 
with CD3+ICAM-1 
Higher 
Concentrations 
with CD3+CD28 
Similar 
Concentrations 
with Both Stimuli 
Low 
Concentrations 
with Both Stimuli           
(< 50 pg/mL) 
        
IL-1R antagonist TNF-α GM-CSF IL-6 
IL-8/CXCL8 IL-2 IL-1β IFN-α 
sIL-2Rα IL-17 IFN-γ Eotaxin/CCL11 
IL-4 MIP-1β/CCL4 IL-5 IP-10/CXCL10 
IL-10   IL-7   
IL-12   IL-13   
IL-15   MCP-1/CCL2   
MIP-1α/CCL3   MIG/CXCL9   
RANTES/CCL5       
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Figure 5.6.  Kinase Substrate Array.  Naïve CD4+ T cells were stimulated for 4.5 days through 
either CD3+ICAM-1 or CD3+CD28.  Cell lysates were prepared and a Kinase Substrate Array 
experiment was performed as described in the Materials and Methods.  Densitometry was used to 
assign a score to each spot by calculating the % Difference from Background using the equation: 
[(Densitometry value of spot – Average densitometry value for negative control spots)/ Average 
densitometry value for negative control spots] x 100%.  Negative control spots used in 
calculating the % Difference from Background score are outlined in blue.  Duplicate spots that 
both had a score equal to or greater than 3.0 are outlined in red and listed in Table 5.3.  Data 
were collected from one experiment.      
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Figure 5.6 
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Table 5.3.  The kinases that are expected to phosphorylate the spots identified in Figure 5.6 are 
listed along with their corresponding full names and common alternative names.  The OMIM 
(Online Mendelian Inheritance in Man) website (www.omim.org) was referenced order to obtain 
the relevant information in the table.  
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Table 5.3 
Kinase Description/Alternative Names 
CD3+ICAM-1 Array   
InsR Insulin receptor 
Met HGFR (hepatocyte growth factor receptor) 
Csk cytoplasmic tyrosine kinase; c-Src tyrosine kinase 
PDGFR group Platelet-derived growth factor receptor group 
PKCα Protein kinase C, alpha 
PKCε Protein kinase C, epsilon 
CD3+CD28 Array   
ErbB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2; HER-2/neu 
FAK Focal adhesion kinase; PTK2 (protein-tyrosine kinase) 
Lck Lymphocyte-specific protein-tyrosine kinase; p56 
Src group v-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene group 
Both Arrays   
EGFR Epidermal growth factor receptor; ErbB1; HER1 
FLT3 Fms-related tyrosine kinase 3; STK1 (stem cell tyrosine kinase 1) 
IGF1R Insulin-like growth factor 1 receptor 
Lyn v-yes-1 Yamaguchi sarcoma viral related oncogene homolog 
PDGFRβ Platelet-derived growth factor receptor, beta 
Src v-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene  
Syk Protein-tyrosine kinase Syk; spleen tyrosine kinase 
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DISCUSSION 
The results shown in this chapter suggest that there are differences in both signaling and 
functional outcome after ligation of ICAM-1 versus CD28 during naïve CD4+ T cell activation.  
Activation occurs more rapidly after costimulation through CD28 than through ICAM-1 (Fig. 
5.1).  One possible explanation for this result is the higher expression of CD28 on naïve CD4+ T 
cells.  It is possible that ICAM-1 expression must be upregulated before signaling using anti-
ICAM-1 can occur effectively.  Another possibility would be if CD28 delivered a stronger 
costimulatory signal leading to more rapid activation, or if cytokines that promoted activation 
were secreted earlier after CD28 costimulation.     
There were differences in cytokine and chemokine secretion between CD3+ICAM-1 and 
CD3+CD28 stimulation detected in the Luminex assay (Fig. 5.2-5.5).  Usually the peak cytokine 
concentration occurs between Days 7-21 of stimulation, but in some cases, cytokine secretion 
occurs sooner with CD3+CD28 which corresponds with the faster activation shown in Figure 
5.1.  In this Luminex experiment, we found that both ICAM-1 and CD28 could produce both TH1 
and TH2 cytokines.  These results differ from those previously obtained from our lab using 
ELISA, which showed that ICAM-1 could induce IFN-γ and IL-2, but not IL-5, while CD28 
could induce secretion of all three cytokines (8).  However, there are differences between the 
methodology of these experiments in both the type of cell populations studied (total T cells 
previously and naïve CD4+ T cells in this chapter) and the timing of analysis (24 hours of 
stimulation previously and 1-21 days in this experiment).  Also, it should be noted that this 
Luminex experiment studied cytokine secretion using cells from one subject, and is therefore 
preliminary.  
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Although preliminary, some of the differences in cytokine/chemokine secretion were 
especially interesting to us.  One such result was that higher levels of MIP-1α (CCL3) and 
RANTES (CCL5) were secreted after costimulation through ICAM-1, while higher levels of 
MIP-1β (CCL4) were secreted after costimulation through CD28 (Fig. 5.5).  These data 
correspond with a gene array that former graduate student Jake Kohlmeier performed in which 
he found higher MIP-1α and RANTES (but not MIP-1β) mRNA expression after costimulation 
through ICAM-1 when compared with costimulation through CD28 (24) and a previously 
published study that showed RANTES production after stimulation of ICAM-1 on human 
bronchial epithelial cells (25).  MIP-1α can bind to the chemokine receptors CCR1 and CCR5, 
while RANTES can bind to CCR1, CCR3, CCR5, Duffy, and D6, and MIP-1β can bind to 
CCR5, CCR8, and D6, and is an antagonist for CCR1 (22).  A recent paper showed that TGF-β-
induced mouse Treg cells could secrete MIP-1α and MIP-1β, and these chemokines could 
enhance the in vitro migration of other Treg cells as well as suppress autoimmune gastritis in vivo.  
In contrast, effector T cells could secrete RANTES, and this chemokine could enhance the in 
vitro migration of other effector cells (26).  So even though MIP-1α, MIP-1β, and RANTES 
share the receptors CCR1 and CCR5, they can exert different effects on the immune system.     
Another interesting result in the Luminex experiment was the high secretion of soluble 
IL-2Rα (sIL-2Rα/soluble CD25) after CD3+ICAM-1 stimulation.  This was interesting since we 
observe a population of Foxp3hiCD25+ Treg cells after costimulation through ICAM-1 (Chapter 2, 
(27)).  However, we cannot determine whether the sIL-2Rα detected had been cleaved from the 
surface of the Treg cells in our culture or another cell subset that expresses IL-2Rα/CD25.  The 
precise function for sIL-2Rα is unknown, although it is detected in the serum of patients with 
some cancers, infections, autoimmune diseases, and inflammatory diseases.  Two recent papers 
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proposed opposing roles for sIL-2Rα released by Treg cells in mediating suppression.  One group 
hypothesized that Treg cells may release sIL-2Rα to bind IL-2 and prevent the IL-2 from being 
able to help activate effector T cells.  They showed that recombinant sIL-2Rα could decrease 
anti-CD3 plus IL-2 induced T cell proliferation in vitro by 50% (28).  In contrast, another group 
found that rather than blocking the function of IL-2, sIL-2Rα bound to IL-2 could enhance the 
function of IL-2 by increasing Stat5 phosphorylation and promoting differentiation to Treg cells.  
They found that adding sIL-2Rα to anti-CD3 plus IL-2 stimulated T cells in vitro could increase 
proliferation (29).              
We also detected differences in the kinases activated after costimulation through ICAM-1 
versus through CD28 (Fig. 5.6).  The only day studied was Day 4.5 of stimulation, so it is not 
known whether there are kinetic differences in kinase activation or if there are truly different 
kinases activated due to different signaling cascades.  Some of the kinases identified were 
growth factor receptors with tyrosine kinase activity (e.g. PDGFRβ), while some were proto-
oncogenes involved in activation after TCR signaling (e.g. Lck) or in cell proliferation (e.g. Src).     
Because we analyzed cytokine/chemokine secretion and kinase activation from the entire 
population of stimulated naïve CD4+ T cells, we cannot determine which cell population 
secreted each particular cytokine and chemokine or expressed each activated kinase.  It is 
possible that differences found between CD3+ICAM-1 and CD3+CD28 stimulated samples were 
related to the presence of Treg cells that differentiated in the CD3+ICAM-1 stimulated cultures, 
either because the cytokines/chemokines or activated kinases promoted Treg differentiation or 
because the Treg cells themselves expressed these cytokines/chemokines or kinases. 
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With a variety of costimulatory molecules expressed on the T cell surface and the 
corresponding ligands expressed on APCs, the question arises as to why more than one type of 
costimulatory molecule is utilized.  Does stimulating through different costimulatory molecules 
lead to different functional outcomes?  If different functional outcomes exist, are they due to 
differences in signaling, or instead due to other factors?  One possibility is that different 
costimulatory molecules have the same function, but act on different subsets of T cells or at 
different stages of the immune response to produce different outcomes.  A second possibility is 
that the signaling pathways used by different costimulatory  molecules truly differ and therefore 
lead to different outcomes.  These two possibilities are not necessarily mutually exclusive.   
Our data using our in vitro cell differentiation model suggest that differentiation 
outcomes can differ between costimulatory molecules. For example, when comparing 
costimulation of naïve CD4+ T cells between ICAM-1 and CD28, costimulation though either 
molecule can lead to proliferation, protection from apoptosis, and differentiation to effector and 
memory cells (10), but ICAM-1 can and CD28 cannot lead to differentiation of Foxp3hi 
regulatory T cells (27).  Figures 5.2-5.5 in this chapter demonstrate further that cytokine 
production can vary between stimuli.  Our model also suggests that costimulatory molecules can 
use different signaling pathways.  Supporting evidence for this is shown in Figure 5.6 in this 
chapter.   
A possibility not addressed by our data is whether costimulatory  molecules act on 
different subsets of cells.  This seems likely in the context of the many T cell and APC 
populations involved in different stages of the immune response.  Although the naïve CD4+ T 
cells population is generally thought of as primarily a homogeneous population, new evidence 
suggests that subpopulations may exist within the naïve population.  For example, Bendall and 
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colleagues used single-cell “mass cytometry” to group naïve CD4+ T cells into 16 distinct 
subsets based on varied expression of 13 cell-surface antigens (30).  However, it is not known 
whether stimulation of these subsets by ICAM-1 or CD28 would lead to different functional 
outcomes of these newly proposed subsets of naïve cells.    
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DISSERTATION CONCLUSIONS 
Naïve CD4+ T cells that are activated through a TCR antigenic signal plus a 
costimulatory signal can proliferate and differentiate into a variety of T cell subsets.  These 
subsets include effector T cells (e.g. TH1, TH2 cells), memory T cells, and Treg cells.  A variety of 
signals can influence the eventual cell fate of the differentiating naïve CD4+ T cell.  First, cues 
in the microenvironment such as cytokines, chemokines, growth factors, and costimulatory 
ligands expressed by APCs can direct T cell phenotype and function (1).  Second, new evidence 
suggests that naïve CD4+ T cells can be subdivided based on surface molecule expression (2).  
Differential expression of costimulatory ligands or cytokine receptors by the naïve T cell would 
be expected to impact differentiation potential.  In this scenario, the same microenvironment 
could yield distinct differentiation outcomes due to naïve T cell-specific differences.  In this 
dissertation, we presented data that 1) further described the role of ICAM-1 in the activation and 
differentiation of naïve T cells and 2) supported the concept that cell fate can be influenced by 
the costimulatory signal.  
A previously unknown role for ICAM-1 in the generation of inducible regulatory T (iTreg) 
cells was described in Chapter 2.  Stimulation of human naïve CD4+ T cells through 
CD3+ICAM-1 induced a population of cells with a standard Treg phenotype: 
Foxp3hiCD25+CTLA-4+CD127lo (Fig. 2.2).  In contrast, a population of Foxp3hi cells was not 
detected after stimulation through CD3+CD28.  IL-2 signaling was necessary for Treg induction 
in vitro after costimulation through ICAM-1 (Fig. 2.6).  We also verified that the Treg cells 
induced after ICAM-1 costimulation could function to inhibit responder cell proliferation in an in 
vitro suppression assay (Fig. 2.9).   
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In Chapter 3, we studied the in vitro immune responses of naïve CD4+ T cells from older 
individuals, aged 65 years and older.  In contrast to the results obtained with naive CD4+ T cells 
from younger individuals, naïve CD4+ T cells from older individuals did not typically 
differentiate into a subset of Treg cells after costimulation through ICAM-1 (Fig. 3.5).  However, 
the percentage of Foxp3hi cells did increase in one preliminary experiment if exogenous TGF-β1 
and IL-2 were added to the stimulation treatment (Fig. 3.6).  These preliminary data suggest that 
naïve CD4+ T cells from older individuals retained the ability to differentiate to Treg cells, but 
this differentiation was not associated with ICAM-1 signaling.  However, aging did not appear to 
affect the ability of costimulation through ICAM-1 to generate effector and memory T cells (Fig. 
3.4, Abby Dotson’s dissertation).  These in vitro data suggest a skewing of differentiation toward 
effector and memory subsets and away from the Treg subset after naïve CD4+ T cells from older 
individuals are costimulated through ICAM-1. 
Chapter 4 examined the effect of costimulation through ICAM-1 expressed on mouse T 
cells, both in vitro and in vivo.  When mouse CD4+ T cells were stimulated with antibodies 
against CD3 and ICAM-1, we did not detect cells with a Treg phenotype or with suppressive 
function unless exogenous TGF-β1 plus IL-2 were included in the culture conditions (Fig. 4.2, 
4.3).  However, we also did not observe typical signs of costimulation such as increased 
proliferation, which might indicate that the antibodies that were used to attempt to stimulate 
ICAM-1 were not effective.  Another possibility is that the mouse ICAM-1 cytoplasmic domain 
might lack specific motifs necessary for certain signal transduction pathways.  However, our in 
vivo studies that assessed CD8+ T cell cytokine production, cytotoxic ability, and memory T cell 
differentiation during VSV infection suggest that mouse ICAM-1 can function as a signaling 
molecule; although ICAM-1 was not required for the parameters we evaluated (Fig. 4.5, 4.8).  
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Interestingly, ICAM-1-/- mice had slightly elevated immune responses compared to wild-type 
controls.  ICAM-1-/-CD28-/- mice had decreased acute responses compared to ICAM-1-/- mice 
and wild-type controls, but slightly increased memory responses compared to wild-type controls 
(Fig. 4.4-4.8).  Together, these data demonstrate that a deficiency in both of these important 
costimulatory molecules does not completely prevent CD8+ T cell activation, differentiation, and 
function, and may even suggest opposing roles for ICAM-1 and CD28 during the immune 
response to VSV. 
Finally, in Chapter 5, we provided supporting evidence for the concept that differential 
costimulatory signals can help direct T cell differentiation outcome.  Activation and proliferation 
was initiated more rapidly after costimulation through CD28 than through ICAM-1 (Fig. 5.1).  
Data from a preliminary Luminex experiment demonstrated differences in cytokine and 
chemokine secretion after costimulation through ICAM-1 versus CD28 (Fig. 5.2-2.5), while a 
preliminary Kinase Array showed differences in kinase activation (Fig. 5.6).  These results 
indicate distinct signaling profiles and functional outcomes after costimulation through ICAM-1 
compared to costimulation through CD28.       
Our Chapter 2 results demonstrating that a subset of naïve CD4+ T cells costimulated 
through ICAM-1 can differentiate to a population of Foxp3hi Treg cells differ from our results in 
Chapter 3 and Chapter 4 where differentiation to a Treg phenotype does not appear to occur after 
costimulation of naïve CD4+ T cells from older individuals or CD4+ T cells from mice.  It is 
known that IL-2 is essential for Treg differentiation (3), and this IL-2 requirement was confirmed 
in our system as well (Fig. 2.6).  We did not assess IL-2 secretion when naïve CD4+ T cells were 
obtained from older individuals or when CD4+ T cells were obtained from mice, so we do not 
know whether IL-2 production was normal or impaired.  In the case of the mouse CD4+ T cells, 
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two other possibilities for a lack of Treg induction are mentioned above.  It is worth noting that 
cells from an older individual (Fig. 3.6) or from mice (Fig. 4.2) that were stimulated in the 
presence of exogenous IL-2 plus TGF-β1 did display a Foxp3hi Treg phenotype.  It might be 
useful to determine if there are any phenotypic or functional differences between cytokine-
induced Treg cells that differentiate in the presence of CD3+ICAM-1 stimulation versus 
CD3+CD28 stimulation.      
Another interesting observation in Chapter 4 was that the immune response to VSV was 
lowered in ICAM-1-/-CD28-/- mice, but slightly heightened in ICAM-1-/- mice.  Because we no 
longer had a colony of CD28-/- mice at the time these experiments were performed, we do not 
know whether the response of the ICAM-1-/-CD28-/- mice would have been intermediate to the 
ICAM-1-/- mice and CD28-/- mice, or lower than the CD28-/- mice.  Also, because we did not test 
for the presence of Treg cells during the VSV experiments, we do not know whether the slightly 
increased response in the ICAM-1-/- mice was due to a Treg defect.  Another group found a 
similarly increased immune response in ICAM-1-/- mice infected with M. tuberculosis, and 
attributed this result to decreased Treg numbers and impaired Treg signaling (4).  However, as 
mentioned in Chapter 4, knocking out specific costimulatory molecules can produce vastly 
different results depending upon the disease model studied. 
Some of the results of costimulation through ICAM-1 were the same as those through 
CD28, while others were different.  For example, our lab has previously published that naïve 
CD4+ T cells costimulated through either molecule can lead to proliferation, protection from 
apoptosis, secretion of IL-2, and differentiation to effector and memory subsets (5).  However, as 
reported here, a subset of Treg cells were also generated after costimulation through ICAM-1, but 
not CD28 (6).  CD8+ T cell responses to VSV were generally slightly increased in mice lacking 
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ICAM-1, while acute CD8+ T cell responses generally decreased in mice lacking both ICAM-1 
and CD28.  In addition, differential cytokine/chemokine and kinase activation profiles were 
observed in preliminary experiments comparing costimulation through ICAM-1 or CD28.  
Together, these results might suggest that some of the signaling pathways utilized by ICAM-1 
and CD28 are shared, leading to some similar outcomes, while other pathways are distinct, 
leading to some unique outcomes.            
 Based on our results, we propose a model whereby the costimulatory signal received by 
the naïve CD4+ T cell can influence differentiation outcome (Fig. 6.1).  We do not know 
whether the observed effect of costimulation on differentiation is due to a direct effect of ICAM-
1 signaling versus CD28 signaling (e.g. determined by differential kinases activated during 
signaling), or rather is an indirect effect (e.g. due to differential cytokine secretion that then 
impacts differentiation).  In addition, we do not know the timing or location that ICAM-1 
costimulation might be especially important during in vivo immune responses.  ICAM-1 will 
interact strongly with its ligands (i.e. β2 integrins) when these ligands are in an active 
conformation (7).  This suggests that costimulation through ICAM-1 would occur when cognate 
antigen is presented by an activated APC.  From our in vitro results, we might also speculate that 
the timing of activation and differentiation might be slower after costimulation through ICAM-1 
compared to CD28, and that ICAM-1 might both initiate effector immune responses and assist in 
Treg-mediated tolerance.    
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Figure 6.1.  The outcome of differentiation can be influenced by costimulation.  Naïve CD4+ T 
cells encounter cognate antigen presented in the context of MHC Class II molecules on APCs 
along with costimulatory signals.  The in vitro data presented in this Dissertation suggest that the 
differentiation possibilities differ when the dominant costimulatory signal is received through 
ICAM-1 compared to CD28.  
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Figure 6.1 
 
 
 
  
211 
 
FUTURE DIRECTIONS 
There are many interesting paths that this research could follow in the future.  As one 
avenue of investigation, it would be important to identify which natural ligands of ICAM-1 can 
provide a costimulatory signal (e.g. LFA-1, Mac-1), or if there is a difference between a signal 
received from LFA-1 versus a signal received from Mac-1.  This study might begin by using 
recombinant proteins instead of stimulating antibodies, or by stimulating using APCs and 
blocking the molecules of interest.  It would also be important to assess how the ligands (i.e. β2 
integrins) might influence ICAM-1 signaling when the β2 integrins are in an active versus an 
inactive conformation.  Work from another group indicates that when LFA-1 or Mac-1 expressed 
on mouse DCs is in an active conformation, DC-T interaction times increase but T cell 
proliferation actually decreases (8, 9).  
It would also be valuable to determine what specific signals initiated by ICAM-1 ligation 
might lead to Foxp3 induction and Treg differentiation, and how they might differ from signals 
from CD28 ligation that did not lead to Treg differentiation.  We do not know whether this is a 
direct effect of ICAM-1 signaling, or is an indirect effect, perhaps mediated by cytokines 
produced after costimulation through ICAM-1.  Some possible cytokines produced after ICAM-1 
costimulation that are implicated in Treg induction are IL-2, TGF-β1, and IL-10.  Our data 
already indicates that IL-2 is necessary for Treg induction (Fig. 2.6).  Windish et al. identified 
that the TGF-β Smad pathway was impaired in ICAM-1-/- mice, but speculated that this was due 
to a lack of signaling through LFA-1  (4).  Our studies indicate that signaling through ICAM-1 
itself on the T cell is important for Treg differentiation.  However, it would be interesting to 
determine if ICAM-1 signaling activates components of the Smad pathway to facilitate Foxp3 
induction.     
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The preliminary Luminex experiment shown in Chapter 5 provided several possibilities 
for further study.  We found that naïve CD4+ T cells costimulated through ICAM-1 produced 
higher concentrations of the chemokines RANTES and MIP-1α than was detected after 
costimulation through CD28 (Fig. 5.5).  This corresponds with data from a gene array previously 
performed by Jake Kohlmeier in our lab (10).  One of our next objectives is to determine which 
cell type is producing these chemokines, which cell types can respond to these chemokines, and 
what type of response these cells have (e.g. migration, differentiation).  Since high levels of 
soluble IL-2Rα (soluble CD25) were detected in supernates from naïve CD4+ T cells 
costimulated through ICAM-1, but not CD28 (Fig. 5.3), it would also be interesting to determine 
which cell type is the source of this soluble cytokine receptor.  Since Treg cells express high 
levels of surface CD25, and Treg cells were found in cultures of naïve CD4+ T cells costimulated 
through ICAM-1 but not CD28, it is tempting to speculate that the Treg cells might be the source 
of the soluble IL-2Rα.  If this were the case, it would be valuable to determine what effect, if 
any, the soluble IL-2Rα has on the function of other leukocytes.   
We demonstrated that the ICAM-1-induced Treg cells can suppress the proliferation of 
responder T cells (Fig. 2.9), but we did not identify the specific mechanism of suppression.  
Potential mechanisms may include perforin, granzyme B, TGF-β, IL-10, or acting an “IL-2 sink” 
(11).  Additional suppression assays could be performed while inhibiting the molecules of 
interest.  Additional flow cytometry staining could be used to detect possible perforin and 
granzyme B expression in Treg cells. 
Understanding the mechanisms by which ICAM-1 costimulation leads to activation and 
differentiation might also possibly assist in the development of immune-targeted therapies.  A 
long-term goal of this research is to determine if ICAM-1 induced Treg cells might be viable for 
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use in adoptive regulatory T cell therapy for diseases such as autoimmunity or transplantation 
tolerance (12, 13).  The research presented in this Dissertation promotes the concept that ICAM-
1 expressed on the naïve T cell surface has distinct roles in both immunity and tolerance and 
should continue to be studied for possible future clinical applications.                     
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ABBREVIATIONS 
 
APC  Antigen Presenting Cell 
CFSE  Carboxyfluorescein diacetate succinimidyl ester 
CTL  Cytotoxic T Lymphocyte 
DTH  Delayed-Type Hypersensitivity 
EAE  Experimental Autoimmune Encephalomyelitis 
ELISA  Enzyme-Linked Immunosorbent Assay 
FOXP3 Forkhead Box P3 
GALT  Gut-Associated Lymphoid Tissue 
GM-CSF Granulocyte-Macrophage Colony-Stimulating Factor 
HSC  Hematopoietic Stem Cell 
ICAM-1 Intercellular Adhesion Molecule-1 
Ig  Immunoglobulin 
IL  Interleukin 
LAP  Latency-Associated Peptide 
LFA-1  Leukocyte Function-associated Antigen-1 
LPAM-1 Lymphocyte Peyer’s patch Adhesion Molecule-1 
LPS  Lipopolysaccharide 
MFI  Mean Fluorescence Intensity 
MHC  Major Histocompatibility Complex 
MLR  Mixed Lymphocyte Reaction 
MS  Multiple Sclerosis 
PBMC  Peripheral Blood Mononuclear Cells 
PBS  Phosphate Buffered Saline 
PHA  Phytohemagglutanin 
RBC  Red Blood Cell 
SEM  Standard Error of the Mean 
TCR  T Cell Receptor 
TGF-β1 Transforming Growth Factor-β1 
TC  T cytotoxic 
TH  T helper 
Treg  T regulatory 
TLR  Toll-Like Receptor 
TNF-α  Tumor Necrosis Factor-α 
TNFR  Tumor Necrosis Factor Receptor 
VLA-4  Very Late Antigen-4 
VSV  Vesicular Stomatitis Virus 
WBC  White Blood Cell 
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APPENDIX 
SELECTED PROTOCOLS 
Protocol 1: Purification of PBMCs from Peripheral Blood 
1. Warm tissue culture (TC) PBS (containing 2% FBS, 1% Penicillin/Streptomycin) at 37° C 
2. After drawing blood: 
-eject blood into appropriately sized bottle or tube depending upon the volume of blood 
 -Dilute 1 part TC PBS : 2 part blood 
 -Gently swirl bottle 
3. Determine number of 50 mL tubes to use 
 -can use 40 mL [blood + TC PBS] per 50 mL tube 
4. Pipet 9 mL Ficoll-Paque PLUS into each tube 
5. Overlay blood over Ficoll 
 -add 25 mL blood to all tubes, then add the remaining 15 mL blood 
 -place pipet tip just above Ficoll and expel blood very slowly 
 -when expelling blood, keep tip above blood and make 2 points of entry 
6. Centrifuge 30 minutes, room temperature, 1800 rpm (Beckman AllegraTM 6R Centrifuge),   
No brake 
7. After blood has spun: 
 -Place four new 50 mL tubes in hood 
 -In the spun tubes, aspirate most of the top (plasma) layer (leave about 10 mL 
above the PBMC layer) 
-Place the pipet tip just above the PBMC layer and move pipet slowly in circle while 
pipetting up PBMC layer (will be about 10 mL) 
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 -Don’t pipet up any RBCs 
 -Pipet PBMCs into the 4 new tubes in approximately equal volumes 
8. Fast spins: 
 -Wash 2x after adding approximately 20 mL TC PBS to each tube 
 -Centrifuge at 2,000 rpm, 10 minutes, room temperature 
 -after the first wash, combine PBMCs into 2 tubes (40 mL TC PBS per tube) 
 -after the second wash, combine PBMCs into 1 tube (40 mL TC PBS per tube) 
9. Slow spins: 
-Wash again (the number of slow spin washes depends upon how much blood is drawn 
and how cloudy the sample is, which indicates how many platelets remain) 
 -Centrifuge at 800 rpm, 10 minutes, room temperature 
10.  Determine PBMC count 
11.  When applicable, proceed to the appropriate magnetic cell separation procedure (e.g. 
StemSep Human Naïve CD4+ T Cell Enrichment Kit) 
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Protocol 2: Purification of Total T cells from Tonsil 
1. Prepare Sheep Red Blood Cells (SRBCs) 
-Dissolve 0.5 g AET in 12.5 mL ddH2O (this amount is appropriate for 15 mL SRBCs) 
 -pH AET solution to pH = 9.0 with NaOH 
 -filter sterilize AET solution through 0.2 µm syringe filter 
-Remove 15 mL SRBCs from bottle by pipetting 
-Eject the SRBCs slowing into a tube 
-Wash the SRBCs (15 mL) with 25 mL cold TC PBS (containing 1% Penicillin/Streptomycin)  
 -centrifuge at 4°C, 2000 rpm (Beckman AllegraTM 6R Centrifuge), 10 minutes 
 -should yield approximately a 5 mL pellet of SRBCs 
-Add 12 mL AET solution to SRBC pellet, resuspend  
-Place in 37°C water bath for 20 minutes 
-Add 25 mL cold TC PBS 
-Wash 3x (or until supernate is clear) at 30 mL total volume 
-Centrifuge each time at 2000 rpm, 10 minutes, 4°C, aspirate supernate 
-Resuspend RBCs in TC PBS (add 25 mL to the 5 mL pellet) 
 
2. Purify WBCs from Tonsils 
-Place 5  50 mL tubes in hood (4 are for Tonsil cells and 1 is for Ficoll) 
-Aspirate any extra fluid in the tonsil tube (Flame opening of tonsil tube before and after 
opening) 
-Place 1 medium (20 mL) Petri dish in hood 
-Open foil-wrapped tools in hood, put strainer in Petri dish 
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-Dip tonsil into 70% ethanol solution for 5 seconds, then dip tonsil into complete RPMI 1640 
medium to wash 
-Place tonsils into strainer 
-To remove cells from the tonsil: 
-Add approximately 45 mL warm TC PBS (containing 2% FBS, 1% 
Penicillin/Streptomycin) to strainer 
-Use forceps and scissors to cut tonsil into small pieces 
-Lift strainer  
-Use a 10 mL pipet to wash the tonsil 3x with the cell solution 
-Pipet cell solution into the 4 tubes 
-Repeat this process 2x, but also use the pestle to gently mash the tonsil tissue 
-Should end with approximately 30 mL cell solution per tube 
-Ficoll underlay: 
-Place approximately 45 mL Ficoll in the 5th tube in the hood 
-Add Ficoll to the 4 cell solution tubes at a 1:3 Ficoll:WBC solution ratio 
-Place pipet tip at bottom of tube and slowly add Ficoll 
-centrifuge 1800 rpm, 30 minutes, room temperature, minimum brake 
-Separating the WBCs: 
-Place 2  50 mL tubes in hood 
-When Ficoll and WBC solution tubes have finished spinning, aspirate some of the top 
(TC PBS) layer 
-Use a 10 mL pipet to remove WBC layer (place tip at WBC/TC PBS interface) 
-Don’t remove any RBCs 
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-Transfer WBCs to the 2 tubes in hood 
-Add 20-25 mL warm TC PBS to tubes  
-Wash WBCs: centrifuge 1800 rpm, room temperature, 8 minutes 
-Aspirate supernates, combine pellets from the 2 tubes, add 20 mL warm TC PBS to each 
pellet, resuspend, and combine into 1 tube) 
-Wash again, 1800 rpm, room temperature, 8 minutes 
-Remove supernate from pelleted cells, resuspend in 40 mL warm TC PBS 
3. Purify Total T Cells from the WBCs 
-Determine WBC concentration using hemacytometer: 
-Resuspend cells in the volume of warm TC PBS so the cells are at a concentration of 6.7 x 106 
cells/mL 
-Add up to 30 mL of WBC solution to new tubes 
-Add warm TC PBS to each tube to bring total volume to 30 mL 
-Add prepared SRBC solution at a 1:10 ratio  
-An alternative to counting cells on hemacytometer: 
-Add 25 mL TC PBS + FBS to 8  50 mL tubes 
-Add 5 mL of cell solution to each tube 
-Add 3 mL prepared SRBC solution per tube 
-After the cells have been diluted to the proper concentration and the SRBCs have been added: 
-Put tubes in the 37°C incubator for 10 minutes 
-Centrifuge tubes 10 minutes, 4°C, 2000 rpm 
-Place WBC-RBC tubes (with pellet) on ice for 30 minutes 
-Place RPMI 1640 complete medium and the ACT bottle in the 37°C H2O bath 
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-Carefully resuspend cells (still at 33 mL) 
-Do a Ficoll underlay (at 1:3 Ficoll:Cell solution ratio) 
-Add 10 mL Ficoll per tube by placing pipet tip at bottom of tube and slowly ejecting the Ficoll 
-Centrifuge tubes 30 minutes, 1800 rpm, 4°C, minimum brake 
-Return centrifuge temperature to 20°C after this spin 
-Aspirate everything but the pellet (contains SRBCs bound to T cells) 
-Aspirate the B cell layer first, then move aspirator pipet tip in circle on top of liquid  
-Treat the pellets with ACT 
 -Add ACT at the same volume as you used Ficoll (10 mL per tube) 
 -Resuspend pellets and combine the solutions into 2 or more tubes 
-Put tubes in 37°C water bath for approximately 7 minutes 
 -Remove the tubes after the solution has become darker red and less turbid 
-Add enough warm TC PBS to go to 50 mL, mix by pipetting 
-Centrifuge 8 minutes, room temperature, 1800 rpm 
-Remove supernate and wash again 2x (add 20 mL warm TC PBS, resuspend, centrifuge 8 
minutes, room temp, 1800 rpm) 
-Remove supernate, resuspend cells in 50 mL complete RPMI 1640 medium 
-Count T cells on hemacytometer and dilute the cell solution to 5x106 cells/mL 
-Pipet T cell solution into a large Petri dish and incubate overnight in 37°C incubator 
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Protocol 3: Plate-Bound Antibody Stimulation 
 
1. Calculate the volume of each antibody (Ab) needed for 200 µL/well (for 96-well plate) of 
stimulating Ab solution.  Antibodies are diluted in sterile PBS to make stimulating Ab solution. 
 
2. Add 200 µL stimulating Ab solution per well and incubate in 37ºC incubator for 2 hours, or at 
4ºC overnight. 
 
3. Wash each well 3x with sterile PBS (with multi-channel pipet if doing multiple wells). 
With each wash, pipet out 200 µL of solution and discard, and then add 200 µL sterile PBS to 
the well.  Take care not to let wells sit dry for too long during washes or before adding cells. 
 
4. After washes, add cells to the 96-well plate at a concentration range of 1x106 cells/ml to 2x106 
cells/ml by adding 200 µL of cells in complete RPMI 1640 medium per well (RPMI 1640 
without L-glutamine + 10% FBS + 1% Pen/Strep + 1% L-glutamine).  This is equal 200,000 to 
400,000 cells per well.  The number of cells to use depends upon the particular experiment being 
performed.   
 
5. Incubate plate at 37ºC in incubator for the determined time to stimulate cells. 
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Protocol 4:  Flow Cytometry Staining of Cell Surface Molecules 
 
Staining Controls for Setting Flow Cytometer Parameters 
-Unstained Cell Sample 
-Cell Sample Single-Stained with FL1 (FITC) Ab only 
-Cell Sample Single-Stained with FL2 (PE) Ab only 
-Cell Sample Single-Stained with FL3 (PE-Cy5) Ab only  
-Cell Samples stained with Abs plus with appropriate Isotype controls (if needed) 
 
Staining Cell Surface Molecules 
1. Prepare Staining Buffer (DPBS + 0.5% BSA), place in ice 
2. Centrifuge cell samples (using Eppendorf Centrifuge 5417R at 4,000 rpm (1699 g) for 3 
minutes at 4°C or using Labnet Spectrafuge 24D at 4,400 rpm (1700 g) for 3 minutes at room 
temperature), aspirate supernate  
3. Resuspend cells in 100 µL Staining Buffer, Incubate on ice for 15 minutes 
4. Centrifuge cell samples, resuspend in 100 µL Staining Buffer + Ab (1˚ Ab conjugated to 
fluorochrome)   
Note: The proper amount of Ab to use varies, so each Ab should be titrated before use 
5. Incubate cells in Ab for 20 minutes, on ice, in dark 
 Note: If the signal is too dim, the time for this incubation step can be increased 
6. Wash: Add 500-900 µL Staining Buffer to sample, centrifuge cells, aspirate supernate (can 
wash again in Staining Buffer if needed) 
7. Centrifuge cells, aspirate supernate, resuspend in 400 µL Staining Buffer 
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8. Pipet cell solution into flow cytometry tubes  (If using the Accuri C6 flow cytometer, the cells 
can be resuspended in 200 µL volume in Step 7, and the cell solution can remain in Eppendorf 
tubes) 
9. Keep on ice in the dark 
10. Analyze on flow cytometer (or if waiting until the next day to analyze, add 
Paraformaldehyde solution to the cell solution so the final paraformaldehyde concentration is 
between 2-4%).  Store at 4°C in the dark.  
 
Notes: Add paraformaldehyde solution to a final concentration of between 2-4% 
paraformadehyde before flow cytometry analysis when using primary human cells or potentially 
infectious samples.  Use caution when using paraformaldehyde due to its toxicity. 
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Protocol 5: Procedure for Removal of Antibody-Cytokine Complexes from Stimulated Cell 
Culture Supernates 
 
-Use Protein G Sepharose 4 Fast Flow (Amersham/GE) so Rat IgG1 isotype can bind 
-Protein G is at 75% in a 20% ethanol solution 
1. Remove [30 µL Protein G solution x  # samples] from stock inside hood 
2. Centrifuge at 4°C, 1 minute, 11,000 rpm, aspirate supernate 
3. Resuspend at 50% in 100 mM Tris pH 8.0 
4. Centrifuge again, aspirate 
5. Perform this wash 5x 
6. Resuspend at 50% in 100 mM Tris pH 8.0  
7. Add 30 µL solution to (# samples)  tubes  
8. Centrifuge, aspirate 
9. Add 110 µL appropriate culture supernate to appropriate tube 
10. Gently agitate tubes at 4°C for 60 minutes (shake 30 minutes, rotate 30 minutes)  
11. Centrifuge, SAVE SUPERNATE 
12. Centrifuge supernate collected in previous step, SAVE SUPERNATE  
13. Supernates are ready for ELISA procedure 
14. Save remaining supernates at -70°C 
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Protocol 6: CFSE Staining Protocol 
 
-CFSE is from Molecular Probes (catalog # C1157), store at -20°C  
-Make a stock solution of 5 mM CFSE in DMSO 
 -use sterile DMSO and add to the CFSE vial, then aliquot into several Eppendorf tubes 
-Store stock solution at –20°C in the dark, with a desiccant present 
 
1. Label human cells with 2.5 μM CFSE for 10 minutes at 37°C (in water bath) in the dark 
(tubes covered in foil) in serum-free medium (e.g. add 2.5 μL of 5 mM stock to 5 mL of cells in 
serum-free RPMI 1640 medium) 
2. Label cells at a concentration of 2 million cells/mL 
-The cells and CFSE should be mixed well so the CFSE stain will be uniform 
3. Centrifuge cells at low speed for 5 minutes, remove supernate 
4. Wash cells 2x in complete (with FBS) medium (e.g. complete RPMI 1640 medium) 
 
Notes:  
-If cell viability decreases, the staining is too bright, or the CFSE stock is newly made, might 
need to decrease the staining incubation time (e.g. to 7 minutes), decrease the CFSE 
concentration, or increase the cell concentration used. 
-If staining mouse cells, it is better to use the CFSE at 1 µM final concentration and label the 
cells for 10 minutes at room temperature (instead of at 37°C). 
-It is sometimes helpful to check the CFSE stain by flow cytometry before proceeding with 
plating the cells 
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Protocol 7: Suppression Assay using Human T cells 
Week 1 (Day 0) 
1. Isolate naïve CD4+ T cells 
2. Stimulate cells using plate-bound anti-CD3 (clone OKT3, 1 µg/mL) and anti-CD54 (anti-
ICAM-1, clone R6.5D6, 10 µg/mL) 
3. Stimulate cells for 10 days 
 
Week 2 (Day 10) 
1. Isolate Total T cells from new blood sample from same donor = Responder T cells 
2. Stain Responder cells with 2.5 µM CFSE 
3. Isolate CD4+CD25+ cells from week 1 culture = Suppressor cells 
4. Isolate CD4+CD25- cells from week 1 culture 
5. Stain CD4+CD25+, CD4+CD25-, and a control group of total T cells with 2.5 µM PKH26 dye 
6. Use the following culture conditions: 
 
Group 1 (Control): PKH26-labeled Responder T cells + CFSE-labeled Responder T cells 
Group 2: PKH26-labeled CD4+CD25+ cells + CFSE-labeled Responder T cells 
Group 3: PKH26-labeled CD4+CD25- cells + CFSE-labeled Responder T cells 
Each Group is cultured at Suppressor: Responder ratios of 1:1, 1:2, and 1:4 
 
6. Stimulate cells with plate-bound anti-CD3 (1 µg/mL) + anti-CD28 (2 µg/mL) for 5 days 
7. Perform flow cytometry 
8. Determine the % Proliferation of CFSE-labeled Responder cells 
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Protocol 8: Purification of Mouse Splenocytes 
1. Sterilely remove spleen and place in 4 mL complete RPMI 1640 (warmed to 37°C) in 14 mL 
tube 
2. Open 70 µm mesh filter, place in small cell culture plate 
3. Flame mouth of tube and pour spleen and medium into filter and plate 
4. Alcohol flame scissors and forceps, Cut spleen into 4 pieces 
5. Gentle mash spleen into mesh filter with sterile plunger from 1 cc syringe until the spleen 
tissue looks white 
6. Use a 5 mL glass pipet to wash the cell solution over the mesh filter 3 times, Transfer all of 
the cell solution to a new 14 mL tube 
7. Centrifuge tube at 70 speed (if using clinical centrifuge) for 5 minutes, Aspirate supernate 
8. Resuspend quickly but gently in 5 mL ACK lysis buffer (room temperature), Incubate 5 
minutes at room temperature 
9. Add 5 mL complete RPMI 1640 
10. Centrifuge at 70 speed for 5 minutes, Aspirate supernate 
11. Resuspend in 5 mL complete RPMI 1640 (can pool spleens at this point if appropriate) 
13. Count on hemacytometer (Make a 1:10 cell dilution in an Eppendorf tube for cell counting 
cells, e.g. 180 µL medium + 20 µL cells) 
18. Proceed to next step of procedure (e.g. StemSep separation Protocol, MACS separation 
protocol, wash cells again, etc.) 
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Protocol 9: Removal of Dead Cells using Ficoll (or Lympholyte-M for Mouse Cells) for 
Small Volumes 
1. Pool cells into Eppendorf tube (e.g. CD3 stimulated wells together into 1 tube, etc.) 
2. Do a fast spin of cells in Eppendorf tubes 
3. Resuspend cells in 500 µL complete RPMI 1640 
4. Carefully layer cells over 500 µL Ficoll (or Lympholyte-M for mouse cells) 
5. centrifuge at 4,000 rpm (1699 g) (using Eppendorf Centrifuge 5417R) at room temperature for 
20 minutes 
6. Carefully save cell layer above the Ficoll 
7. Wash cells 2x in complete RPMI 1640 with fast spin (4,000 rpm) in Eppendorf tube 
8. Perform cell count 
9. Proceed to next step in experiment 
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Protocol 10: Suppression Assay using Mouse T cells 
Week 1 (Day 0) 
 1. Isolate CD4+ T cells 
2. Stimulate cells using plate-bound anti-CD3 (clone 500A2, 0.5 µg/mL) and anti-CD54 (anti-
ICAM-1, clones KAT-1 or YN1/1.7.4, 10 µg/mL) or anti-CD28 (clone 37.51, 2.5 µg/mL) 
-culture cells in supplemented complete RPMI 1640 (contains 10% FBS, 2 mM L-
glutamine, 50 units/mL penicillin, 50 µg/mL streptomycin, 1% sodium pyruvate, 1% 
non-essential amino acids, 50 µM β-mercaptoethanol) 
- culture cells +/- recombinant human TGF-β1 and IL-2 
3. Stimulate cells for 5 days 
 
Week 2 (Day 5) 
I. Responder cells 
1. Isolate total mouse splenocytes from 2 mice using Splenocyte Purification procedure 
2. Isolate total T cells from splenocytes using StemSep Mouse T Cell Enrichment Kit 
3. Stain appropriate number of T cells with 1 µM CFSE using CFSE staining procedure 
4. Check CFSE staining by flow 
5. Stain for CD3 purity by flow 
 
II. Potential Suppressor (Pooled Stimulated cells) 
1. Pipet the appropriate cells from the plate on which they have been stimulated 
2. Remove dead cells/debris using Lympholyte-M spin (see Protocol for Removal of Dead Cells 
using Lympholyte-M) 
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3. Perform cell counts with hemacytometer 
 
III.  Suppression Assay 
1. The day before the Suppression Assay, Plate anti-mouse CD3+CD28 antibodies in 96-well 
flat-bottom plate [anti-CD3 (clone 500A2) at 0.5 µg/mL and anti-CD28 (clone 37.51) at 2.5 
µg/mL in sterile PBS], incubate at 4°C overnight 
2. Wash plate 3x with PBS 
3. Add unlabeled potential Suppressor cells to the CFSE-labeled Responder cells at the proper 
ratios (1:2 Suppressor:Responder, with 300,000 cells per well total) 
4. Plate cells for 3-5 days in 37°C incubator 
5. On Day 3 or 5, wash cells once in staining buffer, resuspend in 200-400 µL staining buffer 
6. Perform flow cytometry  
7. Determine the % Proliferation of CFSE-labeled Responder cells 
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Protocol 11: Intracellular Cytokines Assay using Splenocytes from Mice Infected with VSV 
-For acute response, spleens are taken from infected mice at day 7 post-infection  
-For memory response, spleens are taken from infected mice at day 70 post-infection 
1. Remove spleens from infected mice and one uninfected control (C57Bl/6) 
 -See procedure for Purification of Mouse Splenocytes 
2. Count cells in each sample with hemacytometer 
3. Centrifuge samples (2 x 106 cells/sample, each mouse has 2 samples) at 2000 rpm, 3 minutes 
4. Prepare stimulation media (while cells are spinning) 
-Need (n x 400 µL) stimulation media with and without peptide (+ extra volume), n = # mice)  
 -complete RPMI 1640 + 3 µM monensin (Golgi-stop) + 50 U/mL rIL-2 with or without 
 2 µg/mL MHC Class I specific VSV peptide 
 -Add 1 µL monensin per mL 
 -Add 5 µL rIL-2 per mL (rIL-2 stock is at 10U/µL) 
 -To peptide medium: Add 1 µL peptide per mL (peptide stored at 2 µg/µL) 
-Have n samples with peptide, n samples without peptide 
5. Remove old media with a pipet 
6. Resuspend each sample in 400 µL of appropriate medium (now at 5 x 106 cells/mL) 
7. Plate samples (with and without peptide) in duplicate in 96-well round-bottom plates,  
200 µL per well (1x 106 cells per well in duplicate wells, with and without peptide = 4 wells total 
per mouse) 
8. Duplicate samples will be pooled for staining 
9. Stimulate in 37°C incubator 5-6 hours 
After 5-6 incubation: 
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10. Prepare Staining Buffer (DPBS + 0.5% BSA) 
11. Prepare Blocking Solution [staining buffer + monensin + Fc receptor blocking Ab (anti-
mouse CD16/32)] 
-Pipet [(2n + 1) x 100 µL] staining buffer into an Eppendorf tube 
-Add 1 µL/mL monensin 
-Add 10 µL/mL blocking Ab 
12. Pool duplicate samples from plate and centrifuge  
13. Resuspend in 100 µL of Blocking Solution  
14. Centrifuge 4 staining control samples from extra splenocytes (2 x 106 cells/sample) 
 -Resuspend these in 100 µL of plain staining buffer 
 -Add 1 µL blocking Ab per sample 
15. Incubate 15 minutes on ice, centrifuge 
16. Prepare Ab Solution (staining buffer + monensin + Abs) 
 -Pipet [(2n + 1) x 100 µL] staining buffer into an Eppendorf tube  
-Add 1 µL/mL monensin 
-Add 10 µL/mL of each Ab 
 -F4/80-PE 
 -CD8-PerCP 
17. Resuspend stimulated samples in 100 µL of Ab Solution 
 
18. Resuspend staining control samples in 100 µL of plain staining buffer 
 -Add 1 µL of appropriate Ab 
 -Single Staining controls:  
235 
 
-unstained 
  - ___-FITC (e.g. Thy1.2-FITC) 
 -F4/80-PE 
 -CD8-PerCP 
19. Incubate 20 minutes, on ice, in dark 
20. Centrifuge, resuspend samples in 100 µL Cytofix/Cytoperm Solution (BD Biosciences) 
-(Resuspend single staining controls in 400 µL Staining Buffer + 4% paraformaldehyde.  
Now are finished with these controls.) 
21. Incubate 20 minutes, on ice, in dark 
22. Prepare 1x Perm/Wash Solution (BD Biosciences) by diluting 10x Perm/Wash solution in 
ddH2O 
23. Add 600 µL of 1x Perm/Wash Solution to each sample 
24. Spin  2,000 rpm, 3 minutes 
25. Use aspirator to remove all but ~100 µL of supernate, and use pipet to carefully remove the 
rest of the supernate 
26. Prepare an anti-IFN-γ Solution 
-Pipet [(2n + 1) x 100 µL] staining buffer into Eppendorf tube 
-Add 10 µL/mL IFN-γ-FITC Ab 
27. Resuspend cells in 100 µL of the IFN-γ Solution 
28. Incubate 20 minutes, on ice, in dark 
29. Centrifuge 2000 rpm, 3 minutes 
30. Remove supernate with pipet, resuspend in 400 µL staining buffer + 4% paraformaldehyde 
31. Analyze the cells the next morning by flow cytometry 
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Protocol 12: In Vivo Cytotoxicity Assay to Test Immune Response to VSV 
 
1. Remove spleens from 2 TCRβ KO mice (donor mice) 
2. Determine cell count using hemacytometer 
3. Centrifuge volume containing 10 x 106 cells per recipient mouse 
4. Resuspend cells in 1 mL diluent C (Sigma PKH26 dye kit) 
5. Make 10 µM PKH solution in diluent C (stock PKH is 1 mM) 
-(990 µL diluent C + 10 µL PKH) 
6. Add the 10 µM solution to the cell/diluent C solution, mix (5 µM final) 
7. Incubate 5 minutes, room temperature 
8. Add 1 mL FBS, incubate 1 minute 
9. Add 1x volume (3 mL) complete RPMI 1640 1640 
10. Spin slowly (40 speed on clinical centrifuge) 
11. Resuspend in 10 mL complete RPMI 1640 1640 
12. Split cell solution between 2 tubes (5 mL) each 
13. Add _x_ mL complete RPMI 1640 to make concentration 2 x 106 cells/mL 
14. Make CFSE dilutions for staining (CFSE stock = 5 mM) 
 -Dilute stock 1:10 with DMSO (20 µL stock CFSE + 180 µL DMSO) = 500 µM 
  -Take an aliquot and dilute it 1:10 (20 µL 500 µM CFSE + 180 µL DMSO) 
   = 50 µM CFSE 
 -Add  150 µL of the 500 µM CFSE solution to one tube (15 mL) of cell solution  
  = 5 µM CFSE final concentration (CFSEhi group) 
 -Add 150 µL of the 50 µM CFSE solution to second tube (15 mL) of cell solution  
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  =0.5 µM CFSE final concentration (CFSElo group) 
 
15. Incubate 10 minutes in 37°C water bath 
16. Centrifuge (5 minutes) and resuspend in 6 mL complete RPMI 1640 for each CFSE dilution 
group 
17. Label 5 µM CFSEhi cell solution with 5 µg/mL peptide  
18. Incubate both CFSE groups for 1 hour in 37°C incubator  
19. Count cells from each group, centrifuge equal cell numbers for both groups 
20. Resuspend in _x_ mL sterile PBS [x = (200 µL x # of recipient mice) + extra volume] 
21. Pipet 200 µL from each CFSE group into __n _ Eppendorf tubes (n = # of recipient mice) 
22. Inject 400 µL of the combined cell solution in PBS into infected mice and uninfected control 
mice 
23. Harvest spleens 16 hours post-injection, centrifuge cells, resuspend in Staining Buffer + 4% 
paraformaldehyde 
24.  Perform flow cytometry 
 
 
 
 
